| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Boston Scientific Corporation$44.77
-0.22 (-0.49%)
B 65Pipeline Score MedTech · Commercial
Market Cap
85.88 B
EPS
2.40
P/E Ratio
24.23 $
Value Trade
1.18 B
SEC Financials
Q1 2026Dilution Risk
Revenue
5.20 B
R&D Expenses
516.00 M
Operating CF
348.00 M
Total Assets
44.35 B
Total Liabilities
44.35 B
Equity
25.86 B
D/E Ratio
12,345
6.62 %
Week
-7.57 %
1 Month
-23.43 %
3 Month
-40.09 %
6 Month
37.11 %
5 Year
1,259.53 %
All Time
Cash Data
Cash Position
2.16 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 1, 2026
Overview
Volume
12.04 M
52 Week Range
52.52 - 109.50
% held by Insiders
0.5 %
% held by Institutions
93.23 %
Enterprise Value
95.63 B
Total Shares
1.49 B
Short %
1.89 %
Float Shares
1.48 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Boston Scientific Corporation
1670Total events
4Upcoming
625Tier-1 (high impact)
2009 – 2026Coverage
Upcoming catalysts 4
TBD
T1FDA Filing Accepted
Planned submission to expand indication and coverage for first-line stroke risk reduction
Event history 1666
May 27, 2026
◆Oral PresentationPresentation
Participation in Bernstein's 42nd Annual Strategic Decisions Conference
May 19, 2026
▲Primary Endpoint MetClinical Data
FRACTURE IDE trial meets primary safety and effectiveness endpoints
severely calcified coronary artery diseasesource ↗
May 19, 2026
●Oral PresentationPresentation
Late-breaking data presented at EuroPCR 2026 congress
severely calcified coronary artery diseasesource ↗
May 18, 2026
▲Partnership / LicenseCorporate
Boston Scientific invests $1.5B for 34% equity stake in MiRus LLC with exclusive option to acquire SIEGEL TAVR system
Apr 26, 2026
▲Primary Endpoint MetFARAPULSEClinical Data
AVANT GUARD trial met all safety and effectiveness endpoints; PFA superior to AADs
persistent atrial fibrillationsource ↗
Apr 26, 2026
◆Full ResultsFARAPULSEClinical Data
AVANT GUARD results published in The New England Journal of Medicine
persistent atrial fibrillationsource ↗
Apr 26, 2026
◆Topline ReadoutFARAFLEXClinical Data
ELEVATE-PF feasibility study interim data presented
paroxysmal and persistent atrial fibrillationsource ↗
Apr 26, 2026
Apr 26, 2026
▲Subgroup AnalysisClinical Data
CHAMPION-AF sub-analysis by prior ablation status
non-valvular atrial fibrillationsource ↗
Apr 26, 2026
▲Long Term DataWATCHMANApprovedClinical Data
ASAP-TOO 5-year follow-up data
non-valvular atrial fibrillationsource ↗
Drug Pipeline Intelligence
B65
Pipeline Score $8.2B
Pipeline ValueValuation Signal
16
Drugs Scored0.3x
rNPV / MCap Top 92%
Large Pharma (rank 74 of 912)
Percentile RankBoston Scientific Corporation holds a solid B-grade pipeline (65/100), with $8.2B risk-adjusted pipeline value, led by recombinant tissue plasminogen activator in Pulmonary Embolism (Phase 3), across $94B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| recombinant tissue plasminogen activator Small molecule | Pulmonary Embolism | Phase 3 | NCT01513759 | 50% | $5.3B | COMPLETED | 150 | - | - | Feb 17, 2013 | - | Jul 19, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter | severely calcified coronary artery disease | — | 2026-05-19 | freedom from MACE: 93.3%; procedural success rate: 93.7% | FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints Read More | |
SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter | severely calcified coronary artery disease | — | 2026-05-19 | freedom from MACE: 93.3%; procedural success rate: 93.7% | FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints Read More | |
SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter | severely calcified coronary artery disease | — | 2026-05-19 | freedom from MACE: 93.3%; procedural success rate: 93.7% | FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BSX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BSX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BSXFRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Boston Scientific's FRACTURE IDE trial for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter has successfully met its primary safety and effectiveness endpoints. The study demonstrated a 93.3% rate of freedom from major adverse cardiac events at 30 days and a 93.7% procedural success rate. These results indicate the catheter's potential in treating patients with severely calcified coronary artery disease.
Read more →BSX▲ +6.2%on this newsshared move
Boston Scientific enters into $2 billion accelerated share repurchase agreement
Boston Scientific has announced a $2 billion accelerated share repurchase agreement with JPMorgan Chase. This initiative is part of a broader $5 billion share repurchase authorization. The ASR is expected to positively impact adjusted earnings per share by $0.02 for the full year 2026. The final settlement of the ASR is anticipated by June 30, 2026.
Read more →BSX▲ +6.2%on this newsshared move
Boston Scientific announces strategic investment in MiRus LLC
Boston Scientific has invested $1.5 billion for a 34% stake in MiRus LLC, focusing on the SIEGEL Balloon Expandable TAVR system. This investment includes an exclusive option to acquire the TAVR technology, which is designed to treat severe aortic stenosis. The SIEGEL valve features a unique rhenium alloy and aims to enhance patient outcomes. MiRus has initiated a pivotal trial to evaluate the valve's safety and effectiveness.
Read more →BSXBoston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results
Boston Scientific Corporation will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026. CEO Mike Mahoney and CMO Janar Sathananthan will engage in a Q&A session. The company will also host a conference call on July 29, 2026, to discuss its second-quarter financial results, with a news release issued beforehand.
Read more →BSXData at Heart Rhythm 2026 highlight key Boston Scientific therapies
Boston Scientific presented positive data at Heart Rhythm 2026, highlighting the effectiveness and safety of its FARAPULSE Pulsed Field Ablation and WATCHMAN LAAC devices. The AVANT GUARD trial showed FARAPULSE PFA's superiority over anti-arrhythmic drugs, while the WATCHMAN FLX Pro achieved high procedural success rates. These findings support the expansion of Boston Scientific's cardiovascular portfolio.
Read more →BSX▲ +9%on this newsshared move
Boston Scientific announces results for first quarter 2026
Boston Scientific reported strong financial results for Q1 2026, with net sales of $5.203 billion, reflecting an 11.6% increase year-over-year. The company also achieved a GAAP net income of $1.341 billion, up from $674 million in the prior year. Key growth segments included cardiovascular and MedSurg, while successful clinical trials were highlighted, including studies on the WATCHMAN FLX device and EKOS system. The company remains focused on its long-term strategy and pipeline advancements.
Read more →BSX▼ -9%on this news
CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
The CHAMPION-AF trial demonstrated that the WATCHMAN FLX device is a viable first-line therapy for stroke risk reduction in patients with non-valvular atrial fibrillation. The study met all primary and secondary endpoints, showing superior safety and efficacy compared to traditional blood thinners. With a 99% procedural success rate, the results may influence future clinical guidelines.
Read more →BSX▼ -9%on this news
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
The HI-PEITHO trial revealed that the EKOS™ Endovascular System significantly outperformed standard anticoagulation therapy in treating intermediate-risk pulmonary embolism. The study showed a 61% reduction in clinical events, with no increase in major bleeding risks. These findings were presented at the ACC.26 and published in The New England Journal of Medicine, marking a potential shift in treatment protocols.
Read more →BSX▼ -9%on this newsshared move
Boston Scientific announces conference call discussing first quarter 2026 results
Boston Scientific Corporation will hold a conference call on April 22, 2026, to discuss its financial results for the first quarter. The call will be hosted by CEO Mike Mahoney and CFO Jon Monson. A news release with the financial results will be issued prior to the call. The event will be available via live webcast and replay.
Read more →BSX▼ -9%on this newsshared move
Boston Scientific receives FDA clearance for the Asurys™ Fluid Management System
Boston Scientific has received FDA 510(k) clearance for its Asurys Fluid Management System, aimed at enhancing irrigation management during endoscopic urologic procedures. This innovative system is designed to maintain fluid flow while managing intrarenal pressure, thus improving patient safety and outcomes. The Asurys System will be integrated with the LithoVue Elite Ureteroscope to further streamline urologic workflows.
Read more →BSXBoston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology Boston Scientific Corporation (NYSE: BSX) will host an investor event and live webcast on Saturday, March 28, 2026, at 6:30 p.m. ET / 5:30 p.m. CT to ...
Boston Scientific Corporation will hold an investor event on March 28, 2026, during the 75th Annual Scientific Session of the American College of Cardiology. The event will include discussions on key clinical data presented that day and will be led by prominent medical executives of the company. Investors will have the opportunity to engage through a live webcast, with a replay available shortly after the event concludes.
Read more →BSXBoston Scientific elects Cathy Smith and Christophe Weber to Board of Directors
Boston Scientific Corporation has elected Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026. Smith, a seasoned executive with a strong finance background, and Weber, the current CEO of Takeda Pharmaceutical, bring valuable leadership and strategic insight. Their appointments follow the retirements of John Sununu and Yoshiaki Fujimori, who will not seek re-election.
Read more →BSXBoston Scientific to participate in TD Cowen's 46th Annual Health Care Conference
Boston Scientific Corporation will participate in TD Cowen's 46th Annual Health Care Conference on March 3, 2026. CEO Mike Mahoney and CMO Kenneth Stein will engage in a 30-minute Q&A session. A live webcast will be available, along with a replay shortly after the event. This participation highlights Boston Scientific's ongoing commitment to healthcare innovation.
Read more →BSX▼ -17.6%on this news
Boston Scientific announces results for fourth quarter and full year 2025
Boston Scientific reported robust financial results for Q4 and full year 2025, achieving net sales of $5.286 billion in Q4, a 15.9% increase year-over-year. The company's full-year net sales reached $20.074 billion, marking a 19.9% growth. Adjusted EPS also rose, reflecting strong operational performance and a positive outlook for 2026.
Read more →BSXBoston Scientific announces agreement to acquire Penumbra, Inc.
Boston Scientific has entered into a definitive agreement to acquire Penumbra, Inc. for $374 per share, valuing the deal at approximately $14.5 billion. This acquisition aims to enhance Boston Scientific's presence in the cardiovascular sector and address the rising prevalence of vascular diseases. The transaction is expected to be completed in 2026, pending stockholder approval.
Read more →BSXBoston Scientific Announces Agreement to Acquire Valencia Technologies Corporation Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a...
Boston Scientific Corporation (NYSE: BSX) has announced its agreement to acquire Valencia Technologies Corporation, focusing on enhancing its urology offerings for treating overactive bladder. The acquisition includes the eCoin® System, an implantable device that has received FDA approval and has demonstrated significant efficacy in clinical trials. Expected to close in the first half of 2026, the deal aims to diversify treatment options in the Urology sector, although it may impact earnings per share negatively in accounting terms.
Read more →BSXBoston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results
Boston Scientific Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, in San Francisco. Key executives will engage in a Q&A session. Additionally, the company will host a conference call on February 4, 2026, to discuss its financial results for the fourth quarter and full year 2025.
Read more →BSXBoston Scientific announces upcoming investor conference schedule
Boston Scientific Corporation will participate in two investor conferences in November and December 2025. Key executives will engage in question-and-answer sessions at Wolfe Research's 7th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference. Live webcasts of both events will be available for investors.
Read more →BSXBoston Scientific announces results for third quarter 2025
Boston Scientific reported a strong performance in Q3 2025, with net sales of $5.065 billion, marking a 20.3% increase year-over-year. The company also achieved a GAAP net income of $755 million, translating to $0.51 per share, up from $0.32 in the previous year. Adjusted EPS for the quarter was $0.75, indicating robust growth driven by innovation and strategic leadership.
Read more →BSXBoston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
Boston Scientific has announced a definitive agreement to acquire Nalu Medical, a company specializing in innovative solutions for chronic pain management. The acquisition, valued at approximately $533 million, aims to enhance Boston Scientific's neuromodulation portfolio. Nalu's Neurostimulation System has demonstrated significant pain relief in clinical trials, and the transaction is expected to close in the first half of 2026.
Read more →BSXBoston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results
Boston Scientific Corporation will hold an Investor Day on September 30, 2025, to discuss its financial goals and long-term strategies. This hybrid event will allow investors to participate online. Additionally, a conference call on October 22, 2025, will cover the company's third-quarter financial results, hosted by key executives. A news release will precede the call.
Read more →BSXBoston Scientific announces results for second quarter 2025 Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported ...
Boston Scientific Corporation (NYSE: BSX) reported substantial growth in its second-quarter results for 2025, achieving net sales of $5.061 billion, representing a 22.8% increase year-over-year. The company also recorded a GAAP net income of $797 million, a significant rise from $324 million in the same period of the previous year, equating to $0.53 per share. Adjusted earnings per share were noted at $0.75, exceeding last year's figure. Looking ahead, the company estimates continued growth for the remainder of the year, with a projected sales increase of approximately 18 to 19% and EPS ranging from $1.89 to $1.93 for the full year.
Read more →BSXBoston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System
Boston Scientific has received FDA approval to expand the labeling for its FARAPULSE Pulsed Field Ablation System, now including treatment for drug refractory, symptomatic persistent atrial fibrillation. This approval is supported by positive results from the ADVANTAGE AF clinical trial, which demonstrated high safety and effectiveness rates. The company plans to further study the system in new clinical trials.
Read more →BSXBoston Scientific announces conference call discussing second quarter 2025 results
Boston Scientific Corporation will hold a conference call on July 23, 2025, to discuss its financial results for the second quarter ended June 30, 2025. The call will be led by CEO Mike Mahoney and CFO Jon Monson. A news release with the financial results will be issued prior to the call. The event will be accessible via a live webcast.
Read more →BSXBoston Scientific announces upcoming investor conference schedule Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May. On May 13, 2025, Dan Brennan, executive vice...
Boston Scientific Corporation (NYSE: BSX) has announced its participation in two investor conferences scheduled for May 2025. Among the attendees are Dan Brennan, the CFO, and Joe Fitzgerald, the EVP and group president of Cardiology, who will engage in a Q&A session at the Bank of America's Health Care Conference. This engagement reflects their commitment to keeping investors informed and involved.
Read more →BSXSecond phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
Boston Scientific announced positive results from the second phase of the ADVANTAGE AF trial, which evaluated the FARAPULSE Pulsed Field Ablation System for treating persistent atrial fibrillation. The trial met all primary safety and efficacy endpoints, demonstrating the system's effectiveness. The findings were presented at the PFA Live Case Summit and published in Circulation.
Read more →BSXBoston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan
Boston Scientific's CFO Dan Brennan will retire after nearly 30 years with the company, transitioning to a senior advisor role until October 2025. Jon Monson, currently the senior vice president of Investor Relations, will succeed him as CFO on June 30, 2025. The leadership transition aims to maintain stability and continue the company's financial performance.
Read more →BSXDocument Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire Jon Monson, senior vice president, Investor Relations to succeed Brennan
Boston Scientific Corporation announced the retirement of CFO Dan Brennan, who will step down at the end of June 2025 after nearly 30 years with the company. He will continue to assist as a senior advisor until October 2025. Jon Monson, the current senior vice president of Investor Relations, is set to succeed Brennan as CFO, effective June 30, 2025. Monson brings over 25 years of financial experience within the company and is expected to lead several finance functions while supporting talent development.
Read more →BSXBoston Scientific announces results for first quarter 2025 Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported...
Boston Scientific Corporation reported net sales of $4.663 billion for Q1 2025, marking a substantial 20.9% increase compared to the same period in the previous year. The company also posted a GAAP net income of $674 million, translating to an EPS of $0.45, up from $0.33 a year prior. These results reflect the effectiveness of its global team and product portfolio, and Boston Scientific has set a positive outlook for the remainder of the year, anticipating continued growth in net sales and earnings. The company will discuss these results with analysts on a conference call.
Read more →BSXBoston Scientific announces conference call discussing first quarter 2025 results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ...
Boston Scientific Corporation is scheduled to host a conference call on April 23, 2025, at 8:00 a.m. ET, where executives will discuss the financial results and business highlights for the first quarter ending March 31, 2025. The company will release its financial results prior to the call, providing insight into its performance. The call will be accessible via live webcast, with a replay available shortly after the event concludes. Boston Scientific emphasizes its commitment to innovative medical technologies that improve global health.
Read more →BSXBoston Scientific announces agreement to acquire SoniVie Ltd. Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held...
Boston Scientific Corporation has signed a definitive agreement to acquire SoniVie Ltd., aiming to enhance its Interventional Cardiology Therapies with the TIVUS Intravascular Ultrasound System for treating hypertension. This investigational technology is designed to perform renal nerve denervation, targeting hypertensive disorders. Boston Scientific will pay approximately $360 million for the 90% stake in SoniVie that it doesn't already own, plus potential additional payments based on regulatory milestones. The acquisition is expected to slightly dilute the company's adjusted earnings per share in 2025.
Read more →BSXBoston Scientific announces completion of €1.5 billion offering of senior notes Boston Scientific Corporation (the Company ) (NYSE: BSX) today announced that American Medical Systems Europe B.V. ( AMS Europe ), its wholly owned...
Boston Scientific Corporation (NYSE: BSX) has successfully completed a public offering of €850 million of 3.000% notes due 2031 and €650 million of 3.250% notes due 2034. The offering, managed by its wholly-owned subsidiary AMS Europe, aims to repay existing senior notes maturing in March 2025 and for general corporate purposes. This strategic financial move bolsters the company’s position to potentially pursue acquisitions and enhance working capital.
Read more →BSXBoston Scientific announces pricing of 1.5 billion of senior notes
Boston Scientific Corporation has announced the pricing of a public offering of senior notes totaling $1.5 billion. The notes comprise $850 million of 3.000% notes due in 2031 and $650 million of 3.250% notes due in 2034, all of which will be guaranteed by the company. The proceeds will be used to repay existing debt and for general corporate purposes. The offering is set to close on February 26, 2025, subject to customary conditions.
Read more →BSXBoston Scientific to participate in TD Cowen's 45th Annual Health Care Conference Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025. Dan Brennan,...
Boston Scientific Corporation (NYSE: BSX) will take part in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Executives, including CFO Dan Brennan and CMO Kenneth Stein, are scheduled to engage in a fireside chat. A live webcast of the session will be available for those interested. This event underlines the company's commitment to innovation and market interaction.
Read more →BSXBoston Scientific announces results for fourth quarter and full year 2024 Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported ...
Boston Scientific Corporation reported impressive financial results for the fourth quarter and full year 2024, achieving net sales of $4.561 billion in Q4, a 22.4% increase year-over-year. The company also saw a rise in GAAP net income to $566 million and adjusted EPS to $0.70, reflecting strong operational performance. With a total annual sales figure of $16.747 billion, Boston Scientific remains optimistic about future growth, citing successful product launches and a robust portfolio. Looking ahead, the company projects net sales growth of approximately 12.5% to 14.5% for 2025.
Read more →BSXwho made a books and records demand on Boston Scientific pursuant to 8 Del. C. 220; (iv) individual defendants Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Lu
Boston Scientific Corporation is involved in multiple derivative actions led by shareholders seeking inspection of its books and records. Following extensive negotiations, an agreement-in-principle was reached between the company and plaintiffs to settle ongoing litigation and adopt corporate governance reforms. Approval from the court is pending, which may pave the way for resolving these legal disputes. Recent actions also reveal existing claims regarding breaches of fiduciary duties among senior executives.
Read more →BSXLate-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and the...
Boston Scientific presented late-breaking data at AF Symposium 2025 showcasing the effectiveness of the FARAPULSE Pulsed Field Ablation System and the WATCHMAN FLX Left Atrial Appendage Closure Device. The ADVANTAGE AF clinical trial demonstrated safety and efficacy in treating drug-resistant, symptomatic persistent atrial fibrillation, showing a significant number of patients could discontinue anti-arrhythmic medications. Additionally, a sub-analysis from the OPTION trial highlighted consistent outcomes following the use of the WATCHMAN FLX device. These findings underscore Boston Scientific's commitment to improving patient outcomes in atrial fibrillation management.
Read more →BSXBoston Scientific Announces Agreement to Acquire Bolt Medical, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of...
Boston Scientific has announced a definitive agreement to acquire Bolt Medical, a developer of advanced laser-based technology for treating coronary and peripheral artery disease. The Bolt IVL system utilizes lithotripsy to break up calcium deposits in arteries, enhancing treatment options. The acquisition, valued at approximately $443 million upfront, aims to consolidate Boston Scientific's position in the rapidly growing intravascular lithotripsy market. Despite the potential benefits, the transaction is projected to impact the company's earnings slightly in the immediate term.
Read more →BSXBoston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San...
Boston Scientific Corporation (NYSE: BSX) will take part in the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco. The event will feature a presentation by CEO Mike Mahoney alongside other key executives. Additionally, a conference call on February 5, 2025, will discuss the company’s financial results for the fourth quarter of 2024. The public can access live webcasts and replays of these events.
Read more →BSXBoston Scientific Announces Agreement to Acquire Intera Oncology® Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Intera Oncology® Inc., a privately...
Boston Scientific Corporation has announced a definitive agreement to acquire Intera Oncology Inc., enhancing their interventional oncology portfolio with the Intera 3000 pump and floxuridine chemotherapy. This acquisition aims to provide improved treatment options for liver-dominant metastases, particularly related to colorectal cancer. The Intera 3000 pump is FDA-approved and offers a continuous flow of floxuridine directly to the liver, addressing significant treatment gaps. The transaction is anticipated to close in the first half of 2025, with an immaterial impact on adjusted earnings per share but expected dilution on a GAAP basis.
Read more →BSXBoston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the...
Boston Scientific announced positive results from the OPTION trial for the WATCHMAN FLX device, showing significant bleeding risk reduction compared to oral anticoagulants. The three-year data demonstrated non-inferiority in stroke risk reduction and high procedural success rates among participants. This study positions the WATCHMAN FLX as a potential first-line therapy for patients with atrial fibrillation following cardiac ablation, enhancing patient safety and treatment adherence.
Read more →BSXBoston Scientific Closes Acquisition of Axonics, Inc.
Boston Scientific has officially completed its acquisition of Axonics, Inc., a company specializing in medical devices for treating urinary and bowel dysfunctions. The deal, valued at $3.7 billion, allows Boston Scientific to enhance its Urology product offerings and embrace the growing market for sacral neuromodulation solutions. Although the acquisition is expected to be immaterial to adjusted EPS in the short term, it promises considerable benefits in the long run. However, there are concerns regarding the potential financial dilution on a GAAP basis and challenges associated with integrating Axonics' operations.
Read more →BSXBoston Scientific to Participate in the 2024 UBS Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024. Nick...
Boston Scientific Corporation will participate in the 2024 UBS Global Healthcare Conference scheduled for November 12, 2024. Executives Nick Spadea-Anello and Jon Monson will hold a 35-minute Q&A session during the event. A live webcast and replay of this session will be available for interested parties. Boston Scientific has a longstanding reputation in the medical technology field, focusing on innovative solutions across multiple disease areas.
Read more →BSXBoston Scientific Announces Agreement to Acquire Cortex, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. ...
Boston Scientific Corporation (NYSE: BSX) has announced a definitive agreement to acquire Cortex, Inc., which focuses on advanced solutions for diagnosing atrial fibrillation (AF). The acquisition aims to enhance Boston Scientific's existing electrophysiology offerings with Cortex's OptiMap System, which has demonstrated significant clinical benefits. The completion of the transaction is expected in the first half of 2025, although it may slightly impact earnings due to amortization and related costs. Further development of this technology could significantly improve patient treatment options globally.
Read more →BSXACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024 Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the...
Boston Scientific announced the results of its ACURATE IDE clinical trial for the ACURATE neo2 Aortic Valve System, presented at TCT 2024. The trial aimed to evaluate the valve's performance in severe symptomatic aortic stenosis patients across various surgical risk levels. While the data showed a higher composite rate of adverse events compared to control valves, a post-hoc analysis indicated procedural optimizations could improve future outcomes. Ongoing collaboration with the FDA for regulatory approval is also highlighted.
Read more →BSXBoston Scientific Announces Results for Third Quarter 2024 Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported...
Boston Scientific announced its financial results for the third quarter of 2024, reporting net sales of $4.209 billion, marking a 19.4% increase compared to the previous year. The company also achieved adjusted earnings per share of $0.63, which represents a notable rise from $0.50 in the same quarter last year. Despite the positive growth, GAAP net income decreased to $469 million from $505 million. The company projects continued growth in net sales for both the full year and the fourth quarter of 2024, projecting a robust performance driven by its product pipeline and strategic execution.
Read more →BSXBoston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled ...
Boston Scientific has received FDA approval for its new FARAWAVE NAV Ablation Catheter and FARAVIEW Software aimed at enhancing the FARAPULSE Pulsed Field Ablation System for treating paroxysmal atrial fibrillation. These innovations combine to simplify cardiac ablation procedures by integrating visualization features and eliminating the need for multiple devices. With these advancements, the company aims to improve workflow efficiency and provide physicians with real-time mapping and tracking capabilities. The new technologies are set to be launched immediately in the U.S.
Read more →BSXBoston Scientific Announces Conference Call Discussing Third Quarter 2024 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
Boston Scientific Corporation (NYSE: BSX) will host a conference call on October 23, 2024, to discuss its financial results for the third quarter. The call will feature CEO Mike Mahoney and CFO Dan Brennan. In addition, the company will hold a virtual event on October 30, 2024, focusing on its cardiology business following the TCT symposium. Both events emphasize Boston Scientific's ongoing commitment to innovation in medical technologies.
Read more →BSXBoston Scientific Receives Japanese Regulatory Approval for the FARAPULSE™ Pulsed Field Ablation System Boston Scientific Corporation (NYSE: BSX) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the...
Boston Scientific Corporation has received regulatory approval from the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for its FARAPULSE Pulsed Field Ablation (PFA) System. This system is designed to treat paroxysmal atrial fibrillation by using non-thermal electrical fields, providing a safer alternative to traditional thermal ablation methods. With approval in over 65 countries, the FARAPULSE PFA System has been used in more than 125,000 patients worldwide, showcasing its strong safety and efficacy profile. Boston Scientific plans to launch the device in Japan shortly after securing reimbursement approval and is set to start the OPTION-A clinical trial in 2025 to further explore its applications in cardiac ablation.
Read more →BSXBoston Scientific Closes Acquisition of Silk Road Medical, Inc. Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device...
Boston Scientific Corporation has completed its acquisition of Silk Road Medical, Inc., aiming to enhance its vascular technology offerings. Silk Road Medical is recognized for its innovative TCAR platform designed for stroke prevention and carotid artery disease treatment. The acquisition is valued at approximately $1.18 billion, with an anticipated positive impact on Boston Scientific's earnings profile in the long term. The deal emphasizes their commitment to improving healthcare through accessible and effective treatment options.
Read more →BSXBoston Scientific Receives FDA Approval for Expanded Indication of INGEVITY™+ Pacing Leads to Include Conduction System Pacing of the Left Bundle Branch Area Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the indication for...
Boston Scientific has received FDA approval to expand the indication for its INGEVITY+ Pacing Leads to include conduction system pacing of the left bundle branch area. This alternative to traditional right ventricular pacing aims to enhance patient care for those suffering from symptomatic bradycardia. The approval is backed by clinical evidence from the INSIGHT-LBBA study, which showed that this pacing technique could promote better heart function and reduce long-term heart failure risks. The expanded indication marks a significant step in Boston Scientific's commitment to innovation in cardiac rhythm management.
Read more →BSXBoston Scientific Obtains CE Mark for ACURATE Prime™ Aortic Valve System Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest...
Boston Scientific Corporation has received CE mark approval for its ACURATE Prime™ Aortic Valve System, enhancing its transcatheter aortic valve replacement (TAVR) portfolio. This new system is designed to accommodate a wider patient population and features a self-expanding, supra-annular design that improves fit and deployment. With a new valve size and improved mechanisms for accurate positioning, it aims to restore normal blood flow in patients with severe aortic stenosis. The launch of this technology is expected in Europe soon.
Read more →BSXBoston Scientific to Participate in Wells Fargo's 2024 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 2024 Healthcare Conference on Wednesday, September 4, 2024. Mike Mahoney, ...
Boston Scientific Corporation (NYSE: BSX) announced its participation in the upcoming Wells Fargo 2024 Healthcare Conference scheduled for September 4, 2024. The session will feature CEO Mike Mahoney and Chief Medical Officer Dr. Brad Sutton, who will engage in a 35-minute Q&A with attendees. This event aims to showcase the company's commitment to innovation within the medical technology sector. A live webcast of the session will be available for wider audience engagement.
Read more →BSXBoston Scientific Elects David Habiger to Board of Directors MARLBOROUGH, Mass., (
Boston Scientific Corporation has appointed David Habiger to its board of directors, effective immediately. With over 30 years of experience in business leadership, Habiger currently serves as the CEO of J.D. Power and has a background in leading multiple technology companies. He is well-regarded for his knowledge in technology and has held various significant positions, including being a director on the Chicago Federal Reserve Board. The company expresses optimism about his contributions as it aims to enhance its innovative medical technology solutions.
Read more →BSXBoston Scientific Announces Results for Second Quarter 2024 Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported ...
Boston Scientific reported net sales of $4.120 billion for Q2 2024, representing a year-over-year growth of 14.5%. The company also achieved a GAAP net income of $324 million, or $0.22 per share. Strong operational performance was noted in the Cardiology segment, which saw a growth of 20.1%. The company's adjusted EPS for the quarter reached $0.62, up from $0.53 in the same period last year.
Read more →BSXBoston Scientific Announces Conference Call Discussing Second Quarter 2024 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
Boston Scientific Corporation will host a conference call on July 24, 2024, to discuss its financial results for the second quarter ended June 30, 2024. The call will be led by CEO Mike Mahoney and CFO Dan Brennan. A press release detailing the financial results will be released prior to the call. A live webcast will be accessible for public viewing, showing the company's commitment to transparency and investor engagement.
Read more →BSXBoston Scientific Announces Agreement to Acquire Silk Road Medical, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq:...
Boston Scientific Corporation has announced a definitive agreement to acquire Silk Road Medical, Inc. for approximately $1.16 billion. This acquisition aims to enhance Boston Scientific's vascular portfolio by incorporating Silk Road's TCAR technology, which is recognized for improving stroke prevention through minimally invasive procedures. The transaction is expected to close in the second half of 2024, pending customary conditions. Despite projected revenue growth for Silk Road Medical, the acquisition may initially dilute Boston Scientific's GAAP earnings due to associated costs.
Read more →BSXMODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ ...
Boston Scientific Corporation announced encouraging six-month results from the MODULAR ATP clinical trial for its mCRM System, which integrates the EMBLEM Subcutaneous Implantable Defibrillator and the EMPOWER Leadless Pacemaker. The trial successfully met all specified safety and efficacy endpoints, demonstrating effective communication between devices and a low rate of complications. Positive outcomes were presented at the Heart Rhythm 2024 conference and published in a medical journal. The company expects FDA approval for the mCRM System in 2025.
Read more →BSXBoston Scientific Elects Dr. Cheryl Pegus to Board of Directors MARLBOROUGH, Mass., (
Boston Scientific Corporation announced the election of Dr. Cheryl Pegus to its board of directors, effective immediately. Dr. Pegus has extensive experience in clinical and business leadership, including leadership roles in various health care organizations. She is recognized for her commitment to health care innovation and improving patient outcomes. The addition of Dr. Pegus is expected to enhance the board's diversity and expertise as Boston Scientific continues to grow.
Read more →BSXBoston Scientific Announces Upcoming Investor Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May. On May 14, 2024, Dan Brennan, executive vice...
Boston Scientific Corporation (NYSE: BSX) has announced its participation in two investor conferences scheduled for May 2024. Dan Brennan, Executive Vice President and CFO, along with Ken Stein, M.D., Senior VP and Global Chief Medical Officer, will engage in a 30-minute Q&A session at the Bank of America's Health Care Conference on May 14. Both events will feature live webcasts and replays available for interested stakeholders. This engagement highlights Boston Scientific's commitment to transparency and communication with its investors.
Read more →BSX▲ +5.7%on this news
Boston Scientific Announces Results for First Quarter 2024 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported...
Boston Scientific Corporation reported strong financial results for the first quarter of 2024, with net sales of $3.856 billion, marking a 13.8% increase compared to the previous year. GAAP net income attributable to common stockholders rose to $495 million, translating to an EPS of $0.33. The company anticipates continued growth for the full year 2024, estimating net sales rise of approximately 11% to 13% and adjusted EPS between $2.29 and $2.34. Strong performance was attributed to a diversified business model and the launch of new products, including the FARAPULSE™ system.
Read more →BSXBoston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and...
Boston Scientific has launched the NAVIGATE-PF study to evaluate the FARAVIEW Software Module used with the FARAWAVE Nav Pulsed Field Ablation Catheter for treating patients with atrial fibrillation. This study involves approximately 30 patients across several European centers, aiming to assess the procedural benefits of the new integrated technology, which enhances both mapping and ablation capabilities. Anticipated U.S. regulatory approval for the new catheter and software module is expected in the latter half of 2024. The advancements could potentially improve patient outcomes during cardiac ablation procedures.
Read more →BSXBoston Scientific Announces Conference Call Discussing First Quarter 2024 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ...
Boston Scientific Corporation will host a conference call on April 24, 2024, to discuss its financial results for the first quarter ending March 31, 2024. The call will be led by CEO Mike Mahoney and CFO Dan Brennan, with a news release detailing the financial results expected to be issued before the call. This event reflects Boston Scientific’s commitment to keeping investors informed about its performance and strategic outlook.
Read more →BSXBoston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated ...
Boston Scientific has received FDA approval for the AGENT Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis (ISR). This device is the first drug-coated coronary balloon approved in the U.S. and offers a dedicated treatment alternative for ISR, which impacts a notable percentage of coronary interventions. Supported by positive results from the AGENT IDE trial, the AGENT DCB has demonstrated superior outcomes over traditional therapies. Boston Scientific plans to launch the AGENT DCB for U.S. physicians in the coming months.
Read more →BSXBoston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes Boston Scientific Corporation (NYSE: BSX) (the Company ) today announced that American Medical Systems Europe B.V., its wholly owned finance...
Boston Scientific Corporation has announced the successful completion of a €2.0 billion public offering of senior notes. The offering includes €750 million of 3.375% notes due 2029 and €1.25 billion of 3.500% notes due 2032. Proceeds from the notes will finance the acquisition of Axonics, Inc. and cover related administrative expenses. The notes are guaranteed by Boston Scientific and are set to be listed on the Irish Stock Exchange.
Read more →BSXBoston Scientific Announces Pricing of 2.0 Billion of Senior Notes
Boston Scientific Corporation announced the pricing of a public offering totaling $2.0 billion in senior notes. This includes $750 million of 3.375% notes due 2029 and $1.25 billion of 3.500% notes due 2032. The proceeds will primarily finance the acquisition of Axonics, Inc. and support various corporate purposes. The closing of the offering is expected on February 27, 2024, pending customary conditions.
Read more →BSXSix Boston Scientific benefits that support employee mental health One in five American adults has a diagnosable mental health condition. Yet all too often, our friends, co-workers, neighbors and family members...
Boston Scientific emphasizes its commitment to employee mental health by providing a wide range of supportive benefits. These include covering out-of-network mental health services as in-network, offering telehealth options, and providing free counseling sessions through its Employee Assistance Program. Additionally, employees have access to a digital therapy tool and personal healthcare advocates to navigate mental health challenges. The company also fosters a culture of awareness by integrating mental health topics into events and training for leaders.
Read more →BSXBoston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6, 2024. Mike...
Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024. CEO Mike Mahoney will lead a 30-minute Q&A session, making the event a key opportunity for investors. The session will be webcast live, ensuring broader access to the company's updates and performance insights.
Read more →BSXBoston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field...
Boston Scientific has received FDA approval for the FARAPULSE Pulsed Field Ablation System, designed for the treatment of drug-refractory paroxysmal atrial fibrillation. This system offers a non-thermal approach to ablation, potentially providing safety advantages and efficiency in procedures. Clinical data shows that the FARAPULSE system is as safe and effective as traditional methods, with shorter procedure times. The company plans to launch the system immediately and is actively conducting further clinical trials to expand its application.
Read more →BSXBoston Scientific Announces Results for Fourth Quarter and Full Year 2023 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported ...
Boston Scientific Corporation reported impressive financial results for Q4 and full-year 2023, with net sales reaching $3.725 billion, a 14.9% increase year-over-year. The company also noted a significant rise in net income, achieving $1.570 billion, or $1.07 per share, compared to $642 million the previous year. Adjusted earnings per share for the year was recorded at $2.05. Looking forward, Boston Scientific anticipates steady growth for 2024, projecting net sales to increase by approximately 8.5% to 9.5%.
Read more →BSXBoston Scientific Announces Agreement to Acquire Axonics, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a...
Boston Scientific Corporation has announced a definitive agreement to acquire Axonics, Inc. for $71 per share, reflecting an equity value of approximately $3.7 billion. This acquisition aims to enhance Boston Scientific's urology portfolio and provide access to Axonics' innovative technologies for treating urinary and bowel dysfunction. With an expected net revenue of around $366 million for Axonics in 2023, the acquisition is anticipated to significantly bolster Boston Scientific's Urology segment. The transaction is expected to close in the first half of 2024, subject to customary conditions.
Read more →BSXBoston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth...
Boston Scientific Corporation will host a conference call on January 31, 2024, to discuss its financial results and business highlights for the fourth quarter ended December 31, 2023. The call will be led by CEO Mike Mahoney and CFO Dan Brennan, with a news release issued prior to the call. Investors and interested parties can access the webcast live or as a replay shortly after the event. The company is recognized for its innovative medical technologies aimed at improving patient health worldwide.
Read more →BSXBoston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™...
Boston Scientific has launched the AVANT GUARD clinical trial to evaluate the FARAPULSE Pulsed Field Ablation (PFA) System as a frontline treatment for persistent atrial fibrillation (AF). This innovative trial is the first of its kind to compare PFA with anti-arrhythmic drug therapy in patients. With over 500 patients planned for enrollment at multiple global sites, the trial aims to assess the safety and effectiveness of the FARAPULSE system in improving long-term patient outcomes. Initial data has indicated promising results with the FARAPULSE system in treating AF, and the company anticipates FDA approval in the first quarter of 2024.
Read more →BSXBoston Scientific Closes Acquisition of Relievant Medsystems, Inc. Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U....
Boston Scientific Corporation has successfully completed its acquisition of Relievant Medsystems Inc., which offers the FDA-cleared Intracept Intraosseous Nerve Ablation System for the treatment of vertebrogenic pain. This acquisition is set to expand Boston Scientific's chronic pain treatment options and enhance patient access thanks to new national insurance coverage. The total upfront cost of the acquisition was $850 million, with additional payments tied to sales performance. While the transaction is expected to have a positive long-term financial impact, it may temporarily dilute earnings in the short term.
Read more →BSXBoston Scientific to Participate in Stifel's 2023 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on Tuesday, November 14, 2023. Dan Brennan,...
Boston Scientific Corporation is set to participate in Stifel's 2023 Healthcare Conference on November 14, 2023. The session will feature Dan Brennan, CFO, and Lauren Tengler from Investor Relations, engaging in a Q&A format. A live webcast will be available for attendees, emphasizing the company's focus on investor engagement. The replay will be accessible shortly after the event concludes, ensuring that information is readily available to those who could not attend live.
Read more →BSXBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported...
Boston Scientific Corporation reported net sales of $3.527 billion for the third quarter of 2023, marking a growth of 11.2% year-over-year. The company's GAAP net income reached $505 million, which translates to $0.34 per share, an increase from the previous year's $0.12 per share. Boston Scientific has provided guidance indicating expected net sales growth for the full year and fourth quarter, predicting organic growth rates between 9% to 11%. The company's performance is attributed to its global team and its innovative medical technologies.
Read more →BSXBoston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal AGENT IDE clinical trial of the AGENT™...
Boston Scientific announced positive 12-month results from the AGENT IDE trial, which demonstrated that the AGENT Drug-Coated Balloon (DCB) is superior to uncoated balloon angioplasty in treating coronary in-stent restenosis. The trial showed a 38% relative risk reduction in target lesion failure, attributed to lower rates of heart attacks and the need for further procedures. These findings position the AGENT DCB as a promising treatment for patients facing complications from prior stenting. The device is currently investigational and not available for sale in the U.S.
Read more →BSXREAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism Data from the REAL-PE study was presented today at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the...
Data from the REAL-PE study presented at TCT shows that the Boston Scientific EKOS Endovascular System resulted in significantly lower major bleeding rates compared to the Inari FlowTriever System for treating pulmonary embolism. The study analyzed over 2,200 patients and demonstrated favorable safety outcomes, including reductions in other adverse events such as in-hospital mortality. This analysis utilized extensive electronic health record data, marking a significant advancement in understanding PE treatment outcomes.
Read more →BSXBoston Scientific Announces Conference Call Discussing Third Quarter 2023 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
Boston Scientific Corporation (NYSE: BSX) has announced a webcast for its conference call regarding the financial results and business highlights for the third quarter ending September 30, 2023. Scheduled for October 26, 2023, at 8:00 a.m. EDT, the call will be hosted by CEO Mike Mahoney and CFO Dan Brennan. A press release detailing the financial results will precede the conference call on the same date.
Read more →BSXBoston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a...
Boston Scientific Corporation has announced a definitive agreement to acquire Relievant Medsystems, Inc. for $850 million. This acquisition aims to enhance Boston Scientific's neuromodulation portfolio with the Intracept® Intraosseous Nerve Ablation System, which is FDA-cleared for treating vertebrogenic pain. The deal includes additional contingent payments linked to future sales performance. While the transaction is expected to yield growth, it may initially be dilutive on a GAAP basis due to acquisition-related costs. Closing is anticipated in the first half of 2024, pending customary conditions.
Read more →BSXBoston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation...
Boston Scientific Corporation has received FDA approval for its latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure Device, designed to improve safety and performance in reducing stroke risk for patients with non-valvular atrial fibrillation. The new device includes a polymer coating for reduced thrombus and features such as visualization markers and a broader size matrix. Preclinical studies indicate promising results in terms of reduced inflammation and increased tissue coverage post-procedure. This device is expected to allow for better placement and potentially a simplified post-implant drug regimen for patients.
Read more →BSXBoston Scientific Announces 2023 Investor Day Meeting and Conference Call Discussing Third Quarter 2023 Results Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth...
Boston Scientific Corporation is set to host its 2023 Investor Day meeting on September 20, where it will discuss financial goals and long-term growth strategies. The meeting, which will take place in both in-person and online formats, aims to provide stakeholders with insights into the company's pipeline and upcoming catalysts. In addition, the company will hold a conference call on October 26 to review third quarter 2023 financial results. CEO Mike Mahoney highlighted strong achievements in the first half of the year.
Read more →BSX▲ +6%on this news
ADVENT Study of the FARAPULSE™ Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed...
Boston Scientific Corporation reported positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE Pulsed Field Ablation System, demonstrating its efficacy in treating atrial fibrillation. The trial established the system as noninferior to standard therapies, with notable rates of freedom from atrial arrhythmias and low adverse events. The results were shared at ESC Congress 2023 and published in The New England Journal of Medicine, highlighting the technology's promising role in U.S. treatment strategies for atrial fibrillation.
Read more →BSXBoston Scientific Receives FDA Approval for the POLARx™ Cryoablation System Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the POLARx™...
Boston Scientific Corporation has received FDA approval for its POLARx Cryoablation System, designed for paroxysmal atrial fibrillation treatment. This technology features an expandable balloon catheter that allows physicians to adapt to various patient anatomies, potentially reducing procedure time. The clinical trial data indicated a high safety and effectiveness rate, with a 96.0% event-free rate at 12 months. This innovation represents a significant advancement in the electrophysiology sector and is already being used in over 25,000 patients worldwide.
Read more →BSXBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2023 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported ...
Boston Scientific Corporation reported second quarter 2023 net sales of $3.599 billion, reflecting a growth of 11.0% on a reported basis compared to the previous year. The company achieved a GAAP net income of $261 million, highlighting an increase in earnings per share to $0.18. Looking ahead, Boston Scientific expects full-year sales growth of approximately 10.5 to 11.5%. The company continues to emphasize its innovative product pipeline aimed at meeting patient needs.
Read more →BSXBoston Scientific Announces Conference Call Discussing Second Quarter 2023 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
Boston Scientific Corporation will hold a conference call on July 27, 2023, at 7:30 a.m. EDT to discuss its second quarter financial results and business highlights. This call will be hosted by top executives, including the CEO and CFO. A news release detailing the financial results will precede the call. Investors can access a live webcast and a replay of the event through the company’s investor relations website.
Read more →BSXBoston Scientific Elects Dr. Jessica L. Mega and Susan E. Morano to Board of Directors Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each...
Boston Scientific Corporation has elected Dr. Jessica L. Mega and Susan E. Morano to its board of directors, effective immediately. Dr. Mega, previously a co-founder at Verily Life Sciences, has extensive experience in cardiology and clinical trials. Ms. Morano has a strong background in business development from her tenure at Johnson & Johnson. The leadership expressed optimism about their contributions toward advancing patient care and market innovations.
Read more →BSXBoston Scientific Announces Conversion Date of Series A Mandatory Convertible Preferred Stock Boston Scientific Corporation (NYSE: BSX) announced today that its Series A 5.50% Mandatory Convertible Preferred Stock (the preferred stock) will...
Boston Scientific Corporation announced the automatic conversion of its Series A 5.50% Mandatory Convertible Preferred Stock into common stock on June 1, 2023. This conversion, which affects holders of record as of May 15, 2023, includes a final cash dividend payment of $1.375 per share. Following this event, the company will retire the annual dividend associated with the preferred stock, amounting to approximately $55 million. Overall, about 24 million shares of common stock will be issued as part of this conversion process.
Read more →BSXData at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company's key electrophysiology and cardiac rhythm management...
Boston Scientific Corporation announced significant data at Heart Rhythm 2023, highlighting the effectiveness and safety of its electrophysiology and cardiac rhythm management devices. Key findings included positive results for the FARAPULSE Pulsed Field Ablation System and POLARx Cryoablation System in various trials, demonstrating improved patient outcomes. Additionally, insights from the WATCHMAN FLX LAAC device studies and its innovative therapies were discussed. The data reflects Boston Scientific's commitment to enhancing cardiac care through advanced technology.
Read more →BSXBoston Scientific to Participate in Bernstein's 39th Annual Strategic Decisions Conference Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023. Mike ...
Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on May 31, 2023. CEO Mike Mahoney is scheduled for a 50-minute Q&A session, which will be available via live webcast. This event allows the company to engage with investors and demonstrate its ongoing commitment to transforming lives through innovative medical solutions.
Read more →BSXBoston Scientific Announces Results for First Quarter 2023 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported...
Boston Scientific Corporation announced a successful first quarter for 2023, reporting net sales of $3.389 billion, marking a 12% increase compared to the same quarter last year. The company also reported a significant rise in net income, reaching $300 million, with adjusted earnings per share rising to $0.47. Management expressed confidence in the company's future growth, driven by a strong product pipeline aimed at enhancing healthcare solutions for a broader patient base. Full-year growth guidance suggests a continued positive trend with expected net sales growth of 8.5% to 10.5%.
Read more →BSXBoston Scientific Announces Conference Call Discussing First Quarter 2023 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ...
Boston Scientific Corporation will hold a conference call on April 26, 2023, to discuss its financial performance and business highlights for the first quarter of the year. The call will feature CEO Mike Mahoney and CFO Dan Brennan, who will provide insights into the company's results. A news release with detailed financial information will be issued prior to the call. Investors will be able to access a live webcast and a subsequent replay of the event.
Read more →BSXBoston Scientific to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Wednesday, March...
Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference, scheduled for March 1, 2023. The 40-minute session will feature Dan Brennan, CFO, and Lauren Tengler, VP of Investor Relations, engaging with the host analyst. A live webcast will be available for investors, and a replay will follow shortly after the event concludes. This participation aims to enhance engagement with stakeholders and promote the company’s innovations in medical technology.
Read more →BSXBoston Scientific Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LithoVue™ Elite Single-Use...
Boston Scientific Corporation has received FDA 510(k) clearance for its LithoVue Elite Single-Use Digital Flexible Ureteroscope System. This innovative device features real-time monitoring of intrarenal pressure during ureteroscopy procedures, addressing a significant gap in current practices. The LithoVue Elite System enhances patient care by reducing infection risks associated with reusable scopes and builds on the original LithoVue System's capabilities. A limited market release is expected to begin in the coming weeks, marking an important step forward in the company's single-use imaging portfolio.
Read more →BSXBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported...
Boston Scientific Corporation reported net sales of $3.242 billion in Q4 2022, up 3.7% from the prior year. For the full year, net sales reached $12.682 billion, marking a 6.7% increase. However, the company experienced a negative financial impact due to Italian government payback provisions, notably reflected in adjusted EPS and GAAP net income. Despite these challenges, Boston Scientific's CEO emphasized a commitment to innovation and delivering strong financial performance in 2023.
Read more →BSXBoston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results Boston Scientific Corporation (NYSE: BSX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San ...
Boston Scientific Corporation will take part in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. Key executives, including CEO Mike Mahoney, will present and participate in a Q&A session. Additionally, the company will host a conference call on February 1, 2023, to discuss its fourth-quarter results for 2022, with a news release issued prior to the call.
Read more →BSXBoston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited Boston Scientific Corporation (NYSE: BSX) and Acotec Scientific Holdings Limited ( Acotec and 6669.HK) announced today that Boston Scientific will...
MARLBOROUGH, Mass. , Dec. 11, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) and Acotec Scientific Holdings Limited ("Acotec" and 6669.HK) announced today that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of sha
Read more →BSXBoston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. (Nasdaq:...
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass. , Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has entered into a definitive agreement to acquir
Read more →BSXLate-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2™ Aortic Valve System Boston Scientific Corporation (NYSE:BSX) has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating ...
MARLBOROUGH, Mass. , Nov. 27, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2 TM Aortic Valve System. The findings, whi
Read more →BSXBoston Scientific Announces Upcoming Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On November 15, 2022, Dan Brennan, executive vice...
MARLBOROUGH, Mass. , Nov. 1, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in two upcoming investor conferences. On November 15, 2022 , Dan Brennan , executive vice president and chief financial officer, and Lauren Tengler , vice president, Inv
Read more →BSXBoston Scientific Announces Results for Third Quarter 2022 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.170 billion during the third quarter of 2022, growing 8.1 percent on a reported...
MARLBOROUGH, Mass. , Oct. 26, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $3.170 billion during the third quarter of 2022, growing 8.1 percent on a reported basis, 13.7 percent on an operational 1 basis and 11.5 percent on an organic 2 b
Read more →BSXBoston Scientific Announces Conference Call Discussing Third Quarter 2022 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
MARLBOROUGH, Mass. , Oct. 3, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2022 on Wednesday, October 26, 2022 at 8:00 a.m. EDT . The
Read more →BSXLate-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL™ Cerebral Protection System Boston Scientific Corporation (NYSE:BSX) has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection...
Results from largest randomized TAVR trial to date presented at TCT 2022 MARLBOROUGH, Mass. , Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection Syste
Read more →BSXBoston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling...
WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation MARLBOROUGH, Mass. , Sept. 6, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA)
Read more →BSXBoston Scientific Announces Upcoming Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events. On Wednesday, September 7, 2022, Mike Mahoney, chairman...
MARLBOROUGH, Mass. , Aug. 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in two upcoming investor events. On Wednesday, September 7, 2022 , Mike Mahoney , chairman and chief executive officer, and Lauren Tengler , vice president, Investor Re
Read more →BSXBoston Scientific Announces Acquisition of Obsidio, Inc. Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel...
Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio MARLBOROUGH, Mass. , Aug. 15, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the acquisition of Obsidio, Inc., a priva
Read more →BSX▲ +6.2%on this news
Boston Scientific Announces Results for Second Quarter 2022 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported...
MARLBOROUGH, Mass. , July 27, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported basis, 9.6 percent on an operational 1 basis and 6.6 percent on an organic 2 ba
Read more →BSXBoston Scientific Announces Conference Call Discussing Second Quarter 2022 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
MARLBOROUGH, Mass. , June 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27, 2022 at 8:00 a.m. EDT . The call
Read more →BSXBoston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to...
MARLBOROUGH, Mass. , June 15, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64 percent) of M.I.Tech Co., Ltd, ("M.I.Te
Read more →BSXBoston Scientific to Participate in Bank of America Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in Bank of America's Global Healthcare Conference on Thursday, May 12. Dan Brennan,...
MARLBOROUGH, Mass. , May 2, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in Bank of America's Global Healthcare Conference on Thursday, May 12 . Dan Brennan , executive vice president and chief financial officer, and Lauren Tengler , vice pres
Read more →BSXBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported...
MARLBOROUGH, Mass. , April 27, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational 1 basis and 9.7 percent on an organic 2
Read more →BSXBoston Scientific Announces Conference Call Discussing First Quarter 2022 Results Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter...
MARLBOROUGH, Mass. , April 1, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022 , on Wednesday, April 27, 2022 , at 8:00 a.m. EDT . The c
Read more →BSXBoston Scientific Announces Pricing Terms of Its Cash Tender Offer Boston Scientific Corporation (the Company ) (NYSE:BSX) today announced the pricing terms of the previously announced upsized cash tender offer (the ...
MARLBOROUGH, Mass. , March 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX ) today announced the pricing terms of the previously announced upsized cash tender offer (the "Tender Offer") for $2,852,561,000 in aggregate principal amount (the "Aggre
Read more →BSXBoston Scientific Announces Early Results of Its Cash Tender Offer for Its Outstanding Debt Securities and Increases Aggregate Maximum Principal Amount of Its Cash Tender Offer
Boston Scientific Announces Early Results of Its Cash Tender Offer for Its Outstanding Debt Securities and Increases Aggregate Maximum Principal Amount of Its Cash Tender Offer MARLBOROUGH, Mass., March 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE
Read more →BSXBoston Scientific Announces Completion of €3.0 Billion Offering of Senior Notes Boston Scientific Corporation (NYSE: BSX) (the Company ) today announced that American Medical Systems Europe B.V., its wholly owned finance...
MARLBOROUGH, Mass. , March 8, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) (the "Company") today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of €1,000,000,000 aggregate principal amou
Read more →BSXBoston Scientific Announces Pricing of 3.0 Billion of Senior Notes
Boston Scientific Announces Pricing of 3.0 Billion of Senior Notes MARLBOROUGH, Mass., March 3, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has pric
Read more →BSXBoston Scientific Announces Cash Tender Offer For Up To $2.5 Billion Of Its Outstanding Debt Securities MARLBOROUGH, Mass. (
Boston Scientific Announces Cash Tender Offer For Up To $2.5 Billion Of Its Outstanding Debt Securities MARLBOROUGH, Mass. (March 2, 2022) - Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for
Read more →BSXLate-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX™ LAAC Device Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™...
MARLBOROUGH, Mass. , Feb. 28, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Presented during a late-breaking tr
Read more →BSXDocument Boston Scientific Closes Acquisition of Baylis Medical Company Inc.
Boston Scientific Closes Acquisition of Baylis Medical Company Inc. MARLBOROUGH, Mass., February 15, 2022- Boston Scientific Corporation (NYSE BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solu
Read more →BSXBoston Scientific Closes Acquisition of Baylis Medical Company Inc. Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced ...
MARLBOROUGH, Mass. , Feb. 15, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used
Read more →BSXBoston Scientific to Participate in 11th Annual SVB Leerink Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in SVB Leerink's 11th Annual Global Healthcare Conference on Thursday, February 17, 2022....
MARLBOROUGH, Mass. , Feb. 14, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in SVB Leerink's 11 th Annual Global Healthcare Conference on Thursday, February 17, 2022 . Dan Brennan , executive vice president and chief financial officer, and Laur
Read more →BSXBoston Scientific Announces Results For Fourth Quarter And Full Year 2021 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.127 billion during the fourth quarter of 2021, growing 15.4 percent on a reported ...
MARLBOROUGH, Mass. , Feb. 2, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $3.127 billion during the fourth quarter of 2021, growing 15.4 percent on a reported basis, 16.9 percent on an operational 1 basis and 15.1 percent on an organic 2
Read more →BSXBoston Scientific to Present New Data on Advances in Chronic Pain Care at the 2022 North American Neuromodulation Society (NANS) Meeting Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25th North American Neuromodulation Society (NANS)...
MARLBOROUGH, Mass. , Jan. 7, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced key data that will be featured at the 25 th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida , on Jan.13-15, 2022. More than 20 abstracts
Read more →BSXBoston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2021 Results Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022. Mike...
MARLBOROUGH, Mass. , Jan. 4, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 . Mike Mahoney , chairman and chief executive officer, will present at 8:15 a.m. E
Read more →BSXBoston Scientific Initiates Trial to Evaluate Industry's First Modular CRM System Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the...
MARLBOROUGH, Mass. , Dec. 2, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System consists of two cardiac rhythm mana
Read more →BSXBoston Scientific Announces Upcoming Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On November 15, 2021, Dan Brennan, executive vice...
MARLBOROUGH, Mass. , Nov. 8, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in two upcoming investor conferences. On November 15, 2021 , Dan Brennan , executive vice president and chief financial officer, and Lauren Tengler , vice president, Inv
Read more →BSXBoston Scientific Announces Results For Third Quarter 2021 Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported...
MARLBOROUGH, Mass. , Oct. 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational 1 basis and 10.6 percent on an organic 2 b
Read more →BSXDocument Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc. Acquisition to add new left heart access platforms to electrophysiology and structural heart portfolios
Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc. Acquisition to add new left heart access platforms to electrophysiology and structural heart portfolios MARLBOROUGH, Mass., October 6, 2021 - Boston Scientific Corporation (NYSE BSX) today announced t
Read more →BSXBoston Scientific Eluvia™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a...
LAS VEGAS and MARLBOROUGH, Mass. , Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX ) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVent
Read more →BSXBoston Scientific Announces Agreement to Acquire Baylis Medical Company Inc. Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for...
MARLBOROUGH, Mass. , Oct. 6, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion , subject to closing adjustments. The acquis
Read more →BSXPositive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21 Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical...
LAS VEGAS and MARLBOROUGH, Mass. , Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX ) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) m
Read more →BSXBoston Scientific Announces Positive Late-Breaking Clinical Trial Data for the Ranger™ Drug-Coated Balloon Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial...
LAS VEGAS and MARLBOROUGH, Mass. , Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX ) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in
Read more →BSXBoston Scientific Announces Conference Call Discussing Third Quarter 2021 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
MARLBOROUGH, Mass. , Oct. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2021 on Wednesday, October 27, 2021 at 8:00 a.m. EDT . The
Read more →BSXDocument Boston Scientific Announces Agreement to Acquire Devoro Medical, Inc. Company to add mechanical thrombectomy platform to peripheral interventions portfolio
Boston Scientific Announces Agreement to Acquire Devoro Medical, Inc. Company to add mechanical thrombectomy platform to peripheral interventions portfolio MARLBOROUGH, Mass., September 21, 2021 - Today, Boston Scientific Corporation (NYSE BSX) announced an agreement to acquir
Read more →BSXBoston Scientific Announces Agreement to Acquire Devoro Medical, Inc. Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform....
MARLBOROUGH, Mass. , Sept. 21, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX ) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free WOLF technology targets and rapidl
Read more →BSXLate-Breaking Data Demonstrate Improved Progression-Free Survival in Patients with Metastatic Colorectal Cancer After Treatment with Boston Scientific TheraSphere™ Y-90 Glass Microspheres Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment)...
MARLBOROUGH, Mass. , Sept. 20, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints, including progression-free survival (PFS)
Read more →BSXBoston Scientific Announces 2021 Investor Day Meeting Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth...
MARLBOROUGH, Mass. , Sept. 9, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 22, 2021 , from 8:30 a.m. – 12:30 p.m. EDT . Company
Read more →BSXDocument
BOSTON SCIENTIFIC CLOSES ACQUISITION OF LUMENIS LTD. SURGICAL BUSINESS FROM BARING PRIVATE EQUITY ASIA MARLBOROUGH, Mass., September 1, 2021- Boston Scientific (NYSE BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-he
Read more →BSXBoston Scientific Closes Acquisition Of Lumenis LTD. Surgical Business From Baring Private Equity Asia Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company...
MARLBOROUGH, Mass. , Sept. 1, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, from an affili
Read more →BSXBoston Scientific Receives FDA Clearance for EXALT™ Model B Single-Use Bronchoscope Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use...
MARLBOROUGH, Mass. , Aug. 10, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use Bronchoscope, designed for use in bedside procedures within the intensive care u
Read more →BSXBoston Scientific Initiates Randomized Controlled Trial for the EkoSonic™ Endovascular System Boston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary ...
MARLBOROUGH, Mass. , Aug. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of t
Read more →BSXCMS Grants Additional Reimbursement For EXALT™ Model D Single-Use Duodenoscope Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP)...
MARLBOROUGH, Mass. , Aug. 2, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, applicable to the EXALT™ Model D Single-Use Duodeno
Read more →BSXBoston Scientific Announces Results For Second Quarter 2021 Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported ...
MARLBOROUGH, Mass. , July 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational 1 basis and 52.4 percent on an organic 2
Read more →BSXLate-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX™ Left Atrial Appendage Closure Device Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of...
MARLBOROUGH, Mass. , July 21, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX ) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for
Read more →BSXBoston Scientific Announces Conference Call Discussing Second Quarter 2021 Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
MARLBOROUGH, Mass. , June 29, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2021 on Tuesday, July 27, 2021 at 8:00 a.m. EDT . The call wil
Read more →BSXDocument FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ELECTS DAVID S. WICHMANN TO BOARD OF DIRECTORS Marlborough, Mass. (
BOSTON SCIENTIFIC ELECTS DAVID S. WICHMANN TO BOARD OF DIRECTORS Marlborough, Mass. (June 24, 2021) -- Boston Scientific Corporation (NYSE BSX) announced today the election of David S. Wichmann to its board of directors, effective immediately. Wichmann recently served as chief
Read more →BSXDocument Boston Scientific Exercises Option to Acquire Farapulse, Inc. Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology
Boston Scientific Exercises Option to Acquire Farapulse, Inc. Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology MARLBOROUGH, Mass., June 24, 2021 - Boston Scientific Corporation (NY
Read more →BSXBoston Scientific Elects David S. Wichmann To Board Of Directors Boston Scientific Corporation (NYSE: BSX) announced today the election of David S. Wichmann to its board of directors, effective immediately....
MARLBOROUGH, Mass. , June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced today the election of David S. Wichmann to its board of directors, effective immediately. Wichmann recently served as chief executive officer of UnitedHealth Group from 2017 t
Read more →BSXBoston Scientific Exercises Option to Acquire Farapulse, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition...
MARLBOROUGH, Mass. , June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific electrophysiology portfolio to i
Read more →BSXBoston Scientific erhält CE-Kennzeichnung für EXALT™ Modell B Einwegbronchoskop Die Boston Scientific Corporation (NYSE: BSX) gab heute bekannt, dass sie die CE-Kennzeichnung für das EXALT™ Modell B Einwegbronchoskop...
Unternehmen startet begrenzte Markteinführung in Europa im Juni MARLBOROUGH, Massachusetts , 26. Mai 2021 /PRNewswire/ -- Die Boston Scientific Corporation (NYSE: BSX ) gab heute bekannt, dass sie die CE-Kennzeichnung für das EXALT™ Modell B Einwegbronchoskop abgeschlossen hat,
Read more →BSXBoston Scientific obtient le marquage CE pour le bronchoscope à usage unique EXALT™ Model B Boston Scientific Corporation (NYSE : BSX) a annoncé aujourd'hui avoir obtenu le marquage CE pour le bronchoscope à usage unique EXALT™ Model BB, un...
La société débutera en juin et en Europe la commercialisation de l'appareil destinée à un marché restreint MARLBOROUGH, Massachusetts , 26 mai 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE : BSX ) a annoncé aujourd'hui avoir obtenu le marquage CE pour le bronchoscope
Read more →BSXBoston Scientific conclui a marca CE para broncoscópio de uso único EXALT™ Model B A Boston Scientific Corporation (NYSE: BSX) anunciou hoje que concluiu a marca CE para o broncoscópio de uso único EXALT™ Model B, um dispositivo de...
MARLBOROUGH, Massachusetts , 25 de maio de 2021 /PRNewswire/ -- A Boston Scientific Corporation (NYSE: BSX ) anunciou hoje que concluiu a marca CE para o broncoscópio de uso único EXALT™ Model B, um dispositivo de uso único desenvolvido para procedimentos de beira-leito na unidad
Read more →BSXBoston Scientific completa el marcado CE para el broncoscopio EXALT™ Modelo B de un solo uso Boston Scientific Corporation (NYSE: BSX) anunció hoy que ha completado el marcado CE para el broncoscopio EXALT™ Modelo B de un solo uso, un...
MARLBOROUGH, Massachusetts , 25 de mayo de 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) anunció hoy que ha completado el marcado CE para el broncoscopio EXALT™ Modelo B de un solo uso, un dispositivo de un solo uso diseñado para ejecutar procedimientos a pie de
Read more →BSXBoston Scientific completa la Marca CE para el broncoscopio de un solo uso EXALT™ Model B Boston Scientific Corporation (NYSE: BSX) anunció hoy que ha completado la Marca CE para el broncoscopio de un solo uso EXALT™ Model B, un...
La compañía comienza con el lanzamiento limitado de mercado en Europa en junio MARLBOROUGH, Mass. , 25 de mayo de 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) anunció hoy que ha completado la Marca CE para el broncoscopio de un solo uso EXALT™ Model B, un disp
Read more →BSXBoston Scientific Completes CE Mark for EXALT™ Model B Single-Use Bronchoscope Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use...
Company to begin limited market release in Europe in June MARLBOROUGH, Mass. , May 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedsid
Read more →BSXBoston Scientific to Participate in Bernstein's 37th Annual Strategic Decisions Conference Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Friday, June 4, 2021. Mike...
Mike Mahoney , chairman and chief executive officer, Susie Lisa , vice president, Investor Relations, and Lauren Tengler , director, Investor Relations will participate in a virtual 45-minute question-and-answer session with the host analyst beginning at approximately 8:00 a.m. E
Read more →BSXLate-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including ...
MARLBOROUGH, Mass. , May 18, 2021 /PRNewswire/ -- Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (PVL) and permanent pacemaker implementation (
Read more →BSXBoston Scientific Announces May Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On May 11, 2021, Dan Brennan, executive vice...
MARLBOROUGH, Mass. , ( May 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in two upcoming investor conferences. On May 11, 2021 , Dan Brennan , executive vice president and chief financial officer, and Susie Lisa , vice president, Investor Re
Read more →BSXBoston Scientific Announces Results For First Quarter 2021 Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2...
MARLBOROUGH, Mass. , April 28, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an operational 1 basis and 5.9 percent
Read more →BSXBoston Scientific Announces Conference Call Discussing First Quarter 2021 Results and Participation in Truist Securities 2021 Life Sciences Summit Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ...
MARLBOROUGH, Mass. , March 26, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the first quarter ending March 31, 2021 on Wednesday, April 28, 2021 at 8:00 a.m. EDT . The cal
Read more →BSXLate-Breaking Clinical Trial Data for TheraSphere™ Y-90 Glass Microspheres Demonstrates Improved Survival in Primary Liver Cancer Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a ...
MARLBOROUGH, Mass. , March 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a type of radioembolization comprised of millions of microscopic glass beads co
Read more →BSXBoston Scientific Receives FDA Approval for TheraSphere™ Y-90 Glass Microspheres Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass...
MARLBOROUGH, Mass. , March 18, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carci
Read more →BSXboston scientific ANNOUNCES AGREEMENT TO Acquire LUMENIS LTD. Surgical Business from baring private equity asia Acquisition of a leading laser technology to expand global kidney stone management portfolio
boston scientific ANNOUNCES AGREEMENT TO Acquire LUMENIS LTD. Surgical Business from baring private equity asia Acquisition of a leading laser technology to expand global kidney stone management portfolio MARLBOROUGH, Mass., March 3, 2021- Boston Scientific (NYSE: BSX) today an
Read more →BSXBoston Scientific Announces February and March 2021 Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice...
MARLBOROUGH, Mass. , Feb. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in two upcoming investor conferences. On February 25, 2021 , Dan Brennan , executive vice president and chief financial officer, and Susie Lisa , vice president, Invest
Read more →BSXBoston Scientific Announces Results For Fourth Quarter And Full Year 2020 Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) ...
MARLBOROUGH, Mass. , Feb. 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational 1 basis and (8.0)
Read more →BSXBoston Scientific Receives FDA Approval For The Vercise Genus™ Deep Brain Stimulation System Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep...
MARLBOROUGH, Mass. , Jan. 22, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System. The portfolio, approved for conditional use in
Read more →BSXISSUED BY BOSTON SCIENTIFIC CORPORATION Document BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE PREVENTICE SOLUTIONS, INC. Acquisition of external cardiac monitoring technologies and services provider to
BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE PREVENTICE SOLUTIONS, INC. Acquisition of external cardiac monitoring technologies and services provider to expand rhythm management diagnostics portfolio and capabilities MARLBOROUGH, Mass., January 21, 2021- Boston Scientific
Read more →BSXBoston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In U.S. Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The...
MARLBOROUGH, Mass. , Jan. 14, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has announced a limited market release of the WaveWriter Alpha ™ portfolio of Spinal Cord Stimulator (SCS) systems. The unified portfolio of four MRI conditional, Bluetooth-enabled rechargeable and
Read more →BSXBoston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2020 Boston Scientific Corporation (NYSE: BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion ...
MARLBOROUGH, Mass. , Jan. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This represents a decline of approximately
Read more →BSXBoston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2020 Results Boston Scientific Corporation (NYSE: BSX) will participate in the virtually held 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January...
MARLBOROUGH, Mass. , Jan. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the virtually held 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 . Mike Mahoney , chairman and chief executive officer, will present at 8:
Read more →BSXBoston Scientific Announces Stipulation Of Dismissal Of Nevro Corporation's Patent Infringement Case In California Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO) patent ...
MARLBOROUGH, Mass. , Dec. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO ) patent infringement case against Boston Scientific in the United States District Cou
Read more →BSX, DATED DECEMBER 1, 2020 Document Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business MARLBOROUGH, Mass. (
Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business MARLBOROUGH, Mass. (Dec. 1, 2020) - Boston Scientific Corporation (NYSE BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and
Read more →BSXBoston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and...
MARLBOROUGH, Mass. , Dec. 1, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell
Read more →BSXBoston Scientific to Participate in Evercore ISI 2020 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1. Mike Mahoney,...
MARLBOROUGH, Mass. , Nov. 23, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1 . Mike Mahoney , chairman and chief executive officer, and Susie Lisa , vice president, Investor
Read more →BSXBoston Scientific Announces LOTUS Edge™ Aortic Valve System Voluntary Recall and Product Discontinuation Boston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic ...
MARLBOROUGH, Mass. , Nov. 17, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge ™ Aortic Valve System due to complexities associated with the product delivery system.
Read more →BSXBoston Scientific Announces November 2020 Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On November 12, 2020, Meghan Scanlon, senior ...
MARLBOROUGH, Mass. , Nov. 5, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in two upcoming virtual investor conferences. On November 12, 2020 , Meghan Scanlon , senior vice president and president, Urology and Pelvic Health, and Susie Lisa , vi
Read more →BSXBoston Scientific Receives FDA Approval for the Ranger™ Drug-Coated Balloon Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon,...
MARLBOROUGH, Mass. , Nov. 2, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the supe
Read more →BSXBoston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke Boston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left...
MARLBOROUGH, Mass. , Oct. 29, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within a broad population of patients wi
Read more →BSXBoston Scientific Announces Results For Third Quarter 2020 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1.8)...
MARLBOROUGH, Mass. , Oct. 28, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1.8) percent on a reported basis, (2.5) percent on an operational 1 basis and (5.7) perc
Read more →BSXBoston Scientific Announces Transcatheter Cardiovascular Therapeutics 2020 Investor Update and Conference Call Discussing Third Quarter 2020 Results Boston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) on...
MARLBOROUGH, Mass. , Oct. 1, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) on Thursday, October 15 from 1:00 – 2:00 p.m. EDT . Joe Fitzgerald , executive vice pre
Read more →BSXBoston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In Europe Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The...
MARLBOROUGH, Mass. , Sept. 30, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditional i , Bluetooth-enabled implantable p
Read more →BSXBoston Scientific Launches ACURATE neo2™ Aortic Valve System in Europe Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe....
MARLBOROUGH, Mass. , Sept. 28, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has initiated a controlled launch of the ACURATE neo2 ™ Aortic Valve System in Europe . This next-generation transcatheter aortic valve implantation (TAVI) technology
Read more →BSXBoston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc.,...
MARLBOROUGH, Mass. , Sept. 21, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation (PFA) system for t
Read more →BSXBoston Scientific Launches Vercise Genus™ DBS System In Europe Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise...
MARLBOROUGH, Mass. , Sept. 9, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe . Featuring full-body MRI c
Read more →BSXCMS Grants Additional Reimbursement For The Eluvia™ Drug-Eluting Vascular Stent System Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) ...
MARLBOROUGH, Mass. , Sept. 3, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the Eluvia™ Drug-Eluting Vascular Stent System as part of the 2021 Inpatie
Read more →BSXBoston Scientific Announces September 2020 Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On September 9, 2020, Mike Mahoney, chairman ...
MARLBOROUGH, Mass. , Aug. 26, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in two upcoming virtual investor conferences. On September 9, 2020 , Mike Mahoney , chairman and chief executive officer, and Susie Lisa , vice president, Investor Rela
Read more →BSXBoston Scientific Announces Results For Second Quarter 2020 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.003 billion during the second quarter of 2020. This represents a decline of (23.9)...
MARLBOROUGH, Mass. , July 29, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.003 billion during the second quarter of 2020. This represents a decline of (23.9) percent on a reported basis, (23.1) percent on an operational 1 basis and (28.7)
Read more →BSXBoston Scientific Receives FDA Approval for Next-Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left...
MARLBOROUGH, Mass. , July 21, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX ™ Left Atrial Appendage Closure (LAAC) Device. Experience the interactive Multichannel Ne
Read more →BSXBoston Scientific Announces Conference Call Discussing Second Quarter 2020 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
MARLBOROUGH, Mass. , June 30, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2020 on Wednesday, July 29, 2020 at 8:00 a.m. EDT . The call w
Read more →BSXBoston Scientific Receives FDA 510(k) Clearance for the LUX-Dx™ Insertable Cardiac Monitor System Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx™ Insertable Cardiac Monitor (ICM)...
MARLBOROUGH, Mass. , June 29, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a new, long-term diagnostic device implanted in patients to detect arrh
Read more →BSXBoston Scientific Receives Medicare Transitional Pass-Through Payment for the EXALT™ Model D Single-Use Duodenoscope Boston Scientific (NYSE: BSX) today announced that the Centers for Medicare & Medicaid Services (CMS) has approved its application for a transitional ...
MARLBOROUGH, Mass. , June 8, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced that the Centers for Medicare & Medicaid Services (CMS) has approved its application for a transitional pass-through (TPT) payment category to describe single-use endoscopes, includin
Read more →BSXBoston Scientific Launches DIRECTSENSE™ Technology Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF)...
MARLBOROUGH, Mass. , June 1, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation procedures. Available on the RHYTHMIA HDx™ Ma
Read more →BSXBoston Scientific Completes Approximately $2.0 Billion Aggregate Offerings of Common Stock and Mandatory Convertible Preferred Stock Boston Scientific Corporation (NYSE: BSX) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the...
MARLBOROUGH, Mass. , May 27, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 3,832,500 additi
Read more →BSXBoston Scientific to Participate in Jefferies 2020 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2020 Virtual Healthcare Conference on June 2. Joe Fitzgerald,...
MARLBOROUGH, Mass. , May 26, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Jefferies 2020 Virtual Healthcare Conference on June 2 . Joe Fitzgerald , executive vice president and president, Rhythm Management; Kenneth Stein , M.
Read more →BSXBoston Scientific Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock Boston Scientific Corporation (NYSE: BSX) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock ( Common Stock ) at...
MARLBOROUGH, Mass. , May 21, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock ("Common Stock") at a price to the public of $34.25 per share and 8,750,000 shares of its 5.50% Mand
Read more →BSXBoston Scientific Announces Offerings of Common Stock and Mandatory Convertible Preferred Stock Boston Scientific Corporation (NYSE: BSX) announced that it has commenced concurrent offerings of $750.0 million of shares of its common stock...
MARLBOROUGH, Mass. , May 20, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced that it has commenced concurrent offerings of $750.0 million of shares of its common stock ("Common Stock") and $750.0 million of shares of its Series A Mandatory Convertible Pr
Read more →BSXBoston Scientific Completes $1.7 Billion Offering of Senior Notes Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.7 billion aggregate principal amount of its senior notes. The public...
MARLBOROUGH, Mass. , May 18, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed a public offering of $1.7 billion aggregate principal amount of its senior notes. The public offering consists of $500.0 million of 1.900% notes due 2025 and $1.2 billion of 2.6
Read more →BSXBoston Scientific Prices $1.7 Billion of Senior Notes Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes...
MARLBOROUGH, Mass. , May 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company's shelf registration statement. The public offering consists of
Read more →BSXLate-Breaking Clinical Trial Data Underscore Safety And Efficacy Of Boston Scientific S-ICD System Boston Scientific (NYSE: BSX) today announced the final results from the UNTOUCHED study of the EMBLEM™ Subcutaneous Implantable Defibrillator...
MARLBOROUGH, Mass. , May 8, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced the final results from the UNTOUCHED study of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System presented at HRS 2020 SCIENCE, an online series from the Heart Rhythm So
Read more →BSXPINNACLE FLX Study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device Presented as Late-Breaking Clinical Trial at HRS 2020 SCIENCE Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of...
MARLBOROUGH, Mass. , May 8, 2020 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX ) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for p
Read more →BSXBoston Scientific Announces May 2020 Virtual Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming virtual investor conferences. On May 13, 2020, Dan Brennan, executive...
MARLBOROUGH, Mass. , May 6, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in three upcoming virtual investor conferences. On May 13, 2020 , Dan Brennan , executive vice president and chief financial officer, and Susie Lisa , vice president, Inv
Read more →BSXBoston Scientific Announces Results For First Quarter 2020 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.543 billion during the first quarter of 2020. This represents growth of 2.0 percent...
MARLBOROUGH, Mass. , April 29, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.543 billion during the first quarter of 2020. This represents growth of 2.0 percent on a reported basis, 3.2 percent on an operational 1 basis and a decline of 2.9
Read more →BSXNew Renewable Energy Agreements To Reduce Boston Scientific Carbon Footprint By Half Boston Scientific Corporation (NYSE: BSX) has signed a virtual power purchase agreement (VPPA) that represents the largest step the company has taken ...
MARLBOROUGH, Mass. , April 21, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has signed a virtual power purchase agreement (VPPA) that represents the largest step the company has taken to achieve its goal of global carbon neutral manufacturing and distribution b
Read more →BSXBoston Scientific Announces 2020 Annual Meeting of Stockholders Will Be Conducted in Virtual Format Boston Scientific Corporation (NYSE: BSX) today announced that its Annual Meeting of Stockholders (the Annual Meeting ) will be held exclusively in...
MARLBOROUGH, Mass. , April 10, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held exclusively in a virtual meeting format at the previously announced date and time of May 7, 2
Read more →BSXBoston Scientific Provides Update on COVID-19 Impact and Response Efforts The COVID-19 pandemic has brought unprecedented challenges upon the global community and the many healthcare providers who are caring for patients....
MARLBOROUGH, Mass. , April 2, 2020 /PRNewswire/ -- The COVID-19 pandemic has brought unprecedented challenges upon the global community and the many healthcare providers who are caring for patients. During this time of concern and disruption, Boston Scientific Corporation (NYSE:
Read more →BSXBoston Scientific Announces February and March 2020 Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming investor conferences. On February 27, 2020, Susie Lisa, vice president,...
MARLBOROUGH, Mass. , Feb 18, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in three upcoming investor conferences. On February 27, 2020 , Susie Lisa , vice president, Investor Relations, will participate in a 25-minute question-and-answer sessi
Read more →BSXBoston Scientific Announces Results For Fourth Quarter And Full Year 2019 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent ...
MARLBOROUGH, Mass. , Feb. 5, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an operational 1 basis and 7.3 percent on
Read more →BSXBoston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2019 Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion...
MARLBOROUGH, Mass. , Jan. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents growth of approximately 13.4 pe
Read more →BSXBoston Scientific Announces January Conference Schedule and Conference Call Discussing Fourth Quarter 2019 Results Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San...
MARLBOROUGH, Mass. , Jan. 2, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California . Mike Mahoney , chairman and chief executive officer, will
Read more →BSXBoston Scientific Receives FDA Clearance For World's First Single-Use Duodenoscope, EXALT™ Model D Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use...
MARLBOROUGH, Mass. , Dec. 13, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde cholangiopancreatography (ERCP) pr
Read more →BSXBoston Scientific to Participate in Evercore ISI and Piper Jaffray Healthcare Conferences Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two investor conferences this December. On Wednesday, December 4, 2019,...
MARLBOROUGH, Mass. , Nov. 21, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in two investor conferences this December. On Wednesday, December 4, 2019 , Susie Lisa , vice president, Investor Relations, and Lauren Tengler , director, I
Read more →BSXBoston Scientific Completes €900 million Offering of Senior Notes and $1.0 billion Tender Offer Boston Scientific Corporation (NYSE: BSX) (the Company ) completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior...
MARLBOROUGH, Mass. , Nov. 12, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) (the "Company") completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027 (the "Notes"). The Company has applied to list the Notes on the N
Read more →BSXBoston Scientific Prices €900,000,000 of Senior Notes Boston Scientific Corporation (the Company ) (NYSE: BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of...
MARLBOROUGH, Mass. , Nov. 6, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX ) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's shelf registration statement. The
Read more →BSXBoston Scientific Announces Early Results of Its Cash Tender Offer for up to $1.0 Billion of Its Outstanding Debt Securities Boston Scientific Corporation (the Company ) (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the Tender...
MARLBOROUGH, Mass. , Nov. 5, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX ) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maximum
Read more →BSXBoston Scientific Announces Positive Data for the Ranger™ Drug-Coated Balloon and the Eluvia™ Drug-Eluting Vascular Stent at VIVA19 Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate...
LAS VEGAS and MARLBOROUGH, Mass. , Nov. 5, 2019 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX ) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at Vascular InterVentional
Read more →BSXBoston Scientific Announces Pricing Terms of Its Cash Tender Offer for up to $1.0 Billion of Its Outstanding Debt Securities Boston Scientific Corporation (the Company ) (NYSE:BSX) today announced the pricing terms of the previously announced cash tender offer (the Tender ...
MARLBOROUGH, Mass. , Nov. 5, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX ) today announced the pricing terms of the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maxi
Read more →BSXBoston Scientific Announces November 2019 Conference Schedule Boston Scientific Corporation (NYSE: BSX) will participate in four conferences, including one industry conference and three investor conferences,...
MARLBOROUGH, Mass. , Nov. 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in four conferences, including one industry conference and three investor conferences, this month. On November 5, 2019 , Jeff Mirviss , senior vice president and preside
Read more →BSXBoston Scientific Announces Results For Third Quarter 2019 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.707 billion during the third quarter of 2019. This represents growth of 13.1 percent...
MARLBOROUGH, Mass. , Oct. 23, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.707 billion during the third quarter of 2019. This represents growth of 13.1 percent on a reported basis, 14.2 percent on an operational 1 basis and 9.3 percent on
Read more →BSXBoston Scientific Announces Cash Tender Offer for Up To $1.0 Billion of Its Outstanding Debt Securities Boston Scientific Corporation (the Company ) (NYSE: BSX) today announced the commencement of a cash tender offer (the Tender Offer ) for up to $1.0 ...
MARLBOROUGH, Mass. , Oct. 22, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX ) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maximum Principal Amount")
Read more →BSXBoston Scientific Announces Conference Call Discussing Third Quarter 2019 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
MARLBOROUGH, Mass. , Oct. 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2019 on Wednesday, October 23, 2019 at 8:00 a.m. EDT . The
Read more →BSXBoston Scientific Announces Positive Data from the EVOLVE Short DAPT study with the SYNERGY™ Bioabsorbable Polymer Stent Boston Scientific (NYSE: BSX) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated ...
SAN FRANCISCO and MARLBOROUGH, Mass. , Sept. 26, 2019 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the U.S. to examine the safety of a shortened duration o
Read more →BSXBoston Scientific Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2019 Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 31st Transcatheter Cardiovascular Therapeutics...
MARLBOROUGH, Mass. , Sept. 18, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced key data that will be presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, i
Read more →BSXBoston Scientific to Participate in the 2019 Wells Fargo Securities Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2019 Wells Fargo Securities Healthcare Conference on Thursday, September ...
MARLBOROUGH, Mass. , Aug. 20, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2019 Wells Fargo Securities Healthcare Conference on Thursday, September 5, 2019 in Boston . Mike Mahoney , chairman and chief executive officer, and
Read more →BSXBoston Scientific Announces FDA Approval Of ImageReady™ MRI For Vercise Gevia™ Deep Brain Stimulation System Boston Scientific Corporation (NYSE:BSX) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the...
MARLBOROUGH, Mass. , Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the Vercise Gevia ™ Deep Brain Stimulation (DBS) System to be used in a full-body magne
Read more →BSXBoston Scientific Closes Acquisition of BTG plc. Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously...
MARLBOROUGH, Mass. , Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in mini
Read more →BSXBoston Scientific to Participate in 39th Annual Canaccord Genuity Growth Conference Boston Scientific Corporation (NYSE: BSX) will participate in the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019 in...
MARLBOROUGH, Mass. , July 25, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 39 th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019 in Boston . Susie Lisa , vice president, Investor Relations, and Lauren Tengler , di
Read more →BSXBoston Scientific Announces Results For Second Quarter 2019 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.631 billion during the second quarter of 2019. This represents growth of 5.6 percent...
MARLBOROUGH, Mass. , July 24, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.631 billion during the second quarter of 2019. This represents growth of 5.6 percent on a reported basis, 8.0 percent on an operational 1 basis and 6.3 percent on a
Read more →BSXBoston Scientific Announces Conference Call Discussing Second Quarter 2019 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
MARLBOROUGH, Mass. , July 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2019 on Wednesday, July 24, 2019 at 8:00 a.m. EDT . The call wi
Read more →BSXBoston Scientific Presents Strategies for Sustained Long-Range Growth Targets at 2019 Investor Day Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to review its business and...
MARLBOROUGH, Mass. , June 26, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is hosting a meeting with the investment community today in New York City to review its business and long-term growth strategies. The company is presenting plans for its product pipeline
Read more →BSXBoston Scientific Closes Acquisition Of Vertiflex, Inc. Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Vertiflex, Inc., a privately-held company that developed...
MARLBOROUGH, Mass. , June 11, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the close of its acquisition of Vertiflex, Inc., a privately-held company that developed and commercialized the Superion ® Indirect Decompression System, a minimally-inva
Read more →BSXBoston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™...
MARLBOROUGH, Mass. , May 22, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX ™ left atrial appendage closure (LAAC) platform to first-line oral anticoagulants (O
Read more →BSXBoston Scientific to Participate in Bernstein's 35th Annual Strategic Decisions Conference Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019 in...
Mike Mahoney , chairman and chief executive officer, and Susie Lisa , vice president, Investor Relations, will participate in a 50-minute question-and-answer session with the host analyst beginning at approximately 8:00 a.m. EDT . A live webcast of the question-and-answer session
Read more →BSXBoston Scientific to Participate in the 2019 UBS Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City....
MARLBOROUGH, Mass. , May 7, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City . Art Butcher , senior vice president and president, Endoscopy, Dr. Brian Dunkin ,
Read more →BSXBoston Scientific Announces Scheduled Presentations at Heart Rhythm 2019 Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual ...
MARLBOROUGH, Mass. , May 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San Francisco on May 8-11 . Safety and eff
Read more →BSXBoston Scientific Announces Results For First Quarter 2019 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.493 billion during the first quarter of 2019. This represents growth of 4.8 percent...
MARLBOROUGH, Mass. , April 24, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.493 billion during the first quarter of 2019. This represents growth of 4.8 percent on a reported basis, 7.8 percent on an operational 1 basis and 6.3 percent on a
Read more →BSXBoston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge™ Aortic ...
MARLBOROUGH, Mass. , April 23, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge ™ Aortic Valve System. Delivered via a minimally-invasive procedure, this transcathet
Read more →BSXBoston Scientific Announces Conference Call Discussing First Quarter 2019 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ...
MARLBOROUGH, Mass. , March 27, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2019 on Wednesday, April 24, 2019 at 8:00 a.m. EDT . The call
Read more →BSXLate-breaking Clinical Trial Highlights Positive Safety and Efficacy Data for the LUMINIZE™ RF Balloon Catheter Boston Scientific Corporation (NYSE: BSX) announced data from the AF-FICIENT I study during a late-breaking clinical trial session today at EHRA...
LISBON, Portugal and MARLBOROUGH, Mass. , March 17, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced data from the AF-FICIENT I study during a late-breaking clinical trial session today at EHRA 2019, the annual congress of the European Heart Rhythm Associ
Read more →BSXBoston Scientific Receives CE Mark for Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN...
MARLBOROUGH, Mass. , March 13, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX ™ Left Atrial Appendage Closure (LAAC) Device in Europe . Patients with AF
Read more →BSXBoston Scientific annonce les données programmées au cours du congrès de l'EHRA 2019 Boston Scientific Corporation (NYSE : BSX) a annoncé ce jour que des données clés seront présentées à Lisbonne (Portugal), du 17 au 19 mars, lors de...
MARLBOROUGH, Massachusetts , 12 mars 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE : BSX ) a annoncé ce jour que des données clés seront présentées à Lisbonne ( Portugal ), du 17 au 19 mars, lors de l'EHRA 2019, le congrès annuel de l'Association européenne du rythme c
Read more →BSXBoston Scientific veröffentlicht geplante Daten auf dem Kongress EHRA 2019 Die Boston Scientific Corporation (NYSE: BSX) gab heute Eckdaten bekannt, die auf der EHRA 2019, dem Jahreskongress der European Heart Rhythm...
MARLBOROUGH, Massachusetts , 12. März 2019 /PRNewswire/ -- Die Boston Scientific Corporation (NYSE: BSX ) gab heute Eckdaten bekannt, die auf der EHRA 2019, dem Jahreskongress der European Heart Rhythm Association (EHRA) in Lissabon, Portugal , vom 17. bis 19. März vorgestellt we
Read more →BSXBoston Scientific anuncia datos previstos en el congreso EHRA 2019 Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy los datos clave que figurarán en el EHRA 2019, el congreso anual de la Asociación Europea...
MARLBOROUGH, Massachusetts , 12 de marzo de 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy los datos clave que figurarán en el EHRA 2019, el congreso anual de la Asociación Europea del Ritmo Cardíaco (EHRA, por sus siglas en inglés), que tendrá l
Read more →BSXBoston Scientific Announces Scheduled Data at EHRA 2019 Congress Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart...
MARLBOROUGH, Mass. , March 11, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal , on March 17-19 . Two late-breakin
Read more →BSXBoston Scientific to Participate in the Cowen and Company 39th Annual Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 in ...
MARLBOROUGH, Mass. , Feb. 27, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Cowen and Company 39 th Annual Healthcare Conference on Wednesday, March 13, 2019 in Boston . Dan Brennan , executive vice president and chief financial officer,
Read more →BSXBoston Scientific Completes $4.3 Billion Offering of Senior Notes and Issues Redemption Notice for its 2020 Notes Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public...
MARLBOROUGH, Mass. , Feb. 25, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes due 2024, $850 million of 3.750%
Read more →BSXBoston Scientific Prices $4.3 Billion of Senior Notes Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes...
MARLBOROUGH, Mass. , Feb. 21, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes under the Company's shelf registration statement. The public offering consists o
Read more →BSXBoston Scientific to Participate in the 8th Annual SVB Leerink Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019...
MARLBOROUGH, Mass. , Feb. 14, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 in New York City . Joe Fitzgerald , executive vice president and president, R
Read more →BSXBoston Scientific Announces Results For Fourth Quarter And Full Year 2018 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.561 billion during the fourth quarter of 2018. This represents growth of 6.3 percent...
MARLBOROUGH, Mass. , Feb. 6, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.561 billion during the fourth quarter of 2018. This represents growth of 6.3 percent on a reported basis, 8.2 percent on an operational 1 basis and 7.0 percent on an
Read more →BSXBoston Scientific presenta en Europa el sistema Spectra WaveWriter™ de estimulación de la médula espinal Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy la presentación en Europa del sistema Spectra WaveWriter™ de estimulación de la médula...
El sistema permite ofrecer diversas terapias no farmacológicas para personas aquejadas de dolor crónico PARÍS, 1 de febrero de 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy la presentación en Europa del sistema Spectra WaveWriter™ de estimulaci
Read more →BSXBoston Scientific lanciert Rückenmarksstimulator-System Spectra WaveWriter™ in Europa Boston Scientific Corporation (NYSE: BSX) gab heute die Lancierung des Rückenmarksstimulator-Systems (SCS) Spectra WaveWriter™ in Europa bekannt. Das ...
Das System bietet mehrere nichtmedikamentöse Therapien für Menschen mit chronischen Schmerzen PARIS , 1. Februar 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) gab heute die Lancierung des Rückenmarksstimulator-Systems (SCS) Spectra WaveWriter™ in Europa bekannt
Read more →BSXBoston Scientific lance le système de stimulation de la moelle épinière Spectra WaveWriter™ en Europe Aujourd'hui, Boston Scientific Corporation (NYSE : BSX) a annoncé le lancement de son système de stimulation de la moelle épinière (Spinal Cord...
Ce système propose de multiples traitements non médicamenteux pour les personnes souffrant de douleur chronique PARIS , 1er février 2019 /PRNewswire/ -- Aujourd'hui, Boston Scientific Corporation (NYSE : BSX ) a annoncé le lancement de son système de stimulation de la moelle épi
Read more →BSXNew Four-Year Data Demonstrate Rezūm™ Water Vapor Therapy Offers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms Boston Scientific Corporation (NYSE: BSX) today announced that data from a randomized clinical trial demonstrate that Rezūm™ Water Vapor Therapy, a...
MARLBOROUGH, Mass. , Jan. 25, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that data from a randomized clinical trial demonstrate that Rezūm ™ Water Vapor Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH), provides d
Read more →BSXBoston Scientific Launches Vercise™ Primary Cell And Vercise Gevia™ Deep Brain Stimulation Systems With Directional Leads Boston Scientific Corporation (NYSE: BSX) has launched the Vercise™ Primary Cell (PC) and Vercise Gevia™ Deep Brain Stimulation (DBS) Systems...
MARLBOROUGH, Mass. , Jan. 24, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has launched the Vercise ™ Primary Cell (PC) and Vercise Gevia ™ Deep Brain Stimulation (DBS) Systems featuring the Vercise Cartesia ™ Directional Lead. The new systems, which were recen
Read more →BSXBoston Scientific Announces Preliminary Unaudited Sales for the Fourth Quarter and Full Year 2018 Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.56 billion...
MARLBOROUGH, Mass. , Jan. 8, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales, based upon preliminary unaudited financial information, of approximately $2.56 billion during the fourth quarter of 2018. This represents growth of approximately 6.3 perc
Read more →BSXBoston Scientific Announces Conference Call Discussing Fourth Quarter 2018 Financial Results And Investor Update At NANS 2019 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth...
MARLBOROUGH, Mass. , Jan. 4, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2018 on Wednesday, February 6, 2019 at 8:00 a.m. EST . The
Read more →BSXBoston Scientific Exercises Option to Acquire Millipede, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held ...
MARLBOROUGH, Mass. , Dec. 27, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held company in Santa Rosa, Calif. , upon its recent successful completion of a fir
Read more →BSXBoston Scientific to Participate in 37th Annual J.P. Morgan Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 in San...
MARLBOROUGH, Mass. , Dec. 21, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 in San Francisco, California . Mike Mahoney , chairman and chief executive officer, wi
Read more →BSXBoston Scientific Prevails in U.S. Edwards Lifesciences Litigation Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the United States (U.S.) District Court for the District of Delaware...
MARLBOROUGH, Mass. , Dec. 11, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that a jury in the United States (U.S.) District Court for the District of Delaware determined that the Boston Scientific U.S. patent 8,992,608 is valid and that Edwards
Read more →BSXBoston Scientific to Participate in 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference on...
MARLBOROUGH, Mass. , Dec. 3, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 in New York City . Susie Lisa , vice president, Investor
Read more →BSXBoston Scientific to Participate in Citi's 2018 Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York City....
MARLBOROUGH, Mass. , Nov. 27, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in Citi's 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York City . Art Butcher , senior vice president and president, Endoscopy and Susie Lisa
Read more →BSXBoston Scientific to Participate in the 30th Annual Piper Jaffray Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the 30th Annual Piper Jaffray Healthcare Conference on Thursday, November 29, 2018 in...
MARLBOROUGH, Mass. , Nov. 21, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 30 th Annual Piper Jaffray Healthcare Conference on Thursday, November 29, 2018 in New York City . Jeff Mirviss , senior vice president and president, Peripheral
Read more →BSXBoston Scientific Announces Recommended Offer to Acquire BTG plc. Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a...
MARLBOROUGH, Mass. , Nov. 20, 2018 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom , which develops and commercializes prod
Read more →BSXBoston Scientific to Participate in 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday,...
MARLBOROUGH, Mass. , Nov. 7, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 in New York City . David Pierce , executive vice president and pres
Read more →BSXBoston Scientific to Participate in Stifel 2018 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 in New York City....
MARLBOROUGH, Mass. , Nov. 6, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 in New York City . Dan Brennan , executive vice president and chief financial officer and Susie Li
Read more →BSXBoston Scientific to Participate in 27th Annual Credit Suisse Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the 27th Annual Credit Suisse Healthcare Conference on Wednesday, November 14, 2018 in...
MARLBOROUGH, Mass. , Nov. 6, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 27 th Annual Credit Suisse Healthcare Conference on Wednesday, November 14, 2018 in Scottsdale, Arizona . Joe Fitzgerald , executive vice president and president,
Read more →BSXBoston Scientific Announces Results For Third Quarter 2018 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.393 billion during the third quarter ended September 30, 2018. This represents growth ...
MARLBOROUGH, Mass. , Oct. 24, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.393 billion during the third quarter ended September 30, 2018. This represents growth of 7.7 percent on a reported basis, 9.1 percent on an operational 1 basis and
Read more →BSXBoston Scientific Prevails in German Edwards Lifesciences Litigation Boston Scientific Corporation (NYSE: BSX) today announced the District Court of Dusseldorf, Germany has determined that Edwards Lifesciences...
In 2017, Edwards' currently-available Sapien 3 ™ device was found to infringe two Boston Scientific patents (EP 2 749 254 B1 and EP 2 926 766 B1) by the same Court. Those rulings, which have been appealed by Edwards, enable Boston Scientific to enjoin Sapien 3 from the German mar
Read more →BSXBoston Scientific Closes Acquisition of Augmenix, Inc. Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Augmenix, Inc., a privately-held company that developed and ...
MARLBOROUGH, Mass. , Oct. 16, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the close of its acquisition of Augmenix, Inc., a privately-held company that developed and commercialized the SpaceOAR ® Hydrogel System to help reduce common and debili
Read more →BSXBoston Scientific Announces Conference Call Discussing Third Quarter 2018 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
MARLBOROUGH, Mass. , Oct. 1, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2018 on Wednesday, October 24, 2018 at 8:00 a.m. EDT . The
Read more →BSXBoston Scientific Receives U.S. FDA Approval for the Eluvia™ Drug-Eluting Vascular Stent System Today, Boston Scientific (NYSE: BSX) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application ...
MARLBOROUGH, Mass. , Sept. 24, 2018 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX ) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia ™ Drug-Eluting Vascular Stent System, specifically devel
Read more →BSXBoston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial Today, Boston Scientific (NYSE: BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the ...
SAN DIEGO and MARLBOROUGH, Mass. , Sept. 22, 2018 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX ) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were presented during
Read more →BSXBoston Scientific Launches LithoVue Empower™ Retrieval Deployment Device Boston Scientific Corporation (NYSE: BSX) today announced the global launch of the LithoVue Empower™ Retrieval Deployment Device, designed to be used ...
MARLBOROUGH, Mass. , Sept. 21, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the global launch of the LithoVue Empower™ Retrieval Deployment Device, designed to be used with the LithoVue™ Single-Use Digital Flexible Ureteroscope and compatible ni
Read more →BSXBoston Scientific Announces Scheduled Presentations At Transcatheter Cardiovascular Therapeutics 2018 Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics...
MARLBOROUGH, Mass. , Sept. 17, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, i
Read more →BSXBoston Scientific Announces Agreement To Acquire Augmenix, Inc. Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company...
MARLBOROUGH, Mass. , Sept. 6, 2018 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the SpaceOAR ® System, a therapy used to re
Read more →BSXBoston Scientific to Participate in Morgan Stanley Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13,...
MARLBOROUGH, Mass. , Sept. 6, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Morgan Stanley 16 th Annual Global Healthcare Conference on Thursday, September 13, 2018 in New York City . Mike Mahoney , chairman and chief executive officer,
Read more →BSXBoston Scientific to Participate in 13th Annual Wells Fargo Securities Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 13th Annual Wells Fargo Securities Healthcare Conference on Wednesday,...
MARLBOROUGH, Mass. , Aug. 29, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 13 th Annual Wells Fargo Securities Healthcare Conference on Wednesday, September 5, 2018 in Boston . Susie Lisa , vice president, Investor Relations,
Read more →BSXBoston Scientific Announces Agreement to Acquire VENITI, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire VENITI, Inc., a privately-held company in Fremont,...
MARLBOROUGH, Mass. , Aug. 8, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has signed an agreement to acquire VENITI, Inc., a privately-held company in Fremont, California which has developed and commercialized the VICI VENOUS STENT ® System f
Read more →BSXBoston Scientific Closes Acquisition of Claret Medical, Inc., Announces Positive Reimbursement Decision Boston Scientific Corporation (NYSE: BSX) announced it has recently closed its acquisition of Claret Medical, Inc., a privately-held company that has ...
MARLBOROUGH, Mass. , Aug. 2, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced it has recently closed its acquisition of Claret Medical, Inc., a privately-held company that has developed and commercialized the Sentinel ® Cerebral Embolic Protection System,
Read more →BSXBoston Scientific to Participate in 38th Annual Canaccord Genuity Growth Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8,...
MARLBOROUGH, Mass. , July 30, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018 in Boston . Susie Lisa , vice president, Investor Relations, and Lindsay
Read more →BSXBoston Scientific Announces Results For Second Quarter 2018 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.490 billion during the second quarter ended June 30, 2018. This represents growth of...
MARLBOROUGH, Mass. , July 25, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.490 billion during the second quarter ended June 30, 2018. This represents growth of 10.3 percent on a reported basis, 8.6 percent on an operational 1 basis and 7.9
Read more →BSXBoston Scientific Corporation Recommends Stockholders Reject 'Mini-Tender' Offer by TRC Capital Corporation Boston Scientific Corporation (NYSE: BSX) has been notified of an unsolicited mini-tender offer by TRC Capital Corporation (TRC) to purchase up to...
MARLBOROUGH, Mass. , July 24, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to three million shares of Boston Scientific's common stock, constituting approxim
Read more →BSXBoston Scientific Announces Agreement to Acquire Claret Medical, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire Claret Medical, Inc., a privately-held company that...
MARLBOROUGH, Mass. , July 20, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has signed an agreement to acquire Claret Medical, Inc., a privately-held company that has developed and commercialized the Sentinel ® Cerebral Embolic Protection Syst
Read more →BSXBoston Scientific to Acquire Cryterion Medical, Inc. Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Cryterion Medical, Inc., a privately-held company...
MARLBOROUGH, Mass. , July 5, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced a definitive agreement to acquire Cryterion Medical, Inc., a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation
Read more →BSXBoston Scientific Announces Conference Call Discussing Second Quarter 2018 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
MARLBOROUGH, Mass. , July 2, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2018 on Wednesday, July 25, 2018 at 8:00 a.m. EDT . The call wi
Read more →BSXBoston Scientific Announces Scheduled Presentations At Digestive Disease Week 2018 Boston Scientific (NYSE: BSX) today announced key data that will be presented at Digestive Disease Week (DDW) being held in Washington D.C., June 2...
MARLBOROUGH, Mass. , June 1, 2018 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced key data that will be presented at Digestive Disease Week (DDW) being held in Washington D.C. , June 2 to June 5 . The annual meeting is the largest gathering of medical professionals
Read more →BSXBoston Scientific lance HeartLogic™*, un outil de diagnostic de l'insuffisance cardiaque, en Europe Boston Scientific Europe a annoncé aujourd'hui le lancement de « HeartLogic™ Heart Failure Diagnostic », outil de diagnostic de l'insuffisance...
Le diagnostic HeartLogic™ est le premier et le seul outil de diagnostic de l'insuffisance cardiaque qui a fait ses preuves pour détecter 70 % des épisodes d'insuffisance cardiaque plusieurs semaines à l'avance, réduisant potentiellement l'hospitalisation des patients atteints d'i
Read more →BSXBoston Scientific präsentiert das Herzinsuffizienz-Diagnosetool HeartLogic™* in Europa Boston Scientific Europe gab heute die Einführung des Herzinsuffizienz-Diagnosetools HeartLogic™ in Europa bekannt. Mit dieser Markteinführung steht...
HeartLogic ™ ist das erste und einzige Herzinsuffizienz-Diagnosetool, das nachweislich 70 % der Herzinsuffizienzereignisse mehrere Wochen im Voraus erkennt und so die weitere Einweisung von Patienten mit Herzinsuffizienz ins Krankenhaus reduzieren kann WIEN , 29. Mai 2018 /PRNew
Read more →BSXBoston Scientific presenta HeartLogic™* para el diagnóstico de insuficiencia cardiaca en Europa Boston Scientific Europe anunció hoy el lanzamiento de HeartLogic™ para el diagnóstico de insuficiencia cardiaca en Europa. Con el lanzamiento, la...
HeartLogic™ Diagnostic es la primera y única herramienta de diagnóstico de insuficiencia cardiaca que detecta hasta el 70 % de acontecimientos de insuficiencia cardiaca con varias semanas de antelación, lo que podría reducir, potencialmente, la hospitalización de los pacientes co
Read more →BSXBoston Scientific Announces Schedule of Presentations at EuroPCR 2018 Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will...
MARLBOROUGH, Mass. , May 16, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris , on May 22-25 .
Read more →BSXBoston Scientific To Participate In 34th Annual Strategic decisions Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 34th Annual Strategic Decisions Conference on May 31, 2018 in New York....
Mike Mahoney , chairman and chief executive officer, will participate in a 50-minute presentation and question-and-answer session with the host analyst beginning at approximately 8:00 a.m. EDT . A live webcast of the presentation and question-and-answer session will be available
Read more →BSXBoston Scientific To Participate In Bank of America Merrill Lynch 2018 Health Care Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2018 Health Care Conference on May 16,...
MARLBOROUGH, Mass. , May 7, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Bank of America Merrill Lynch 2018 Health Care Conference on May 16, 2018 in Las Vegas . Dan Brennan , executive vice president and chief financial offi
Read more →BSXBoston Scientific Closes NxThera Acquisition Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of NxThera. The company developed the Rezūm® system, a...
MARLBOROUGH, Mass. , April 30, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the close of its acquisition of NxThera. The company developed the Rezūm ® system, a minimally invasive therapy ( MIT ) for patients with symptomatic benign prostatic hy
Read more →BSXBoston Scientific Announces Results For First Quarter 2018 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.379 billion during the first quarter ended March 31, 2018. This represents growth of...
MARLBOROUGH, Mass. , April 25, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.379 billion during the first quarter ended March 31, 2018. This represents growth of 10.1 percent on a reported basis, 6.2 percent on an operational 1 basis and 5.
Read more →BSXBoston Scientific Announces Positive Late-Breaking Data From The INTREPID Study Boston Scientific Corporation (NYSE: BSX) today announced one-year data from the INTREPID study, the first and only prospective, double-blind,...
MARLBOROUGH, Mass. , April 24, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized, sham-controlled, multi-center study of deep brain stimulation (DBS) for
Read more →BSXBoston Scientific Prevails In European Patent Dispute With Edwards Lifesciences Boston Scientific Corporation (NYSE: BSX) today announced that it, along with several other opponents, successfully opposed Edwards Lifesciences...
MARLBOROUGH, Mass. , April 16, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it, along with several other opponents, successfully opposed Edwards Lifesciences Corporation's European patent EP 2,399,550 ( ' 550) in the European Patent Office
Read more →BSXBoston Scientific Announces Acquisition of Securus Medical Group, Inc. Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Securus Medical Group, Inc., a privately-held company that has developed ...
MARLBOROUGH, Mass. , April 3, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the acquisition of Securus Medical Group, Inc., a privately-held company that has developed a thermal monitoring system for the continuous measurement of esophageal tempe
Read more →BSXBoston Scientific Prevails In U.K. Edwards Lifesciences Litigation Boston Scientific Corporation (NYSE: BSX) today announced the U.K. Court of Appeal dismissed Edwards Lifesciences' appeal and upheld a prior court...
Separately, the company plans to appeal the U.S. Patent Office's recent Inter Partes Review finding that certain claims of the Boston Scientific U.S. patent 8,992,608 asserted against Edwards are invalid. Boston Scientific currently offers the ACURATE neo ™ Aortic Valve System i
Read more →BSXBoston Scientific Announces Conference Call Discussing First Quarter 2018 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ...
MARLBOROUGH, Mass. , March 26, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2018 on Wednesday, April 25, 2018 at 8:00 a.m. EDT . The call
Read more →BSXBoston Scientific to Participate in 17th Annual Needham Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 in...
MARLBOROUGH, Mass. , March 14, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 in New York City . Susie Lisa , vice president, Investor Relations, and Lindsay
Read more →BSXBoston Scientific Announces Scheduled Presentations at EHRA 2018 Congress Boston Scientific Corporation (NYSE: BSX) today announced key data presentations that will be featured at the annual congress of the European Heart...
MARLBOROUGH, Mass. , March 12, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced key data presentations that will be featured at the annual congress of the European Heart Rhythm Association (EHRA) in Barcelona, Spain , on March 18-20 . Notably, ther
Read more →BSXBoston Scientific To Participate In Barclays Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Barclays Global Healthcare Conference on March 13 in Miami Beach, Florida. Dan...
MARLBOROUGH, Mass. , March 5, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Barclays Global Healthcare Conference on March 13 in Miami Beach, Florida . Dan Brennan , executive vice president and chief financial officer, and Susie Lisa ,
Read more →BSXBoston Scientific Announces Acquisition of EMcision, Limited Boston Scientific (NYSE: BSX) today announced that it has acquired EMcision, Limited, a privately held company located in the United Kingdom and...
Patients with pancreaticobiliary cancers often develop jaundice as a result of tissue ingrowth that blocks ducts that enable bile to drain out of the GI tract. The Habib EndoHPB probe coagulates this tissue to help ensure that the fluids are able to drain, which can result in an
Read more →BSXBoston Scientific Completes $1.0 Billion Offering of Senior Notes Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.0 billion aggregate principal amount of its 4.000% senior notes due March ...
MARLBOROUGH, Mass. , Feb. 26, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed a public offering of $1.0 billion aggregate principal amount of its 4.000% senior notes due March 1, 2028 . The Company previously announced that it intends to use the net pro
Read more →BSXBoston Scientific Prices $1.0 Billion of Senior Notes Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.0 billion aggregate principal amount of its 4.000% senior...
MARLBOROUGH, Mass. , Feb. 22, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced the pricing of a public offering of $1.0 billion aggregate principal amount of its 4.000% senior notes due March 1, 2028 under the company's shelf registration statement. The
Read more →BSXBoston Scientific Announces Results for Fourth Quarter and Full Year 2017 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.408 billion during the fourth quarter ended December 31, 2017. This represents growth ...
MARLBOROUGH, Mass. , Feb. 1, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.408 billion during the fourth quarter ended December 31, 2017. This represents growth of 9.9 percent on a reported basis and 8.1 percent on an operational basis (exc
Read more →BSXBoston Scientific to Participate in LEERINK Partners 7th Annual Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the LEERINK Partners 7th Annual Global Healthcare Conference on February 15, ...
MARLBOROUGH, Mass. , Jan. 29, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the LEERINK Partners 7th Annual Global Healthcare Conference on February 15, 2018 in New York . Dan Brennan , executive vice president and chief financial
Read more →BSXBoston Scientific Announces Investment and Acquisition Option Agreement with Millipede, Inc. Boston Scientific Corporation (NYSE: BSX) today announced it has closed an investment and entered into an acquisition option agreement with...
MARLBOROUGH, Mass. , Jan. 24, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has closed an investment and entered into an acquisition option agreement with Millipede, Inc., a privately-held company that has developed the IRIS Transcatheter Annu
Read more →BSXBoston Scientific Announces Updated Time For Webcast Conference Call Discussing Fourth Quarter 2017 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth...
MARLBOROUGH, Mass. , Jan. 19, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2017 on Thursday, February 1, 2018 at 7:30 a.m. EST . The
Read more →BSXBoston Scientific Announces Positive Results from WHISPER Spinal Cord Stimulation Study Boston Scientific Corporation (NYSE: BSX) today announced positive results from the WHISPER randomized controlled trial (RCT). The data, presented at ...
MARLBOROUGH, Mass. , Jan. 12, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced positive results from the WHISPER randomized controlled trial (RCT). The data, presented at the 2018 Annual Meeting of the North American Neuromodulation Society in Las V
Read more →BSXBoston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.41 billion...
MARLBOROUGH, Mass. , Jan. 9, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales, based upon preliminary unaudited financial information, of approximately $2.41 billion during the fourth quarter ended December 31, 2017 . This represents growth of appro
Read more →BSXBoston Scientific To Participate In 36th Annual J.P. Morgan Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th annual J.P. Morgan Healthcare Conference on Tuesday, January 9,...
MARLBOROUGH, Mass. , Dec. 22, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 36th annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 in San Francisco, CA. Mike Mahoney , chairman and chief executive officer, w
Read more →BSXBoston Scientific to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January ...
MARLBOROUGH, Mass. , Dec. 21, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018 in Boston, MA. Mike Mahoney , chairman and chief executive officer, w
Read more →BSXBoston Scientific Receives U.S. FDA Approval for the Vercise™ Deep Brain Stimulation System Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the...
MARLBOROUGH, Mass. , Dec. 11, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Vercise ™ Deep Brain Stimulation (DBS) System. DBS is used to treat the symptoms of
Read more →BSXBoston Scientific To Participate In BMO Capital Markets Prescriptions For Success Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the BMO Capital Markets Prescriptions for Success Healthcare Conference on December 14, ...
MARLBOROUGH, Mass. , Dec. 4, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the BMO Capital Markets Prescriptions for Success Healthcare Conference on December 14, 2017 in New York . Susie Lisa , vice president, investor relations, and Lindsa
Read more →BSXBoston Scientific Announces Update on LOTUS Edge™ Aortic Valve System Boston Scientific (NYSE: BSX) announces a delay to previously communicated timelines for commercialization of the LOTUS Edge™ Aortic Valve System* in ...
MARLBOROUGH, Mass. , Nov. 28, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) announces a delay to previously communicated timelines for commercialization of the LOTUS Edge ™ Aortic Valve System* in Europe and the U.S. After initiating a voluntary recall for the LOTUS and LO
Read more →BSXBoston Scientific To Participate In Citi 2017 Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Citi 2017 Global Healthcare Conference on December 7, 2017 in New York. Kevin...
MARLBOROUGH, Mass. , Nov. 27, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Citi 2017 Global Healthcare Conference on December 7, 2017 in New York . Kevin Ballinger , executive vice president and president, interventional cardiology, and
Read more →BSXBoston Scientific To Participate In Piper Jaffray 29th Annual Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Piper Jaffray 29th Annual Healthcare Conference on November 28, 2017 in New York....
MARLBOROUGH, Mass. , Nov. 13, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Piper Jaffray 29th Annual Healthcare Conference on November 28, 2017 in New York . Susie Lisa , vice president, investor relations and Lindsay Fish , senior mana
Read more →BSXBoston Scientific To Participate In Stifel 2017 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Stifel 2017 Healthcare Conference on November 14, 2017 in New York. Dan Brennan,...
MARLBOROUGH, Mass. , Nov. 8, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Stifel 2017 Healthcare Conference on November 14, 2017 in New York . Dan Brennan , executive vice president and chief financial officer and Susie Lisa , vice pres
Read more →BSXBoston Scientific To Participate In 26th Annual Credit Suisse Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the 26th Annual Credit Suisse Healthcare Conference on November 7, 2017 in Scottsdale,...
MARLBOROUGH, Mass. , Nov. 6, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the 26th Annual Credit Suisse Healthcare Conference on November 7, 2017 in Scottsdale, Arizona . Joe Fitzgerald , executive vice president & president, rhythm managem
Read more →BSXFive-year Follow-up Data Demonstrate the WATCHMAN™ Left Atrial Appendage Closure Device Provides Stroke Risk Reduction Comparable to Warfarin Therapy Boston Scientific (NYSE: BSX) announced final five-year outcomes data from the PREVAIL study of the WATCHMAN™ Left Atrial Appendage Closure (LAAC)...
DENVER and MARLBOROUGH, Mass. , Nov. 2, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) announced final five-year outcomes data from the PREVAIL study of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device today during a late-breaking clinical trial session at the 29th
Read more →BSXBoston Scientific Announces Results For Third Quarter 2017 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.222 billion during the third quarter ended September 30, 2017. This represents growth ...
MARLBOROUGH, Mass. , Oct. 26, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.222 billion during the third quarter ended September 30, 2017. This represents growth of 5.6 percent on a reported basis and 5.7 percent on an operational basis (ex
Read more →BSXBoston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Desiree Ralls-Morrison as senior vice president, general counsel and...
MARLBOROUGH, Mass. , Oct. 4, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the appointment of Desiree Ralls-Morrison as senior vice president, general counsel and corporate secretary. Ralls-Morrison will join Boston Scientific on November 30, 201
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Third Quarter 2017 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
MARLBOROUGH, Mass. , Oct. 2, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2017 on Thursday, October 26, 2017 at 8:00 a.m. EDT . The c
Read more →BSXBoston Scientific Announces Agreement to Acquire Apama Medical Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is...
MARLBOROUGH, Mass. , Oct. 2, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon Catheter System for the treatment o
Read more →BSXBoston Scientific Announces U.S. FDA Approval for MRI Labeling on High-Voltage Devices and U.S. Launch of Resonate™ Devices with the HeartLogic™ Heart Failure Diagnostic Boston Scientific (NYSE: BSX) has launched the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy ...
MARLBOROUGH, Mass. , Sept. 25, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has launched the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic™ Heart Failure Diagnos
Read more →BSXLos datos pragmáticos confirman la efectividad a largo plazo de la termoplastia bronquial Boston Scientific (NYSE: BSX) ha anunciado hoy los resultados de un seguimiento a tres años de una cohorte en su estudio realizado con posterioridad...
Pacientes con asma grave muestran una mejoría clínica sostenida MARLBOROUGH, Massachusetts , 18 de septiembre de 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) ha anunciado hoy los resultados de un seguimiento a tres años de una cohorte en su estudio realizado con posterior
Read more →BSXDaten aus der Praxis bestätigen die Langzeitwirkung von bronchialer Thermoplastie Boston Scientific (NYSE: BSX) gab heute die Ergebnisse einer Kohorte aus einer klinischen Folgestudie nach drei Jahren zur Beurteilung von...
Patienten mit schwerem Asthma weisen nachhaltige klinische Verbesserung auf MARLBOROUGH, Massachusetts , 18. September 2017 PRNewswire/ -- Boston Scientific (NYSE: BSX ) gab heute die Ergebnisse einer Kohorte aus einer klinischen Folgestudie nach drei Jahren zur Beurteilung von
Read more →BSXDes données réelles confirment l'efficacité à long terme de la thermoplastie bronchique Aujourd'hui, Boston Scientific (NYSE : BSX) a communiqué les résultats d'une cohorte de suivi de trois ans dans son essai clinique sur la...
Les patients atteints d'asthme sévère présentent une amélioration clinique durable MARLBOROUGH, Massachussetts, le 18 septembre 2017 /PRNewswire/ -- Aujourd'hui, Boston Scientific (NYSE : BSX ) a communiqué les résultats d'une cohorte de suivi de trois ans dans son essai cliniqu
Read more →BSXBoston Scientific To Participate In Morgan Stanley Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2017 in New York City. ...
MARLBOROUGH, Mass. , Aug. 28, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2017 in New York City . Mike Mahoney , chairman and chief executive officer, and Dan Brennan , execu
Read more →BSXBoston Scientific To Participate In Wells Fargo 2017 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, 2017 in Boston. Susie...
MARLBOROUGH, Mass. , Aug. 21, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, 2017 in Boston . Susie Lisa , vice president, Investor Relations, will participate in a 30-minute qu
Read more →BSXBoston Scientific To Participate In 2017 Canaccord Genuity Growth Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity Growth Conference on August 9, 2017 in Boston. Boston...
MARLBOROUGH, Mass. , July 31, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Canaccord Genuity Growth Conference on August 9, 2017 in Boston . Boston Scientific investor relations representatives, Susie Lisa and Lindsay Fish ,
Read more →BSXBoston Scientific Announces Results for Second Quarter 2017 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of...
MARLBOROUGH, Mass. , July 27, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on an operational basis (excludes t
Read more →BSXBoston Scientific to Webcast Conference Call Discussing Second Quarter 2017 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
MARLBOROUGH, Mass. , July 5, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2017 on Thursday, July 27, 2017 at 8:00 a.m. EDT . The call wil
Read more →BSXBoston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day Updated -- Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview ...
MARLBOROUGH, Mass. , June 27, 2017 /PRNewswire/ -- Updated -- Boston Scientific Corporation (NYSE: BSX ) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. Chairman of the Board and Chi
Read more →BSXBoston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System Boston Scientific (NYSE: BSX) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS) System*, a rechargeable, magnetic resonance...
MARLBOROUGH, Mass. , June 6, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS) System*, a rechargeable, magnetic resonance (MR) conditional device indicated for the treatment of movement disorder symptoms
Read more →BSXBoston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty Boston Scientific (NYSE: BSX) today announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe ...
MARLBOROUGH, Mass. , May 24, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study evaluating patients treated with the Alair ™ Sys
Read more →BSXBoston Scientific to Participate in 2017 UBS Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 in New...
MARLBOROUGH, Mass. , May 17, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 in New York City . Susie Lisa , vice president, investor relations and Lindsay Fish , se
Read more →BSXThe Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific...
PARIS and MARLBOROUGH, Mass. , May 16, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated that the LOTUS ™ Valve S
Read more →BSXBoston Scientific Closes Symetis Acquisition Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company ...
MARLBOROUGH, Mass. , May 16, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) de
Read more →BSXNew Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater understanding of...
NEW ORLEANS and MARLBOROUGH, Mass. , May 12, 2017 /PRNewswire/ -- New analyses from the Boston Scientific Corporation (NYSE: BSX ) sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can adversely affect s
Read more →BSXBoston Scientific Announces Schedule of Presentations at EuroPCR 2017 Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including four late-breaking clinical trials, that will be...
MARLBOROUGH, Mass. , May 10, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced the schedule of key data presentations, including four late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris , on May 16-19 . The lat
Read more →BSXBoston Scientific Receives U.S. FDA Approval For Resonate™ Family Of High-Voltage Devices Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate™ family of implantable cardioverter...
MARLBOROUGH, Mass. , May 9, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA) approval for the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) syste
Read more →BSXBoston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2017 Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be...
MARLBOROUGH, Mass. , May 3, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of the Heart Rhythm Society in Chicago
Read more →BSXBoston Scientific to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday,...
MARLBOROUGH, Mass. , May 1, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 in Las Vegas . Susie Lisa , vice president, investor relations, will
Read more →BSXBoston Scientific Announces Results For First Quarter 2017 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.160 billion during the first quarter ended March 31, 2017. This represents growth of...
MARLBOROUGH, Mass. , April 27, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.160 billion during the first quarter ended March 31, 2017. This represents growth of 10 percent compared to the prior year period on a reported and operational bas
Read more →BSXBoston Scientific To Webcast Conference Call Discussing First Quarter 2017 Financial Results And Announces Revised Date For 2017 Investor Day Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ...
MARLBOROUGH, Mass. , March 30, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2017 on Thursday, April 27, 2017 at 8:00 a.m. EDT . The call
Read more →BSXBoston Scientific Announces Agreement to Acquire Symetis Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart...
MARLBOROUGH, Mass. , March 30, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI
Read more →BSXNICE Recommends Boston Scientific CRT-D Devices Powered By EnduraLife™ Battery Technology For Treatment Of Heart Failure Today, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific...
MARLBOROUGH, Mass. , March 16, 2017 /PRNewswire/ -- Today, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX ) cardiac resynchronization therapy defibrillators (CRT-D) p
Read more →BSXBoston Scientific Receives Favorable Rulings In Edwards Lifesciences Litigation Boston Scientific Corporation (NYSE: BSX) today announced the German District Court of Düsseldorf has determined that Edwards Lifesciences...
MARLBOROUGH, Mass. , March 9, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the German District Court of Düsseldorf has determined that Edwards Lifesciences Corporation and its German subsidiary's Sapien 3™ device infringed two patents of Boston
Read more →BSXBoston Scientific To Participate In Barclays Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Barclays Global Healthcare Conference on March 15 in Miami Beach, Florida. Mike...
MARLBOROUGH, Mass. , March 7, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Barclays Global Healthcare Conference on March 15 in Miami Beach, Florida . Mike Mahoney , chairman and chief executive officer, and Dan Brennan , executive vice
Read more →BSXBoston Scientific Announces Six Finalists in 2nd Annual Connected Patient Challenge, Focused on Healthcare Data Analytics Boston Scientific Corporation (NYSE: BSX) today announced six finalists in its second annual Connected Patient Challenge, an open competition focused ...
MARLBOROUGH, Mass. , March 3, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced six finalists in its second annual Connected Patient Challenge , an open competition focused on turning big data into actionable intelligence that optimizes patient care
Read more →BSXBoston Scientific to Participate in Cowen and Company 37th Annual Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen and Company 37th Annual Healthcare Conference on Tuesday, March 7, ...
MARLBOROUGH, Mass. , Feb. 21, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Cowen and Company 37 th Annual Healthcare Conference on Tuesday, March 7, 2017 in Boston . Dan Brennan , executive vice president and chief financial
Read more →BSXBoston Scientific to Participate in 2017 RBC Capital Markets Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 RBC Capital Markets Global Healthcare Conference on Thursday,...
MARLBOROUGH, Mass. , Feb. 15, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2017 RBC Capital Markets Global Healthcare Conference on Thursday, February 23, 2017 in New York . Dan Brennan , executive vice president and chief fi
Read more →BSXBoston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.191 billion during the fourth quarter ended December 31, 2016. This represents growth ...
MARLBOROUGH, Mass. , Feb. 2, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.191 billion during the fourth quarter ended December 31, 2016. This represents growth of 11 percent compared to the prior year period on a reported and operational b
Read more →BSXBoston Scientific To Participate In LEERINK Partners 6th Annual Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the LEERINK Partners 6th Annual Global Healthcare Conference on February 15, ...
MARLBOROUGH, Mass. , Feb. 1, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the LEERINK Partners 6th Annual Global Healthcare Conference on February 15 , in New York . Susie Lisa , vice president, Investor Relations, will participa
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Fourth Quarter 2016 Financial Results And Announces 2017 Investor Day Business Review Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter ended December 31,...
MARLBOROUGH, Mass. , Jan. 3, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the fourth quarter ended December 31, 2016 on Thursday, February 2, 2017 , at 8:00 a.m. EST . The call will be hosted by
Read more →BSXBoston Scientific To Participate In 35th Annual J.P. Morgan Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10,...
MARLBOROUGH, Mass. , Dec. 30, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 in San Francisco . Mike Mahoney , chairman and chief executive officer, wil
Read more →BSXBoston Scientific Closes Acquisition of Advanced Biological Tissue Capabilities and Acquires Common Shares of Neovasc, Inc. Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of certain manufacturing assets and capabilities of the...
MARLBOROUGH, Mass. , Dec. 13, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the close of its acquisition of certain manufacturing assets and capabilities of the Neovasc, Inc., (NASDAQ: NVCN ) (TSX: NVC) advanced biological tissue business. With t
Read more →BSXBoston Scientific To Participate In Citi 2016 Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Citi 2016 Global Healthcare Conference on December 7 in New York City....
MARLBOROUGH, Mass. , Nov. 23, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Citi 2016 Global Healthcare Conference on December 7 in New York City . Dan Brennan , executive vice president & chief financial officer, and Susie Li
Read more →BSXBoston Scientific Closes EndoChoice Acquisition Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of EndoChoice Holdings, Inc. (NYSE: GI). With the completion...
MARLBOROUGH, Mass. , Nov. 22, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the close of its acquisition of EndoChoice Holdings, Inc. (NYSE: GI ). With the completion of the acquisition, EndoChoice will become part of the Boston Scientific Endosc
Read more →BSXBoston Scientific Receives 2016 Shingo Prize for Operational Excellence Boston Scientific today announced that its Cork, Ireland manufacturing facility has received the 2016 Shingo Prize for Excellence in Manufacturing...
MARLBOROUGH, Mass. , Nov. 21, 2016 /PRNewswire/ -- Boston Scientific today announced that its Cork, Ireland manufacturing facility has received the 2016 Shingo Prize for Excellence in Manufacturing from the Shingo Institute, part of the Jon M. Huntsman School of Business at Utah
Read more →BSXBoston Scientific Acquires Resectr™ Tissue Resection Device from Distal Access, LLC Boston Scientific (NYSE: BSX) has acquired the gynecology and urology portfolio of Distal Access, LLC, a Salt Lake City based company that designs...
MARLBOROUGH, Mass. , Nov. 15, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has acquired the gynecology and urology portfolio of Distal Access, LLC, a Salt Lake City based company that designs minimally invasive medical devices. The portfolio includes the Resectr ™ Tissue R
Read more →BSXBoston Scientific Announces Extension of the Cash Tender Offer for All Shares of EndoChoice Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has extended its previously...
MARLBOROUGH, Mass. , Nov. 4, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has extended its previously announced tender offer for all shares of EndoChoice Holdings, Inc. (GI) at a pric
Read more →BSXBoston Scientific Announces Acquisition Of The LumenR™ Tissue Retractor System Boston Scientific (NYSE: BSX) today announced the acquisition of the LumenR™ Tissue Retractor System from LumenR LLC, a privately held Newark,...
MARLBOROUGH, Mass. , Nov. 3, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced the acquisition of the LumenR ™ Tissue Retractor System from LumenR LLC, a privately held Newark, California based company. The LumenR Tissue Retractor System is currently in developm
Read more →BSXBoston Scientific To Participate In Stifel 2016 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Stifel 2016 Healthcare Conference on November 15 in New York City. Dan...
MARLBOROUGH, Mass. , Oct. 27, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Stifel 2016 Healthcare Conference on November 15 in New York City . Dan Brennan , executive vice president & chief financial officer, and Susie Lisa ,
Read more →BSXBoston Scientific Announces Results For Third Quarter 2016 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.105 billion during the third quarter ended September 30, 2016, compared to the...
MARLBOROUGH, Mass. , Oct. 26, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.105 billion during the third quarter ended September 30, 2016, compared to the company's guidance range for the quarter of $2.035 to $2.085 billion . This represent
Read more →BSXBoston Scientific To Participate In 25th Annual Credit Suisse Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Credit Suisse Healthcare Conference on November 7, in...
MARLBOROUGH, Mass. , Oct. 25, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 25 th Annual Credit Suisse Healthcare Conference on November 7 , in Scottsdale, Arizona . Joe Fitzgerald , executive vice president & president, rhyth
Read more →BSXBoston Scientific Launches Resolution 360™ Clip Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Resolution 360™ Clip, a novel technology designed to improve hemostatic...
MARLBOROUGH, Mass. , Oct. 17, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the launch of the Resolution 360™ Clip, a novel technology designed to improve hemostatic clipping by providing physicians controlled rotation designed for more accurate
Read more →BSXProfessor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer Boston Scientific Corporation (NYSE: BSX) announced today that Professor Ian Meredith AM will join the company as executive vice president and global ...
MARLBOROUGH, Mass. , Oct. 10, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017 . In his new position, Professor Meredit
Read more →BSXBoston Scientific Commences Cash Tender Offer For All Shares Of EndoChoice For $8.00 Per Share In Cash Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has launched its previously...
MARLBOROUGH, Mass. , Oct. 7, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has launched its previously announced tender offer for all shares of EndoChoice Holdings, Inc. (GI) at a pric
Read more →BSXBoston Scientific to Webcast Conference Call Discussing Third Quarter 2016 Financial Results on October 26 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
MARLBOROUGH, Mass. , Oct. 3, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2016 on Wednesday, October 26, 2016 at 8:00 a.m. ET . The
Read more →BSXBoston Scientific to Acquire EndoChoice Boston Scientific (NYSE: BSX) and EndoChoice Holdings, Inc. (NYSE: GI) today announced the companies have entered into a definitive agreement under...
MARLBOROUGH, Mass. and ALPHARETTA, Ga. , Sept. 27, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) and EndoChoice Holdings, Inc. (NYSE: GI ) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire EndoChoice.
Read more →BSXBoston Scientific Receives CE Mark For LOTUS Edge™ Valve System Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic...
In comparison to the Lotus™ Valve System, this next iteration incorporates a more flexible, lower profile catheter designed to improve ease of use and accommodate tortuous anatomy. Another differentiating feature of the LOTUS Edge valve system is the inclusion of Depth Guard™, a
Read more →BSXBoston Scientific To Participate In Morgan Stanley Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 13, in New York City. Mike ...
MARLBOROUGH, Mass. , Aug. 30, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will participate in the Morgan Stanley Global Healthcare Conference on September 13 , in New York City . Mike Mahoney , chief executive officer, and Dan Brennan , executive vice preside
Read more →BSXBoston Scientific To Participate In Wells Fargo 2016 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, in Boston. Mike...
MARLBOROUGH, Mass. , Aug. 24, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7 , in Boston . Mike Mahoney , chief executive officer, Dan Brennan , executive vice president and chie
Read more →BSXBoston Scientific Announces U.S. FDA Approval Of EMBLEM™ MRI S-ICD System Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable...
MARLBOROUGH, Mass. , Aug. 9, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling for al
Read more →BSXBoston Scientific To Participate In Canaccord Genuity Growth Conference And Wedbush PacGrow Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th Annual Canaccord Genuity Growth Conference on August 11 in Boston...
MARLBOROUGH, Mass. , Aug. 1, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 36 th Annual Canaccord Genuity Growth Conference on August 11 in Boston and the 2016 Wedbush PacGrow Healthcare Conference on August 16 in New York . S
Read more →BSXBoston Scientific Announces Results For Second Quarter 2016 Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's...
MARLBOROUGH, Mass. , July 28, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to $2.060 billion . This represents gr
Read more →BSXBoston Scientific Announces Acquisition of Cosman Medical Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer...
MARLBOROUGH, Mass. , July 27, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer of radiofrequency ablation (RFA) systems. The Cosman Medical team and products
Read more →BSXBoston Scientific Elects Yoshiaki Fujimori to Board of Directors Boston Scientific Corporation (NYSE: BSX) announced today the election of Yoshiaki Fujimori to its board of directors, effective immediately....
MARLBOROUGH, Mass. , July 13, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced today the election of Yoshiaki Fujimori to its board of directors, effective immediately. Yoshiaki Fujimori is an adviser to the LIXIL Group Corporation ("LIXIL"), for which h
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Second Quarter 2016 Financial Results On July 28 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
MARLBOROUGH, Mass. , July 1, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 at 8:00 a.m. ET . The call wil
Read more →BSXNational Institute for Health and Care Excellence Provides Positive Guidance for Use of Boston Scientific GreenLight XPS™ Laser Therapy System in the Treatment of BPH Boston Scientific Corporation (NYSE: BSX) today announced that its GreenLight XPS™ Laser Therapy System, used for the treatment of prostatic...
MARLBOROUGH, Mass. , June 14, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that its GreenLight XPS™ Laser Therapy System, used for the treatment of prostatic enlargement, known as benign prostatic hyperplasia (BPH), received positive guidance fr
Read more →BSXBoston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation Boston Scientific Corporation (NYSE: BSX) today announced a global restructuring program to build on the progress the company has made in executing...
MARLBOROUGH, Mass. , June 8, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced a global restructuring program to build on the progress the company has made in executing long-term growth strategies and bringing differentiated value and innovation to p
Read more →BSXBoston Scientific To Participate In Goldman Sachs 2016 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs Global Healthcare Conference on June 9 in Rancho Palos...
MARLBOROUGH, Mass. , May 26, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Goldman Sachs Global Healthcare Conference on June 9 in Rancho Palos Verdes. Dan Brennan , executive vice president and chief financial officer, and Su
Read more →BSXBoston Scientific to Participate in Jefferies 2016 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2016 Healthcare Conference on June 7, in New York City. Susie...
MARLBOROUGH, Mass. , May 24, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Jefferies 2016 Healthcare Conference on June 7 , in New York City . Susie Lisa , vice president, Investor Relations, will participate in a 25-minute pr
Read more →BSXBoston Scientific Receives U.S. FDA Approval for Precision Montage™ MRI Spinal Cord Stimulator System Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Precision Montage™ MRI Spinal Cord Stimulator (SCS) System after...
Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance
Read more →BSXBoston Scientific Announces Schedule of Presentations at EuroPCR 2016 Boston Scientific (NYSE: BSX) today announced the schedule of key data that will be featured at the annual EuroPCR Scientific Program, May 17-20 in...
MARLBOROUGH, Mass. , May 13, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced the schedule of key data that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris . Data from the 1,000-patient EWOLUTION registry, the observational, prosp
Read more →BSXBoston Scientific Announces Positive Long-Term Outcomes For S-ICD System In The EFFORTLESS Study Boston Scientific (NYSE: BSX) today announced results from the largest post-market registry for the Subcutaneous Implantable Defibrillator (S-ICD)...
SAN FRANCISCO and MARLBOROUGH, Mass. , May 6, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced results from the largest post-market registry for the Subcutaneous Implantable Defibrillator (S-ICD) System. Data collected from the EFFORTLESS study were presented a
Read more →BSXBoston Scientific To Participate In Bank Of America 2016 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2016 Health Care Conference on May 12, in...
MARLBOROUGH, Mass. , April 29, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Bank of America Merrill Lynch 2016 Health Care Conference on May 12 , in Las Vegas . Dan Brennan , executive vice president and chief financial offic
Read more →BSXBoston Scientific Announces Scheduled Presentations At Heart Rhythm Society 2016 Boston Scientific (NYSE: BSX) today announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual...
MARLBOROUGH, Mass. , April 28, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in San Francisco on May 4-7 . D
Read more →BSXBoston Scientific Announces Results For First Quarter 2016 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.964 billion during the first quarter ended March 31, 2016, compared to the company's...
MARLBOROUGH, Mass. , April 27, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.964 billion during the first quarter ended March 31, 2016, compared to the company's guidance range for the quarter of $1.890 to $1.940 billion . This represents 1
Read more →BSXBoston Scientific To Participate In Deutsche Bank 2016 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 41st Annual Health Care Conference on May 5, in Boston....
MARLBOROUGH, Mass. , April 21, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Deutsche Bank 41st Annual Health Care Conference on May 5 , in Boston . Dan Brennan , executive vice president and chief financial officer, will part
Read more →BSXBoston Scientific Announces CE Mark For MRI Labeling Of Emblem™ S-ICD Systems Boston Scientific (NYSE: BSX) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as ...
MARLBOROUGH, Mass. , April 20, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling for all previously implanted EMB
Read more →BSXBoston Scientific To Webcast Conference Call Discussing First Quarter 2016 Financial Results On April 27 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ...
MARLBOROUGH, Mass. , April 1, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2016 on Wednesday, April 27, 2016 at 8:00 a.m. ET . The call
Read more →BSXBoston Scientific To Participate In 15th Annual Needham Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 15th Annual Needham Healthcare Conference on April 12, in New York City. ...
MARLBOROUGH, Mass. , March 29, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 15th Annual Needham Healthcare Conference on April 12 , in New York City . Susie Lisa , vice president, Investor Relations, will participate in a 40-
Read more →BSXBoston Scientific Announces Scheduled Presentations at American College of Cardiology's 65th Annual Scientific Session Boston Scientific (NYSE: BSX) today announced key data presentations spanning its interventional cardiology, rhythm management and structural heart...
MARLBOROUGH, Mass. , March 24, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced key data presentations spanning its interventional cardiology, rhythm management and structural heart portfolios, that will be featured at the American College of Cardiology's 65th
Read more →BSXBoston Scientific Launches the AXIOS™ Stent and Electrocautery Enhanced Delivery System Boston Scientific Corporation (NYSE: BSX) today announced the launch of the AXIOS™ Stent and Electrocautery Enhanced Delivery System to help...
MARLBOROUGH, Mass. , March 22, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the launch of the AXIOS ™ Stent and Electrocautery Enhanced Delivery System to help physicians manage two serious complications from pancreatitis using a minimally invas
Read more →BSXBoston Scientific, Mayo Clinic Collaborate to Speed Development of Medical Devices Boston Scientific Corporation (NYSE: BSX) and Mayo Clinic today announced a continuing collaboration where the two organizations share intellectual...
MARLBOROUGH, Mass. and ROCHESTER, Minn. , March 16, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) and Mayo Clinic today announced a continuing collaboration where the two organizations share intellectual property and stimulate the rapid development of medical de
Read more →BSXBoston Scientific Receives U.S. FDA Approval For Blazer™ Open-Irrigated Catheter Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Blazer™ Open-Irrigated (OI) radiofrequency...
MARLBOROUGH, Mass. , March 10, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA) approval for the Blazer™ Open-Irrigated (OI) radiofrequency ablation catheter. The Blazer OI catheter has been approved to treat Type I atrial f
Read more →BSXBoston Scientific to Participate in Barclays Global Health Care Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays Global Health Care Conference on March 15, in Miami Beach. Dan...
MARLBOROUGH, Mass. , March 1, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Barclays Global Health Care Conference on March 15 , in Miami Beach . Dan Brennan , executive vice president and chief financial officer, and Susie Li
Read more →BSXBoston Scientific Announces Changes to Board of Directors Boston Scientific Corporation (NYSE: BSX) announced today a number of changes to the leadership and membership of its Board of Directors. Pete M....
MARLBOROUGH, Mass. , Feb. 25, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced today a number of changes to the leadership and membership of its Board of Directors. Pete M. Nicholas , the company's co-founder and chairman of its board, has announced that
Read more →BSXBoston Scientific to Participate in Cowen & Company 2016 Health Care Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen & Co. 36th Annual Health Care Conference on March 8, in Boston....
MARLBOROUGH, Mass. , Feb. 23, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Cowen & Co. 36th Annual Health Care Conference on March 8 , in Boston . Dan Brennan , executive vice president and chief financial officer, and Susie
Read more →BSXBoston Scientific Receives U.S. FDA Approval For Quadripolar Leads And Initiates Global Trial To Expand MRI Labeling To The U.S. And Asia Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the ACUITY™ X4 Quadripolar Left Ventricular (LV)...
MARLBOROUGH, Mass. , Feb. 23, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA) approval for the ACUITY™ X4 Quadripolar Left Ventricular (LV) leads. The FDA approval of the quadripolar leads, the wires that connect cardiac re
Read more →BSXBoston Scientific Receives CE Mark For Eluvia™ Drug-Eluting Vascular Stent and Announces Initiation of New Clinical Trial Boston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing...
MARLBOROUGH, Mass. , Feb. 22, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing commercialization immediately in the European Union and other countries where CE Mark is re
Read more →BSXBoston Scientific Announces Medicare Will Cover WATCHMAN™ Left Atrial Appendage Closure Device Boston Scientific Corporation (NYSE: BSX) announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial...
The WATCHMAN Device, the first and only percutaneous LAAC therapy approved by the U.S. Food and Drug Administration (FDA) in March 2015 , is indicated for patients with non-valvular atrial fibrillation (AF) who are at high stroke risk, suitable for warfarin, and are seeking an al
Read more →BSXBoston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2015 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.978 billion during the fourth quarter ended December 31, 2015. This represents 10...
MARLBOROUGH, Mass. , Feb. 4, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.978 billion during the fourth quarter ended December 31, 2015. This represents 10 percent operational revenue growth (constant currency basis, excluding divested bus
Read more →BSXBoston Scientific and Accenture Develop Data-Driven Digital Health Solution to Help Improve Patient Outcomes and Reduce Cost of Treating Chronic Cardiovascular Conditions Boston Scientific Corporation (NYSE: BSX) and Accenture (NYSE: ACN) have developed a cloud-based, data-driven digital health solution for hospitals...
MARLBOROUGH, Mass. and NEW YORK , Jan. 28, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) and Accenture (NYSE: ACN ) have developed a cloud-based, data-driven digital health solution for hospitals that is designed to help improve patient outcomes and reduce costs
Read more →BSXBoston Scientific to Participate in Leerink Partners 2016 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink Partners 5th Annual Global Healthcare Conference on February 10, ...
MARLBOROUGH, Mass. , Jan. 27, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Leerink Partners 5 th Annual Global Healthcare Conference on February 10 , in New York City . Dan Brennan , executive vice president and chief financi
Read more →BSXBoston Scientific Launches The LithoVue™ Single-Use Digital Flexible Ureteroscope In U.S. And Europe Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the LithoVue™ Single-Use Digital Flexible Ureteroscope for...
MARLBOROUGH, Mass. , Jan. 12, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the U.S. and European launch of the LithoVue™ Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to diagnose and treat stones and other
Read more →BSXBoston Scientific To Webcast Fourth Quarter 2015 Earnings Call On February 4 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth...
MARLBOROUGH, Mass. , Jan. 4, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year ended December 31, 2015 on Thursday, February 4, 2016 at 8 a.m.
Read more →BSXBoston Scientific To Participate In 2016 J.P. Morgan Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12,...
MARLBOROUGH, Mass. , Dec. 22, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 34 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 in San Francisco . Mike Mahoney , president and chief executive officer, w
Read more →BSXLUMINA Data Demonstrate 70 Percent Greater Low Back Pain Relief with Boston Scientific Precision Spectra™ Spinal Cord Stimulator System Final results evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the...
"As the LUMINA data show, the Boston Scientific Illumina 3D Algorithm allows me to treat low back pain more consistently and effectively than before," said James North , M.D. of the Carolinas Pain Institute. "These data are impressive because they demonstrate sustained long term
Read more →BSXBoston Scientific To Participate In Oppenheimer 2015 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Oppenheimer 26th Annual Healthcare Conference on December 8, in New York ...
MARLBOROUGH, Mass. , Nov. 24, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Oppenheimer 26th Annual Healthcare Conference on December 8 , in New York City . Susie Lisa , vice president, Investor Relations, will participate in
Read more →BSXBoston Scientific Scores Perfect 100 on Human Rights Campaign's 2016 Corporate Equality Index Boston Scientific (NYSE: BSX) has received a score of 100 percent on the 2016 Corporate Equality Index (CEI), a national benchmarking survey and...
MARLBOROUGH, Mass. , Nov. 18, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has received a score of 100 percent on the 2016 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices related to lesbian, gay, bisexual and tr
Read more →BSXBoston Scientific To Participate In Canaccord Genuity 2015 Medical Technology And Diagnostics Forum Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity 9th Annual Medical Technology and Diagnostics Forum on ...
MARLBOROUGH, Mass. , Nov. 5, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Canaccord Genuity 9 th Annual Medical Technology and Diagnostics Forum on November 19 , in New York City . David Pierce , executive vice president & pr
Read more →BSXBoston Scientific To Participate In Stifel Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Stifel Healthcare Conference on November 17, in New York City. Susie...
MARLBOROUGH, Mass. , Nov. 3, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Stifel Healthcare Conference on November 17 , in New York City . Susie Lisa , vice president, Investor Relations, will participate in a 40-minute quest
Read more →BSXBoston Scientific Announces Results For Third Quarter 2015 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.888 billion during the third quarter ended September 30, 2015, compared to the...
MARLBOROUGH, Mass. , Oct. 28, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.888 billion during the third quarter ended September 30, 2015, compared to the company's guidance range for the quarter of $1.790 to $1.840 billion . This represent
Read more →BSXBoston Scientific Announces Additional Investment And Right To Acquire MValve Technologies Boston Scientific Corporation (NYSE: BSX) today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a...
MARLBOROUGH, Mass. and HERZLIYA, Israel , Oct. 8, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve replacement system, d
Read more →BSXBoston Scientific Announces Scheduled Presentations At TCT 2015 Boston Scientific (NYSE: BSX) today announced key data presentations spanning its broad interventional cardiology, structural heart and peripheral...
MARLBOROUGH, Mass. , Oct. 7, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced key data presentations spanning its broad interventional cardiology, structural heart and peripheral interventions portfolios to be shared at the 27th Transcatheter Cardiovascular The
Read more →BSXBoston Scientific To Webcast Third Quarter 2015 Earnings Call On October 28 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
MARLBOROUGH, Mass. , Oct. 1, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2015 on Wednesday, October 28, 2015 at 8 a.m. ET . The cal
Read more →BSXBoston Scientific Launches The Captivator™ EMR Device To Treat Diseases Of The Upper GI Tract Boston Scientific Corporation (NYSE: BSX) announced today the launch of the Captivator™ EMR Device for Endoscopic Mucosal Resection (EMR), a...
MARLBOROUGH, Mass. , Sept. 29, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced today the launch of the Captivator™ EMR Device for Endoscopic Mucosal Resection (EMR), a minimally invasive alternative to an esophagectomy, a surgical procedure that removes
Read more →BSXBoston Scientific Announces CE Mark for the Vercise™ Primary Cell Deep Brain Stimulation System Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is...
MARLBOROUGH, Mass. , Sept. 10, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting to address the varying needs of pa
Read more →BSXBoston Scientific To Participate In 2015 Morgan Stanley Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2015 Morgan Stanley Global Healthcare Conference on September 17, in New ...
MARLBOROUGH, Mass. , Sept. 2, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2015 Morgan Stanley Global Healthcare Conference on September 17 , in New York City . Mike Mahoney , chief executive officer, and Dan Brennan , execut
Read more →BSXBoston Scientific To Participate In The 2015 Wells Fargo Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2015 Wells Fargo Healthcare Conference on September 9 in Boston, MA. Dan ...
MARLBOROUGH, Mass. , Aug. 26, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2015 Wells Fargo Healthcare Conference on September 9 in Boston, MA. Dan Brennan, executive vice president and chief financial officer, and Susie Lisa
Read more →BSXBoston Scientific Announces CE Mark For MRI Compatible Labeling For ICD And CRT-D Systems Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL...
MARLBOROUGH, Mass., Aug. 24, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable cardioverter defibrillator (ICD) and t
Read more →BSXBoston Scientific Announces FDA Approval of Innova™ Vascular Self-Expanding Stent System Boston Scientific Corporation (NYSE: BSX) has received Food and Drug Administration (FDA) approval for the Innova™ Vascular Self-Expanding Stent...
MARLBOROUGH, Mass. , Aug. 19, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received Food and Drug Administration (FDA) approval for the Innova™ Vascular Self-Expanding Stent System, an advanced treatment option for patients with narrowing or blockages in th
Read more →BSXBoston Scientific Announces Results For Second Quarter 2015 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.843 billion during the second quarter ended June 30, 2015, compared to the company's...
MARLBOROUGH, Mass. , July 23, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.843 billion during the second quarter ended June 30, 2015 , compared to the company's guidance range for the quarter of $1.800 to $1.850 billion . This represents 6
Read more →BSXBoston Scientific Elects Donna A. James To Board Of Directors Boston Scientific Corporation (NYSE: BSX) announces the election of Donna A. James to its board of directors, effective immediately. Donna A. James...
MARLBOROUGH, Mass. , July 15, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the election of Donna A. James to its board of directors, effective immediately. Donna A. James is the founder and managing director of Lardon & Associates LLC, a business dev
Read more →BSXBoston Scientific Bronchial Thermoplasty Treatment Recognized By American College Of Allergy, Asthma And Immunology Boston Scientific Corporation (NYSE: BSX) announces that Bronchial Thermoplasty (BT) delivered by the Alair™ System has received support from the...
MARLBOROUGH, Mass. , July 9, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces that Bronchial Thermoplasty (BT) delivered by the Alair ™ System has received support from the American College of Allergy, Asthma and Immunology (ACAAI). BT is an outpatient pr
Read more →BSXBoston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second...
MARLBOROUGH, Mass. , July 1, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2015 on Thursday, July 23, 2015 at 8 a.m. ET . The call will b
Read more →BSXNew Data Demonstrate Greater Pain Relief With Boston Scientific Precision Spectra™ Spinal Cord Stimulator System Boston Scientific Corporation (NYSE: BSX) presented new data demonstrating that the Precision Spectra™ Spinal Cord Stimulator (SCS) System provided 1....
Key findings of the study included: LUMINA Spectra group: LUMINA Surgical group: The LUMINA cohort is part of the Boston Scientific PRO observational study. About Chronic Pain More than 100 million Americans suffer from chronic pain. Living in constant pain for an extended p
Read more →BSXBoston Scientific Launches The Precision Novi™ Spinal Cord Stimulator System in Europe Boston Scientific announces the European launch of the Precision Novi™ Spinal Cord Stimulator (SCS) System at the International Neuromodulation...
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high perf
Read more →BSXBoston Scientific To Participate In The Goldman Sachs 36th Annual Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 36th Annual Global Healthcare Conference on June 9 in...
MARLBOROUGH, Mass. , May 26, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Goldman Sachs 36 th Annual Global Healthcare Conference on June 9 in Rancho Palos Verdes, CA. Dan Brennan , executive vice president and chief financia
Read more →BSXPost-Market Study Evaluating The Boston Scientific Lotus™ Valve System Demonstrates Extremely Low PVL Rates A new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System demonstrated an extremely low rate of paravalvular aortic regurgitation...
MARLBOROUGH, Mass. , May 20, 2015 /PRNewswire/ -- A new study evaluating the Boston Scientific (NYSE: BSX ) Lotus™ Valve System demonstrated an extremely low rate of paravalvular aortic regurgitation (leakage) for a transcatheter aortic replacement valve, plus a cardiovascular mo
Read more →BSXBoston Scientific Completes $1.85 Billion Senior Notes Offering Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.85 billion aggregate principal amount of its senior notes under the...
MARLBOROUGH, Mass. , May 12, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed a public offering of $1.85 billion aggregate principal amount of its senior notes under the company's shelf registration statement. The public offering consists of $600 million
Read more →BSXBoston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2015 Boston Scientific (NYSE: BSX) today announced that key data from 42 abstracts will be featured at the 36th Annual Scientific Sessions of the Heart...
MARLBOROUGH, Mass. , May 11, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced that key data from 42 abstracts will be featured at the 36th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in Boston on May 13-16. Following recent successes – includi
Read more →BSXBoston Scientific Prices $1.85 Billion Of Senior Notes Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.85 billion aggregate principal amount of its senior notes...
MARLBOROUGH, Mass. , May 7, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced the pricing of a public offering of $1.85 billion aggregate principal amount of its senior notes under the company's shelf registration statement. The public offering consists of
Read more →BSXBoston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day Boston Scientific Corporation (NYSE: BSX) is presenting an overview of its continued business momentum and long-term growth strategies at a meeting...
MARLBOROUGH, Mass. , May 1, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is presenting an overview of its continued business momentum and long-term growth strategies at a meeting with the investment community today in New York City . President and Chief Executi
Read more →BSXNew Data Evaluating The Boston Scientific Eluvia(TM) Drug-Eluting Vascular Stent System Demonstrate 94.4 Percent Primary Patency Rate At Nine Months In an important clinical advancement in the treatment of peripheral artery disease (PAD), a key trial evaluating the Boston Scientific (NYSE: BSX)...
MARLBOROUGH, Mass. , April 28, 2015 /PRNewswire/ -- In an important clinical advancement in the treatment of peripheral artery disease (PAD), a key trial evaluating the Boston Scientific (NYSE: BSX ) Eluvia™ Drug-Eluting Vascular Stent System met its primary endpoint, with more t
Read more →BSXBoston Scientific Announces Results for First Quarter 2015 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.768 billion during the first quarter ended March 31, 2015, compared to the company's...
MARLBOROUGH, Mass. , April 28, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.768 billion during the first quarter ended March 31, 2015 , compared to the company's guidance range for the quarter of $1.740 to $1.800 billion . This represents
Read more →BSXBoston Scientific Announces Strategic Collaboration With Brainlab AG Boston Scientific Corporation (NYSE: BSX) announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps ...
MARLBOROUGH, Mass. , April 27, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and surgical navigation. The collaboration
Read more →BSXBoston Scientific To Participate In The Bank Of America Merrill Lynch 2015 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2015 Healthcare Conference on May 12 in...
MARLBOROUGH, Mass. , April 27, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Bank of America Merrill Lynch 2015 Healthcare Conference on May 12 in Las Vegas . Dan Brennan , executive vice president and chief financial officer,
Read more →BSXBoston Scientific To Participate In The Deutsche Bank 40th Annual Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 40th Annual Healthcare Conference on May 6 in Boston. Dan...
MARLBOROUGH, Mass. , April 24, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Deutsche Bank 40 th Annual Healthcare Conference on May 6 in Boston . Dan Brennan , executive vice president and chief financial officer, and Susie L
Read more →BSXLong-Term Data Underscore Safety And Efficacy Of The Boston Scientific S-ICD™ System Today the Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific...
MARLBOROUGH, Mass. , April 20, 2015 /PRNewswire/ -- Today the Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific Corporation (NYSE: BSX ) S-ICD System ™ (subcutaneous implantable defibrillator) for pa
Read more →BSXBoston Scientific Enrolls First Patient In New Study Designed To Demonstrate The Effect Of The Vessix™ Renal Denervation System Boston Scientific Corporation (NYSE: BSX) is taking a new approach to evaluate the performance of the Vessix™ Renal Denervation System, initiating a...
MARLBOROUGH, Mass. , April 16, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is taking a new approach to evaluate the performance of the Vessix™ Renal Denervation System, initiating a study with a novel design to isolate the effects of the therapy in patients wi
Read more →BSXBoston Scientific Signs Strategic Alliance With Frankenman Medical Equipment Company Boston Scientific Corporation (NYSE: BSX), a leading global medical device company, announced the signing of a strategic alliance with Frankenman...
MARLBOROUGH, Mass. and SUZHOU, China , April 14, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ), a leading global medical device company, announced the signing of a strategic alliance with Frankenman Medical Equipment Company, a recognized leader with deep local
Read more →BSXBoston Scientific To Webcast Conference Call On First Quarter 2015 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast a conference call on Tuesday, April 28, 2015 at 8 a.m. ET to review financial results and...
MARLBOROUGH, Mass. , April 1, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast a conference call on Tuesday, April 28, 2015 at 8 a.m. ET to review financial results and business highlights for the first quarter 2015. The company will issue a news relea
Read more →BSXBoston Scientific Agrees to Acquire Xlumena Boston Scientific Corporation (NYSE: BSX) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical...
MARLBOROUGH, Mass. and MOUNTAIN VIEW, Calif. , April 1, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical device company that develops, manufactures and sells mini
Read more →BSXBoston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device This week, four patients in the United States received the first implants of the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial...
MARLBOROUGH, Mass. , March 24, 2015 /PRNewswire/ -- This week, four patients in the United States received the first implants of the Boston Scientific Corporation (NYSE: BSX ) WATCHMAN ™ Left Atrial Appendage Closure (LAAC) Device. The WATCHMAN Device offers a novel stroke risk r
Read more →BSXBoston Scientific announces FDA and CE Mark Approval Of The EMBLEM™ S-ICD System Boston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. ...
MARLBOROUGH, Mass. , March 17, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment option that provides protection for pa
Read more →BSXBoston Scientific Receives FDA Approval for WATCHMAN™ Left Atrial Appendage Closure Device Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage...
MARLBOROUGH, Mass. , March 13, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new stroke risk reduction option for hi
Read more →BSXBoston Scientific Elects Charles J. Dockendorff And Stephen P. MacMillan To Board Of Directors Boston Scientific Corporation (NYSE: BSX) announces the election of Charles J. Dockendorff and Stephen P. MacMillan to its board of directors,...
MARLBOROUGH, Mass. , March 3, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the election of Charles J. Dockendorff and Stephen P. MacMillan to its board of directors, effective April 1, 2015 . Two current members of the board, Uwe E. Reinhardt and Bruc
Read more →BSXBoston Scientific Announces Definitive Agreement To Acquire American Medical Systems' Urology Portfolio For Up To $1.65 Billion Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Endo International plc (NASDAQ: ENDP)...
MARLBOROUGH, Mass. , March 2, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has entered into a definitive agreement with Endo International plc (NASDAQ: ENDP ) (TSX: ENL) to acquire the American Medical Systems urology portfolio, which in
Read more →BSXBoston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays 2015 Annual Healthcare Conference on March 10 in Miami Beach....
MARLBOROUGH, Mass. , Feb. 27, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Barclays 2015 Annual Healthcare Conference on March 10 in Miami Beach . Dan Brennan , executive vice president and chief financial officer, and Susie
Read more →BSXBoston Scientific Launches Next Generation SpyGlass™ DS Direct Visualization System For Advanced Diagnosis And Treatment Of Pancreatico-biliary Diseases Boston Scientific Corporation (NYSE: BSX) announces 510(k) clearance and the first cases of the SpyGlass DS Direct Visualization System used for...
MARLBOROUGH, Mass. , Feb. 26, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces 510(k) clearance and the first cases of the SpyGlass DS Direct Visualization System used for cholangioscopy and pancreatoscopy procedures. Built on the technology of the origin
Read more →BSXBoston Scientific To Participate In The Cowen 35th Annual Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen 35th Annual Healthcare Conference on March 4 in Boston. Dan...
MARLBOROUGH, Mass. , Feb. 25, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Cowen 35 th Annual Healthcare Conference on March 4 in Boston . Dan Brennan , executive vice president and chief financial officer, and Susie Lisa , v
Read more →BSXBoston Scientific Announces Agreement With Johnson & Johnson To Resolve Guidant Litigation Boston Scientific Corporation (NYSE: BSX) today announced the settlement of the breach of merger agreement lawsuit brought by Johnson & Johnson...
MARLBOROUGH, Mass. , Feb. 17, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the settlement of the breach of merger agreement lawsuit brought by Johnson & Johnson against Guidant Corporation, stemming from Boston Scientific's acquisition of Guidan
Read more →BSXBoston Scientific To Participate In The RBC Capital Markets 2015 Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the RBC Capital Markets 2015 Global Healthcare Conference on February 25 in...
MARLBOROUGH, Mass. , Feb. 13, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the RBC Capital Markets 2015 Global Healthcare Conference on February 25 in New York City . Dan Brennan , executive vice president and chief financial off
Read more →BSXBoston Scientific To Participate In The Leerink 2015 Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink 2015 Global Healthcare Conference on February 11 in New York...
MARLBOROUGH, Mass. , Feb. 9, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Leerink 2015 Global Healthcare Conference on February 11 in New York City . Susan Lisa , vice president, Investor Relations, will participate in a 20-m
Read more →BSXBoston Scientific And C. R. Bard Announce Distribution Agreement For Lutonix® Drug Coated Balloon Boston Scientific Corporation (NYSE: BSX) and C. R. Bard, Inc. (NYSE: BCR) ( Bard ) today announced that Boston Scientific will distribute the...
MARLBOROUGH, Mass. , and MURRAY HILL, N.J. , Feb. 9, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) and C. R. Bard, Inc. (NYSE: BCR ) ("Bard") today announced that Boston Scientific will distribute the Lutonix® 035 Drug Coated Balloon Percutaneous Transluminal An
Read more →BSXBoston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2014 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.887 billion during the fourth quarter ended December 31, 2014, compared to the...
MARLBOROUGH, Mass. , Feb. 4, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.887 billion during the fourth quarter ended December 31, 2014 , compared to the company's guidance range for the quarter of $1.875 to $1.925 billion . This represent
Read more →BSXBoston Scientific Maple Grove Operations Named A 2014 Best Plants Winner The Boston Scientific (NYSE: BSX) Maple Grove Operations facility, Maple Grove, Minn., has been named a 2014 Best Plants winner by IndustryWeek...
MARLBOROUGH, Mass. , Feb. 3, 2015 /PRNewswire/ -- The Boston Scientific (NYSE: BSX ) Maple Grove Operations facility, Maple Grove, Minn. , has been named a 2014 Best Plants winner by IndustryWeek magazine. IndustryWeek annually recognizes manufacturing plants populated with stron
Read more →BSXBoston Scientific Launches World's Longest Lasting ICD Boston Scientific Corporation (NYSE: BSX) announces the launch and first U.S. implant of its line of Extended Longevity (EL) implantable cardioverter ...
MARLBOROUGH, Mass. , Feb. 2, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the launch and first U.S. implant of its line of Extended Longevity (EL) implantable cardioverter defibrillators (ICD), including DYNAGEN™ EL and INOGEN™ EL device models. The f
Read more →BSXBoston Scientific To Host And Webcast Investor Day Business Review May 1, 2015 Boston Scientific Corporation (NYSE: BSX) will host and webcast an Investor Day business review meeting for the investment community on Friday, May...
MARLBOROUGH, Mass. , Jan. 15, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will host and webcast an Investor Day business review meeting for the investment community on Friday, May 1, 2015 . The meeting and webcast are scheduled to begin at 8:00 a.m. ET and exp
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Fourth Quarter 2014 Financial Results On February 4 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth...
MARLBOROUGH, Mass. , Jan. 7, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year ended December 31, 2014 on Wednesday, February 4, 2015 at 8:00 a
Read more →BSXBoston Scientific To Participate In 33rd Annual J.P. Morgan Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13,...
MARLBOROUGH, Mass. , Dec. 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 33 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 in San Francisco . Mike Mahoney , president and chief executive officer, w
Read more →BSXBoston Scientific To Participate In Goldman Sachs CEOs Unscripted Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs CEOs Unscripted Healthcare Conference on Tuesday, January...
MARLBOROUGH, Mass. , Dec. 18, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Goldman Sachs CEOs Unscripted Healthcare Conference on Tuesday, January 6, 2015 in Boston . Mike Mahoney , president and chief executive officer, and
Read more →BSXBoston Scientific Earns Top Marks In Corporate Equality Index Boston Scientific has scored the highest rating of 100 percent in the Human Rights Campaign (HRC) Foundation's 2015 Corporate Equality Index (CEI)....
MARLBOROUGH, Mass. , Nov. 19, 2014 /PRNewswire/ -- Boston Scientific has scored the highest rating of 100 percent in the Human Rights Campaign (HRC) Foundation's 2015 Corporate Equality Index (CEI). The top mark distinguishes the company as one of the "Best Places to Work for LGB
Read more →BSXFirst U.S. Procedures Completed With The Symphion™ Hysteroscopic Tissue Removal System Boston Scientific Corporation (NYSE: BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the...
MARLBOROUGH, Mass. , Nov. 17, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interuterine fibroids and polyps. The all-in-one Symph
Read more →BSXSubcutaneous Implantable Defibrillator Receives Favorable Coding And Payment Designations For 2015 Boston Scientific Corporation (NYSE: BSX) announced that its subcutaneous implantable defibrillator (S-ICD System™) will have designated Current...
MARLBOROUGH, Mass. , Nov. 13, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced that its subcutaneous implantable defibrillator (S-ICD System™) will have designated Current Procedural Terminology (CPT®) Category I codes by the American Medical Association
Read more →BSXBoston Scientific To Participate In 2014 Stifel Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New...
MARLBOROUGH, Mass. , Nov. 5, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New York City. Dan Brennan , executive vice president and chief financial officer, wi
Read more →BSXBoston Scientific To Host And Webcast Investor Event Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on...
MARLBOROUGH, Mass. , Nov. 4, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and discuss data from the EVOLVE II stu
Read more →BSXBoston Scientific Announces Schedule For Presentations At The Upcoming North American Neuromodulation Society (NANS) Meeting Boston Scientific Corporation (NYSE: BSX) is reinforcing the company's commitment to developing innovative and effective therapies in neuromodulation....
MARLBOROUGH, Mass. , Nov. 3, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is reinforcing the company's commitment to developing innovative and effective therapies in neuromodulation. The company will present data on key clinical programs at the 18th North Ameri
Read more →BSXBoston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Credit Suisse Annual Healthcare Conference on Tuesday, November 11, ...
MARLBOROUGH, Mass. , Oct. 30, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2014 Credit Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 in Phoenix , AZ. Dan Brennan , executive vice president and chief financi
Read more →BSXBoston Scientific Announces Results For Third Quarter Ended September 30, 2014 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.846 billion during the third quarter ended September 30, 2014, compared to the...
MARLBOROUGH, Mass. , Oct. 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.846 billion during the third quarter ended September 30, 2014 , compared to the company's guidance range for the quarter of $1.790 to $1.840 billion . This represen
Read more →BSXBoston Scientific Receives FDA And CE Mark Approval For New CoverEdge™ Surgical Leads For The Precision Spectra™ Spinal Cord Stimulator (SCS) System Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) and CE Mark approval for the CoverEdge™ 32 and...
Previous surgical leads have delivered pain therapy with a maximum of 16 independent contacts. By offering 32 contacts – each powered by a dedicated power source – CoverEdge Surgical Leads are designed to deliver more focused coverage of the spinal cord for more pain relief. Avai
Read more →BSXBoston Scientific Initiates Study Of Promus PREMIER™ Coronary Stent System In Underserved Patient Populations As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation (NYSE: BSX) has initiated the PLATINUM...
MARLBOROUGH, Mass. , Oct. 20, 2014 /PRNewswire/ -- As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation (NYSE: BSX ) has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER ™ Everolimus
Read more →BSXBoston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's...
MARLBOROUGH, Mass. , Oct. 16, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark approval for the ACCOLADE TM pacemaker family. When implanted with the company's INGEVITY TM leads, ACCOLADE pacemakers are the first to enable patients to receive f
Read more →BSXFDA Advisory Committee Panel Votes In Favor Of The WATCHMAN™ Left Atrial Appendage Closure Device After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device,...
MARLBOROUGH, Mass. , Oct. 8, 2014 /PRNewswire/ -- After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX ) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of th
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Third Quarter 2014 Financial Results On October 22 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ...
MARLBOROUGH, Mass. , Oct. 1, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2014 on Wednesday, October 22, 2014 at 8:00 a.m. ET . The
Read more →BSXBoston Scientific Enrolls First Patients In U.S. Trial Of The Lotus™ Valve System Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of...
MARLBOROUGH, Mass. , Sept. 23, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with severe aortic stenosis and who are con
Read more →BSXBoston Scientific Receives CE Mark For The Vercise™ Deep Brain Stimulation (DBS) System For Treating Patients With Tremor Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor,...
MARLBOROUGH, Mass. , Sept. 17, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement disorder known as essential tremor
Read more →BSXBoston Scientific Announces Schedule For Presentations At Upcoming TCT 2014 Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life ...
MARLBOROUGH, Mass. , Sept. 10, 2014 /PRNewswire/ -- Beginning Saturday, Boston Scientific Corporation (NYSE: BSX ) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in interventional cardiology. The comp
Read more →BSXBoston Scientific To Participate In 2014 Bank Of America Merrill Lynch Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Bank of America Merrill Lynch Global Healthcare Conference on...
MARLBOROUGH, Mass. , Sept. 3, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2014 Bank of America Merrill Lynch Global Healthcare Conference on September 17, 2014 in London, England . Michael Onuscheck , senior vice president a
Read more →BSXBoston Scientific Closes Acquisition Of Interventional Business Of Bayer AG Boston Scientific Corporation (NYSE: BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer AG. The...
MARLBOROUGH, Mass. , Sept. 2, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) closed on its previously announced agreement to purchase the Interventional business of Bayer AG. The acquisition enhances the ability of Boston Scientific to offer physicians and health
Read more →BSXBoston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first...
MARLBOROUGH, Mass. , Aug. 30, 2014 /PRNewswire/ -- Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical trial investigating vagus nerve stim
Read more →BSXBoston Scientific To Participate In 2014 Morgan Stanley Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Morgan Stanley Global Healthcare Conference on September 8 in New...
MALBOROUGH, Mass., Aug. 25, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2014 Morgan Stanley Global Healthcare Conference on September 8 in New York, NY . Mike Mahoney , chief executive officer, and Dan Brennan , executive vi
Read more →BSXBoston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs Boston Scientific Corporation (NYSE: BSX) and ASAHI INTECC (Securities Code 7747, Second Section, Tokyo and Nagoya Stock Exchange) have formalized...
MARLBOROUGH, Mass. and NAGOYA, Japan , Aug. 19, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) and ASAHI INTECC (Securities Code 7747, Second Section, Tokyo and Nagoya Stock Exchange) have formalized plans to develop a new, differentiated fractional flow reserve
Read more →BSXBoston Scientific Announces Results For Second Quarter Ended June 30, 2014 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's...
MARLBOROUGH, Mass. , July 24, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.873 billion during the second quarter ended June 30, 2014 , compared to the company's guidance range for the quarter of $1.840 to $1.890 billion . This represents 4
Read more →BSXBoston Scientific Receives CE Mark For Agent™ Drug-Coated Balloon Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has...
MARLBOROUGH, Mass. , July 23, 2014 /PRNewswire/ -- Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX ) has received CE Mark and begun the European market launch of the Agent™ Paclitaxel-Coat
Read more →BSXBoston Scientific Launches POLARIS™ Imaging System Boston Scientific Corporation (NYSE: BSX) has initiated full commercial launch of the new POLARIS™ Imaging System. This system will support the...
MARLBOROUGH, Mass. , July 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has initiated full commercial launch of the new POLARIS™ Imaging System. This system will support the Boston Scientific family of intravascular ultrasound (IVUS) catheters, including cor
Read more →BSXBoston Scientific Receives FDA Approval for REBEL™ Platinum Chromium Coronary Stent System Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest...
MARLBOROUGH, Mass. , July 21, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received FDA approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease (CAD). Bar
Read more →BSXBoston Scientific Receives CE Mark For Ranger™ Drug-Coated Balloon Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation...
MARLBOROUGH, Mass. , July 14, 2014 /PRNewswire/ -- Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX ) has received CE Mark for the Ranger™ Paclitaxel-Coated PTA Balloon Cath
Read more →BSXBoston Scientific Receives CE Mark For The New 25 mm Lotus™ Valve System Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus™ Transcatheter Aortic...
MARLBOROUGH, Mass. , July 14, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus™ Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm a
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Second Quarter 2014 Financial Results On July 24 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results, business highlights and outlook for the...
MARLBOROUGH, Mass. , July 1, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results, business highlights and outlook for the second quarter ended June 30, 2014 on Thursday, July 24, 2014 at 8:00 a.m. ET . The
Read more →BSXBoston Scientific Announces One-Year Results In The VANTAGE Clinical Study Evaluating The Vercise™ DBS System Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System...
NATICK, Mass. , June 11, 2014 /PRNewswire/ -- Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX ) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent improvement in motor scores, according to
Read more →BSXClinical Study Results Demonstrate Therapeutic Advantages Of The Boston Scientific Vercise™ DBS System For Patients With Parkinson's Disease A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain...
NATICK, Mass. , June 10, 2014 /PRNewswire/ -- A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX ) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease (PD). The CUSTOM-D
Read more →BSXBoston Scientific Initiates the RESPOND Post Market Registry Evaluating Clinical Outcomes in Patients Implanted With Lotus™ Valve System Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. ...
NATICK, Mass. , June 4, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on clinical outcomes and device performance i
Read more →BSXBoston Scientific To Participate In Goldman Sachs 35th Annual Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 in...
NATICK, Mass. , June 3, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 in Rancho Palos Verdes, CA. David Pierce , senior vice president and president, Endoscopy,
Read more →BSXBoston Scientific To Participate In Wells Fargo 2014 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo 2014 Healthcare Conference on June 17 in Boston, MA. Dan...
NATICK, Mass. , June 3, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Wells Fargo 2014 Healthcare Conference on June 17 in Boston, MA. Dan Brennan , executive vice president and chief financial officer, and Susan Lisa , vice p
Read more →BSXBoston Scientific Lotus™ Valve System Demonstrates Strong Performance And Safety Profile At Six Months Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve ...
PARIS , May 21, 2014 /PRNewswire/ -- Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation (NYSE: BSX ) Lotus™ Valve System continued to demonstrate impressive performance at six months, according to new data
Read more →BSXBoston Scientific Reports Strong Performance Data For SYNERGY™ Stent System Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and...
NATICK, Mass. , May 21, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium (PtCr
Read more →BSXBoston Scientific Announces Definitive Agreement To Acquire Interventional Division Of Bayer AG In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation (NYSE: BSX) has...
NATICK, Mass. , May 15, 2014 /PRNewswire/ -- In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation (NYSE: BSX ) has entered into a definitive agreement to acquire the Interventional Division of Bayer AG fo
Read more →BSXStudy Of Boston Scientific Latitude™ Remote Patient Management System Presented At Heart Rhythm 2014 Demonstrates Significant Reduction In Mortality And Hospitalization Patients using the Boston Scientific Corporation (NYSE: BSX) LATITUDE™ Remote Patient Management system with wireless telemetry demonstrated...
NATICK, Mass. , May 10, 2014 /PRNewswire/ -- Patients using the Boston Scientific Corporation (NYSE: BSX ) LATITUDE ™ Remote Patient Management system with wireless telemetry demonstrated significantly lower mortality and fewer hospitalizations than patients with LATITUDE-compati
Read more →BSXLargest Randomized Clinical Trial Of Implantable Cardioverter Defibrillator Recipients Demonstrates Excellent Patient Outcomes With Or Without Defibrillation Testing A Boston Scientific Corporation (NYSE: BSX) study demonstrated that outcomes for patients with the company's transvenous implantable cardioverter...
NATICK, Mass. , May 8, 2014 /PRNewswire/ -- A Boston Scientific Corporation (NYSE: BSX ) study demonstrated that outcomes for patients with the company's transvenous implantable cardioverter defibrillators (ICD) who received routine defibrillation testing (DT) at implant were sim
Read more →BSXNew Data Presented At WIP 2014 Demonstrate Sustained Low Back Pain Relief With The Boston Scientific Precision Spectra™ Spinal Cord Stimulator System New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate...
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high perf
Read more →BSXBoston Scientific Announces Results For First Quarter Ended March 31, 2014 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.774 billion during the first quarter ended March 31, 2014. This represents 4 percent...
NATICK, Mass. , April 29, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.774 billion during the first quarter ended March 31, 2014 . This represents 4 percent operational revenue growth (constant currency basis, excluding divested businesses
Read more →BSXBoston Scientific Begins Clinical Trial of ACUITY™ X4 LV Pacing Leads and RELIANCE™ 4-FRONT ICD Leads Boston Scientific Corporation (NYSE: BSX) has conducted the first implant in the clinical trial of the next generation ACUITY™ X4 left-ventricular...
NATICK, Mass. , April 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has conducted the first implant in the clinical trial of the next generation ACUITY™ X4 left-ventricular (LV) pacing leads and RELIANCE™ 4-FRONT defibrillation (ICD) leads. The clinical tria
Read more →BSXBoston Scientific To Host And Webcast Investor Event Boston Scientific Corporation (NYSE: BSX) will host an investor event on May 8, 2014 to provide an update on company Cardiac Rhythm Management and...
NATICK, Mass. , April 17, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will host an investor event on May 8, 2014 to provide an update on company Cardiac Rhythm Management and Electrophysiology initiatives as well as developments and technologies in connection
Read more →BSXBoston Scientific Announces FDA Approval Of Innovative New Defibrillators And Heart Failure Devices Boston Scientific Corporation (NYSE: BSX) has received FDA approval for its latest generation of defibrillators and heart failure devices designed to ...
NATICK, Mass. , April 15, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN™ MINI and INO
Read more →BSXFirst Patient Enrolled In Clinical Registry Assessing Boston Scientific Vercise™ Deep Brain Stimulation System In Patients With Parkinson's Disease Boston Scientific Corporation (NYSE: BSX) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of...
NATICK, Mass. , April 10, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise™ Deep Brain Stimulation (DBS) System in patients with Parkinson's disease
Read more →BSXBoston Scientific Introduces the Expect™ Slimline (SL) Needle for Use During Endoscopic Ultrasound Fine Needle Aspiration Procedures Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for...
NATICK, Mass. , April 7, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which is now globally available for Endoscopic Ult
Read more →BSXBoston Scientific Begins Expansion of The S-ICD™ System in Asia Boston Scientific Corporation (NYSE: BSX) has expanded the launch of its S-ICD System into parts of Asia. The first implant of the S-ICD System in...
NATICK, Mass. , April 7, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has expanded the launch of its S-ICD System into parts of Asia . The first implant of the S-ICD System in Asia was performed in Hong Kong by Prof. Hung Fat Tse , Professor of Cardiovascular M
Read more →BSXBoston Scientific Reports Key Data At ACC 2014 For Cardiac Resynchronization Therapy Technology, Platinum Chromium Stents And Lotus™ Valve System Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific...
NATICK, Mass. , April 1, 2014 /PRNewswire/ -- Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation (NYSE: BSX ) reported favorable results in studies related to cardiac resynchroniza
Read more →BSXBoston Scientific To Webcast Conference Call Discussing First Quarter 2014 Financial Results On April 29 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on ...
NATICK, Mass. , April 1, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on Tuesday, April 29, 2014 at 8:00 a.m. ET . The call will be hosted by Mike Mahoney
Read more →BSXNew Data Illustrate Long-Term Safety And Effectiveness Of The Boston Scientific S-ICD™ System Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this...
NATICK, Mass. , April 1, 2014 /PRNewswire/ -- Real-world data on the Boston Scientific Corporation (NYSE: BSX ) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week in the European Heart Journal. The interim analysis of the ongoing EFFORTLESS S-I
Read more →BSXNew Long-term Data Demonstrate Patients with Mild Heart Failure Sustained Lower Mortality Rates After Receiving Boston Scientific CRT Defibrillators In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE:...
NATICK, Mass. , March 30, 2014 /PRNewswire/ -- In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE: BSX ) exclusively sponsored and landmark Multicenter Automatic Defibrillator Implanta
Read more →BSXBoston Scientific Announces Schedule for Presentations at American College of Cardiology 2014 At the 63rd Annual Scientific Session of the American College of Cardiology (ACC), March 29 – 31 in Washington, D.C., Boston Scientific Corporation...
NATICK, Mass. , March 27, 2014 /PRNewswire/ -- At the 63 rd Annual Scientific Session of the American College of Cardiology (ACC), March 29 – 31 in Washington, D.C. , Boston Scientific Corporation (NYSE: BSX ) will reinforce its commitment to research and development of innovativ
Read more →BSXBoston Scientific gibt CE-Kennzeichnung und erste Implantation der INGEVITY™ MRT-Schrittmacher-Elektroden bekannt Die erste Implantation wurde an den Nouvelles Cliniques Nantaises in Nantes, Frankreich, durchgeführt. Boston Scientific Corporation (NYSE: BSX) hat...
NATICK, Massachusetts , March 26, 2014 /PRNewswire/ -- Die erste Implantation wurde an den Nouvelles Cliniques Nantaises in Nantes, Frankreich, durchgeführt. Boston Scientific Corporation (NYSE: BSX ) hat die CE-Kennzeichnung und die europäische Einführung der MRT-kompatiblen S
Read more →BSXBoston Scientific anuncia el marcado CE y primeros implantes para los electrodos de estimulación cardiacarm INGEVITY(TM) content= MSHTML 8.00.6001.19394 El primer implante se ha realizado en Francia, en las Nouvelles Cliniques Nantaises de Nantes. Boston Scientific...
NATICK, Massachusetts , March 25, 2014 /PRNewswire/ -- content="MSHTML 8.00.6001.19394"> El primer implante se ha realizado en Francia, en las Nouvelles Cliniques Nantaises de Nantes. Boston Scientific Corporation (NYSE: BSX ) ha anunciado la aprobación del marcado CE y la come
Read more →BSXBoston Scientific annuncia l'ottenimento del marchio ce e l'esecuzione dei primi impianti degli elettrocateteri per la stimolazione cardiaca INGEVITY™, compatibili con la RMN Il primo impianto è stato eseguito in Francia, presso la Nouvelles Cliniques Nantaises di Nantes Boston Scientific Corporation (NYSE: BSX) annuncia...
NATICK, Massachusetts , March 24, 2014 /PRNewswire/ -- Il primo impianto è stato eseguito in Francia, presso la Nouvelles Cliniques Nantaises di Nantes Boston Scientific Corporation (NYSE: BSX ) annuncia l'ottenimento del marchio CE e l'immissione in commercio, in Europa, della
Read more →BSXBoston Scientific Receives Prestigious Shingo Award for Operational Excellence Boston Scientific has received a Shingo award from the Shingo Institute, part of the Jon M. Huntsman School of Business at Utah State University, in...
NATICK, Mass. , March 19, 2014 /PRNewswire/ -- Boston Scientific has received a Shingo award from the Shingo Institute, part of the Jon M. Huntsman School of Business at Utah State University , in recognition for delivering world class results and demonstrating an ongoing commitm
Read more →BSXBoston Scientific annonce l'obtention du marquage CE et les premières implantations des sondes de stimulation IRM-compatibles INGEVITY(TM) La première implantation a eu lieu en France, aux Nouvelles Cliniques Nantaises de Nantes. Boston Scientific Corporation (NYSE : BSX) a annoncé ce...
NATICK, Massachusetts , March 19, 2014 /PRNewswire/ -- La première implantation a eu lieu en France , aux Nouvelles Cliniques Nantaises de Nantes. Boston Scientific Corporation (NYSE : BSX ) a annoncé ce jour l'obtention du marquage CE ainsi que le lancement sur le marché europ
Read more →BSXBoston Scientific Announces CE Mark Approval and First Implants of Ingevity[TM] MRI Pacing Leads Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance imaging ...
NATICK, Massachusetts , March 14, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance imaging (MRI) compatible pacing leads. Pacing leads are insulated wires that conn
Read more →BSXBoston Scientific Receives CE Mark Approval for REBEL™ Platinum Chromium Coronary Stent System Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum...
NATICK, Mass. , March 12, 2014 /PRNewswire/ -- Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX ) has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the
Read more →BSXBoston Scientific Elects Edward J. Ludwig To Its Board Of Directors The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected Edward J. Ludwig as a Director. The appointment of Mr. Ludwig will...
Mr. Ludwig was formerly the Chief Executive Officer, President and Chairman of the Board of Directors of Becton, Dickinson and Company, a global medical technology company. Mr. Ludwig currently serves as Lead Director on Aetna Inc.'s Board of Directors and chairs its Finance Comm
Read more →BSXBoston Scientific To Participate In The Barclays 2014 Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays Global Healthcare Conference on March 11 in Miami Beach. Dan...
NATICK, Mass. , Feb. 28, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Barclays Global Healthcare Conference on March 11 in Miami Beach . Dan Brennan , executive vice president and chief financial officer, will make a presenta
Read more →BSXBoston Scientific WallFlex™ Esophageal Stent Gains CE Mark For The Treatment Of Refractory Benign Esophageal Strictures Boston Scientific Corporation (NYSE: BSX) has received CE Mark in Europe for its WallFlex™ Esophageal Fully Covered Stent to treat refractory benign...
NATICK, Mass. , Feb. 14, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark in Europe for its WallFlex ™ Esophageal Fully Covered Stent to treat refractory benign esophageal strictures. Benign esophageal strictures are a narrowing of the esophag
Read more →BSXBoston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2013 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.838 billion during the fourth quarter ended December 31, 2013. This represents 5...
NATICK, Mass. , Feb. 4, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.838 billion during the fourth quarter ended December 31 , 2013. This represents 5 percent operational revenue growth (constant currency basis, excluding divested business
Read more →BSXBoston Scientific To Participate In The 2014 Leerink Swann Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Leerink Swann Global Healthcare Conference on Wednesday, February...
NATICK, Mass. , Feb. 3, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2014 Leerink Swann Global Healthcare Conference on Wednesday, February 12, 2014 in New York, NY . Dan Brennan , executive vice president and chief financial
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Fourth Quarter 2013 Financial Results On February 4 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
NATICK, Mass. , Jan. 21, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the fourth quarter and full year ended December 31, 2013 on Tuesday, February 4 , at 8:00 a.m. ET . The call will be hosted
Read more →BSXBoston Scientific Names Craig Thompson, M.D. As New Chief Medical Officer, Interventional Cardiology Boston Scientific Corporation (NYSE: BSX) announces the appointment of Craig Thompson, M.D., as senior vice president and chief medical officer,...
NATICK, Mass. , Jan. 6, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the appointment of Craig Thompson , M.D., as senior vice president and chief medical officer, Interventional Cardiology, effective immediately. Dr. Thompson, a global leader in compl
Read more →BSXBoston Scientific To Participate In 32nd Annual J.P. Morgan Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14,...
NATICK, Mass. , Jan. 2, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 32 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 in San Francisco . Mike Mahoney , president and chief executive officer, will ma
Read more →BSXBoston Scientific Announces CE Mark Approval And First Implants Of Its Next-Generation X4 Quadripolar CRT-D Systems Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4,...
NATICK, Mass. , Dec. 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4, DYNAGEN™ X4, and INOGEN™ X4 cardiac resynchronization therapy defibrillators (CRT-Ds), a
Read more →BSXBoston Scientific Elects David Roux To Its Board of Directors The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected David Roux as a Director. The appointment of Mr. Roux will fill a...
Mr. Roux is a co-founder and Senior Director of Silver Lake, a private equity firm focused on technology investing. He was formerly Chairman and Chief Executive Officer of Liberate Technologies, Executive Vice President at Oracle Corporation and Senior Vice President at Lotus Dev
Read more →BSXFDA Advisory Panel Votes Favorably on the Boston Scientific WATCHMAN™ Left Atrial Appendage Closure Device The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, ...
"We are pleased with the outcome of today's Panel, which represents an important milestone toward making this innovative technology available to patients with AF at higher risk for stroke who need an alternative to long-term warfarin therapy," said Kenneth Stein , M.D., Chief Med
Read more →BSXBoston Scientific Reports Favorable Results Assessing Real-World Experience with the Precision Spectra™ Spinal Cord Stimulator System New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate...
More than 100 million Americans suffer from chronic pain. Living in constant pain for an extended period of time can have a devastating impact on quality of life for many patients. Without pain relief, or the hope for relief, many patients lose the ability to sleep, work, and fun
Read more →BSXBoston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER™ Stent System Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the Boston Scientific Promus ...
NATICK, Mass. and PARSIPPANY, N.J. , Dec. 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) and The Medicines Company (NASDAQ: MDCO ) announce a co-promotion agreement for the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent S
Read more →BSXVercise™, systeme de stimulation cerebrale profonde de Boston Scientific, obtient le marquage CE dans le traitement de la dystonie Premier système stimulant sélectivement des régions ciblées du cerveau afin de soulager les symptômes de la dystonie, une maladie invalidante Le...
NATICK , Massachussetts, November 26, 2013 /PRNewswire/ -- Premier système stimulant sélectivement des régions ciblées du cerveau afin de soulager les symptômes de la dystonie, une maladie invalidante Le système de stimulation cérébrale profonde (DBS Deep Brain Stimulation ) VE
Read more →BSXIl sistema di stimolazione cerebrale profonda di Boston Scientific, Vercise™, riceve l'approvazione del marchio ce per il trattamento della distonia Il primo sistema che stimola in maniera selettiva aree mirate del cervello per gestire i sintomi di questa patologia debilitante Il sistema di...
NATICK, Massachusetts , November 26, 2013 /PRNewswire/ -- Il primo sistema che stimola in maniera selettiva aree mirate del cervello per gestire i sintomi di questa patologia debilitante Il sistema di stimolazione cerebrale profonda (DBS) di Boston Scientific Corporation (NYSE:
Read more →BSXEl sistema de estimulación cerebral profunda Vercise™ recibe el marcado CE para el tratamiento de la distonía Primer sistema que estimula selectivamente áreas cerebrales concretas para tratar los síntomas debilitadores de esta enfermedad El sistema Vercise™...
NATICK , Massachussets, November 26, 2013 /PRNewswire/ -- Primer sistema que estimula selectivamente áreas cerebrales concretas para tratar los síntomas debilitadores de esta enfermedad El sistema Vercise™ de Boston Scientific Corporation (NYSE: BSX ) para la estimulación cereb
Read more →BSXBoston Scientific Receives FDA Approval For Promus Premier™ Everolimus-Eluting Platinum Chromium Coronary Stent System Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...
NATICK, Mass. , Nov. 25, 2013 /PRNewswire/ -- Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium C
Read more →BSXDas Vercise™-System zur tiefen Hirnstimulation von Boston Scientific hat die CE-Kennzeichnung zur Behandlung von Dystonie erhalten Das erste System zur selektiven Stimulation ausgewählter Hirnbereiche zur Behandlung der Symptome dieser schwer beeinträchtigenden Erkrankung Boston...
NATICK, Massachusetts , November 25, 2013 /PRNewswire/ -- Das erste System zur selektiven Stimulation ausgewählter Hirnbereiche zur Behandlung der Symptome dieser schwer beeinträchtigenden Erkrankung Boston Scientific Corporation (NYSE: BSX ) hat bekannt gegeben, dass sein Verc
Read more →BSXBoston Scientific To Participate In 25th Annual Piper Jaffray Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Piper Jaffray Healthcare Conference on December 3 in New...
NATICK, Mass. , Nov. 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 25 th Annual Piper Jaffray Healthcare Conference on December 3 in New York . Mike Mahoney , president and chief executive officer, and Dan Brennan , senior
Read more →BSXSusan Lisa Named Vice President Of Investor Relations Of Boston Scientific Boston Scientific Corporation (NYSE: BSX) announces the appointment of Susan (Susie) Vissers Lisa as vice president, Investor Relations, effective...
NATICK, Mass. , Nov. 21, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the appointment of Susan (Susie) Vissers Lisa as vice president, Investor Relations, effective December 2 , 2013. Lisa has more than 20 years of diverse financial and healthcare ind
Read more →BSXBoston Scientific Receives FDA Clearance And CE Mark Approval For Direxion™ Torqueable Microcatheter Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation (NYSE: BSX) has received U.S....
NATICK, Mass. , Nov. 19, 2013 /PRNewswire/ -- Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation (NYSE: BSX ) has received U.S. Food and Drug Administration clearance and CE Mark approval for its Direxion™ Torque
Read more →BSXBoston Scientific Vercise™ Deep Brain Stimulation System Receives CE Mark Approval for Treatment of Dystonia The Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment of...
NATICK, Massachusetts , November 19, 2013 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX ) Vercise™ Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment of intractable primary and secondary dystonia, a neurological movement disorder c
Read more →BSXBoston Scientific Announces First Commercial Implants Of The Lotus™ Valve System in Europe Marking a major step forward in the evolution of Transcatheter Aortic Valve Implantation (TAVI) technology, the first two commercial implants of the...
NATICK, Mass. , Nov. 15, 2013 /PRNewswire/ -- Marking a major step forward in the evolution of Transcatheter Aortic Valve Implantation (TAVI) technology, the first two commercial implants of the Boston Scientific (NYSE: BSX ) Lotus™ Valve System have taken place in a German hospi
Read more →BSXBoston Scientific Completes Acquisition Of Bard Electrophysiology Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business...
NATICK, Mass. , Nov. 1, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc. The completion of this transaction advances Boston Scientific's ab
Read more →BSXBoston Scientific To Participate In 2013 Credit Suisse Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale,...
NATICK, Mass. , Oct. 31, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale, AZ. Jeff Capello , executive vice president and chief financial officer, and Dan Bre
Read more →BSXBoston Scientific Lotus™ Valve System Meets Primary Performance Endpoint In REPRISE II Trial The Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System met a key performance measure in the treatment of symptomatic patients with severe...
San Francisco , Oct. 31, 2013 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX ) Lotus™ Valve System met a key performance measure in the treatment of symptomatic patients with severe aortic valve stenosis considered at high risk for surgical valve replacement, accord
Read more →BSXBoston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013 Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...
NATICK, Mass. , Oct. 28, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful innovation to clinicians and patients through a robust schedule of sponsored research pres
Read more →BSXBoston Scientific Receives CE Mark For Lotus™ Valve System Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Lotus™ Valve System, the company's advanced transcatheter aortic valve...
NATICK, Mass. , Oct. 28, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark for the Lotus™ Valve System, the company's advanced transcatheter aortic valve replacement (TAVR) technology. This key approval offers a unique and effective new treatmen
Read more →BSXBoston Scientific Announces Transition Plan For New Chief Financial Officer Boston Scientific Corporation (NYSE: BSX) has initiated a transition plan for its new chief financial officer. Noting a desire to pursue...
NATICK, Mass. , Oct. 24, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has initiated a transition plan for its new chief financial officer. Noting a desire to pursue opportunities for a broader management position, Jeffrey Capello , Boston Scientific's executive
Read more →BSXBoston Scientific Announces Results For Third Quarter Ended September 30, 2013 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.17 for the third quarter ended...
NATICK, Mass. , Oct. 24, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.735 billion and adjusted earnings per share of $0.17 for the third quarter ended September 30 , 2013. The company reported a $5 million GAAP loss, or approximately $0.00
Read more →BSXBoston Scientific Receives Prestigious 2013 Prix Galien Award For Best Medical Technology The Boston Scientific Corporation (NYSE: BSX) S-ICD® System has received the Prix Galien USA 2013 Award for Best Medical Technology. The S-ICD System ...
NATICK, Mass. , Oct. 23, 2013 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX ) S-ICD ® System has received the Prix Galien USA 2013 Award for Best Medical Technology. The S-ICD System is the world's first and only commercially available subcutaneous implantable defi
Read more →BSXBoston Scientific Alair® Bronchial Thermoplasty System Approved In China Boston Scientific Corporation (NYSE: BSX) has received China Food and Drug Administration approval for the Alair® Bronchial Thermoplasty System, an...
SHANGHAI , Oct. 23, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received China Food and Drug Administration approval for the Alair ® Bronchial Thermoplasty System, an innovative medical device designed to treat severe asthma. Expected to be available in th
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Third Quarter 2013 Financial Results On October 24 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
NATICK, Mass. , Oct. 10, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the third quarter ended September 30, 2013 on Thursday, October 24 , at 8:00 a.m. ET . The call will be hosted by Mike Mahon
Read more →BSXBoston Scientific Begins Clinical Trial Of Innova™ Peripheral Vascular Drug-Eluting Stent System Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has...
NATICK, Mass. , Oct. 9, 2013 /PRNewswire/ -- Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed the first patient implant of the Boston Scientific Corporation (NYSE: BSX ) Innova™
Read more →BSXNew Data Published In EP EuroPace Journal Highlights Differences In CRT-ICD Battery Longevity Across Manufacturers An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there...
NATICK, Mass. , Oct. 8, 2013 /PRNewswire/ -- An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are significant differences in battery longevity between contemporary cardiac resynchro
Read more →BSXBoston Scientific Reports Favorable Clinical Trial Results Assessing The OffRoad™ Re-Entry Catheter System The Boston Scientific (NYSE: BSX) OffRoad™ Re-Entry Catheter System demonstrated excellent performance in facilitating the treatment of complete...
NATICK, Mass. , Oct. 8, 2013 /PRNewswire/ -- The Boston Scientific (NYSE: BSX ) OffRoad™ Re-Entry Catheter System demonstrated excellent performance in facilitating the treatment of complete blockages in the major arteries that supply blood to the legs. These blockages, called ch
Read more →BSXBoston Scientific Opens Institute For Advancing Science, Innovation Center In Shanghai Reinforcing its ongoing commitment to leadership in the global medical technology market, Boston Scientific Corporation (NYSE: BSX) today officially...
SHANGHAI , Sept. 17, 2013 /PRNewswire/ -- Reinforcing its ongoing commitment to leadership in the global medical technology market, Boston Scientific Corporation (NYSE: BSX ) today officially opened the China branch of the Boston Scientific Institute for Advancing Science (IAS) a
Read more →BSXBoston Scientific Concludes Enrollment In Randomized, Multicenter, Pivotal Study Of SYNERGY™ Coronary Stent System In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE:...
NATICK, Mass. , Sept. 12, 2013 /PRNewswire/ -- In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE: BSX ) has completed enrollment in the EVOLVE II randomized, controlled clinical trial
Read more →BSXBoston Scientific To Participate In 2013 Stifel Nicolaus Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Stifel Nicolaus Healthcare Conference on Sept. 11 in Boston. Jeff...
NATICK, Mass. , Sept. 4, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2013 Stifel Nicolaus Healthcare Conference on Sept. 11 in Boston . Jeff Capello , executive vice president and chief financial officer, will participate in
Read more →BSXBoston Scientific To Participate In 2013 Morgan Stanley Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Morgan Stanley Global Healthcare Conference on Sept. 9 in New York. ...
NATICK, Mass. , Sept. 3, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2013 Morgan Stanley Global Healthcare Conference on Sept. 9 in New York . Mike Mahoney , president and chief executive officer, and Jeff Capello , executiv
Read more →BSXBoston Scientific Receives FDA Approval For IntellaTip MiFi™ XP Ablation Catheter And 510(k) Clearance Of Zurpaz™ 8.5F Steerable Sheath Boston Scientific Corporation (NYSE: BSX) continues to expand its electrophysiology (EP) offerings with U.S. Food and Drug Administration (FDA)...
NATICK, Mass. , Aug. 21, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) continues to expand its electrophysiology (EP) offerings with U.S. Food and Drug Administration (FDA) approval of its IntellaTip MiFi™ XP catheter and 510(k) clearance of its Zurpaz™ 8.5F ste
Read more →BSXBoston Scientific Completes Enrollment In SuperNOVA Trial Evaluating Innova™ Self-Expanding Stent System Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter trial...
NATICK, Mass. , Aug. 19, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter trial evaluating the long-term (12 month) safety and effectiveness of the Innova™ Self-Expandi
Read more →BSXBoston Scientific Completes $1.05 Billion Senior Notes Offering Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.05 billion aggregate principal amount of its senior notes under the...
NATICK, Mass. , Aug. 13, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed a public offering of $1.05 billion aggregate principal amount of its senior notes under the company's shelf registration statement. The public offering consists of $600 million of 2
Read more →BSXBoston Scientific Prices $1.05 Billion Of Senior Notes Boston Scientific Corporation (NYSE: BSX) announces the pricing of a public offering of $1.05 billion aggregate principal amount of its senior notes...
NATICK, Mass. , Aug. 8, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the pricing of a public offering of $1.05 billion aggregate principal amount of its senior notes under the company's shelf registration statement. The public offering consists of $60
Read more →BSXBoston Scientific Announces Results For Second Quarter Ended June 30, 2013 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.809 billion and adjusted earnings per share of $0.18 for the second quarter ended...
NATICK, Mass. , July 25, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.809 billion and adjusted earnings per share of $0.18 for the second quarter ended June 30 , 2013. The company reported GAAP earnings of $0.10 per share. Second quarter
Read more →BSXBoston Scientific Receives FDA 510(k) Clearance for the Rhythmia™ Mapping System Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rhythmia™ Mapping System, a...
NATICK, Mass. , July 24, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation solution for use in cardiac catheter ablati
Read more →BSXBoston Scientific Launches OptiCross™ Coronary Imaging Catheter in U.S., Europe and Japan The Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its...
NATICK, Mass. , July 24, 2013 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX ) has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its OptiCross™ Coronary Imaging Catheter and has launched the device in the U.S. and Europe.
Read more →BSXBoston Scientific Launches Trial To Evaluate Neurostimulation For Treatment Of Chronic Migraine Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™...
Migraine is a neurological disorder affecting one in 10 adults worldwide. Sufferers have headaches that last more than four hours a day with some adults experiencing headaches 15 or more days per month. Migraine is considered by the World Health Organization (WHO) to be one of th
Read more →BSXBoston Scientific Launches Guidezilla™ Guide Extension Catheter in U.S. and Europe Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla™...
NATICK, Mass. , July 12, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla™ Guide Extension Catheter and has launched the device in the U.S. and Europe. The Guide
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Second Quarter 2013 Financial Results On July 25 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2013 on ...
NATICK, Mass. , July 11, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the second quarter ended June 30, 2013 on Thursday, July 25 , at 8:00 a.m. ET . The call will be hosted by Michael Mahoney ,
Read more →BSXBoston Scientific To Acquire C.R. Bard Electrophysiology Business In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific...
NATICK, Mass. , June 28, 2013 /PRNewswire/ -- In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation (NYSE: BSX ) has entered into a definitive agreement to acquire Bard EP, the
Read more →BSXBoston Scientific Vercise™ DBS System demonstrates Improvement In Motor Function For Patients With Parkinson's Disease Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a...
NATICK, Mass. , June 18, 2013 /PRNewswire/ -- Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX ) Vercise™ DBS (deep brain stimulation) System showed a significant improvement in motor scores according to interim data from the VANTAGE DBS study.
Read more →BSXBoston Scientific Begins Patient Enrollment In U.S. Clinical Trial For Use Of Vercise™ DBS System In Treatment Of Parkinson's Disease Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial....
NATICK, Mass. , June 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled study to ev
Read more →BSXBoston Scientific Announces Collaboration with Pelvic Floor Disorders Network to Study Treatment Strategies for Uterine Prolapse Boston Scientific Corporation (NYSE: BSX) continues to demonstrate its commitment to women's health by providing a research and education grant of...
NATICK, Mass. , June 3, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) continues to demonstrate its commitment to women's health by providing a research and education grant of more than $1 million to the Pelvic Floor Disorders Network (PFDN) for the SUPeR clinica
Read more →BSXBoston Scientific Receives CE Mark Approval For GUIDE™ DBS System Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of the GUIDE™ DBS System, the world's first deep brain stimulation...
NATICK, Mass. , May 27, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark approval for use of the GUIDE™ DBS System, the world's first deep brain stimulation (DBS) visualization system. GUIDE DBS provides clinicians with 3D visualization informa
Read more →BSXNew Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix™ Renal Denervation System Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and...
PARIS , May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix™ Renal Denervation
Read more →BSXBoston Scientific Reports Lotus™ Valve System Met Primary Performance Endpoint in REPRISE II Trial Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II...
PARIS , May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of the Lotus™ Valve System in symptomatic patient
Read more →BSXBoston Scientific Promus PREMIER™ And SYNERGY™ Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy Data Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies,...
PARIS , May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human us
Read more →BSXBoston Scientific Long Term Data Demonstrate Bronchial Thermoplasty Treatment Benefits Persist Out to Five Years in Patients with Severe Asthma Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation...
NATICK, Mass. , May 21, 2013 /PRNewswire/ -- Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX ) Alair ® Bronchial Thermoplasty (BT) System continues to show therapy benefits
Read more →BSXBoston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. We are pleased to...
NATICK, Mass. , May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris . Schedule of Events All events are Paris time and take place at the Palais des Congres. Tuesday, May
Read more →BSXBoston Scientific Presents Clinical Data at Digestive Disease Week® Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in Digestive Disease Week (DDW®) 2013, May 18-21 in Orlando, Fla. More than 24...
NATICK, Mass. , May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in Digestive Disease Week (DDW®) 2013, May 18-21 in Orlando , Fla. More than 24 clinical presentations will feature new data and analyses on products including the
Read more →BSXFirst Patient Enrolled In Boston Scientific Randomized Study Comparing WallFlex® Biliary RX Stent To Absence Of Biliary Drainage In Patients With Pancreatic Or Periampullary Cancers The first patient has been enrolled in a clinical investigation evaluating the use of the Boston Scientific Corporation (NYSE: BSX) WallFlex® Biliary ...
NATICK, Mass. , May 15, 2013 /PRNewswire/ -- The first patient has been enrolled in a clinical investigation evaluating the use of the Boston Scientific Corporation (NYSE: BSX ) WallFlex® Biliary RX Stent, a self-expanding metal stent (SEMS), as a bridge to surgery compared with
Read more →BSXBoston Scientific Receives CE Mark Approval For The Rhythmia™ Mapping System Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation ...
NATICK, Mass. , May 10, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) proc
Read more →BSXNew Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The PROTECT AF Trial Boston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN®...
NATICK, Mass. , May 9, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left Atrial Appendage (LAA) Closure device was statistically superior to warfarin for pre
Read more →BSXBoston Scientific To Participate In The Bank Of America Merrill Lynch 2013 Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2013 Healthcare Conference on May 15 in...
NATICK, Mass. , May 8, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Bank of America Merrill Lynch 2013 Healthcare Conference on May 15 in Las Vegas . Jeff Capello , executive vice president and chief financial officer, will p
Read more →BSXBoston Scientific Completes First-In-Human Clinical Trial of the IntellaTip MiFi™ XP Ablation Catheter For Patients With Type 1 Atrial Flutter Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi™ XP Ablation Catheter for the...
NATICK, Mass. , May 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed a first-in-human clinical trial utilizing the IntellaTip MiFi™ XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia originating in the right atrium of the he
Read more →BSXBoston Scientific Schedule of Major Events and Presentations at Heart Rhythm 2013 Boston Scientific Corporation (NYSE: BSX) is scheduled to participate at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific...
NATICK, Mass. , May 3, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate at Heart Rhythm 2013, the Heart Rhythm Society's 34 th Annual Scientific Sessions May 8-11 in Denver . Forty-two clinical presentations will provide new insights abo
Read more →BSXBoston Scientific Announces Results For First Quarter Ended March 31, 2013 Boston Scientific Corporation (NYSE: BSX) generated sales of $1.761 billion and adjusted earnings per share of $0.16 for the first quarter ended...
NATICK, Mass. , April 25, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.761 billion and adjusted earnings per share of $0.16 for the first quarter ended March 31 , 2013. The company reported a GAAP loss of $0.26 per share, primarily due to
Read more →BSXBoston Scientific Begins Clinical Trial To Evaluate New Pacing System in MRI Environment The first patient in the United States has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation ImageReady™ MR...
The next generation ImageReady pacing system is comprised of the Boston Scientific Ingenio™ MRI pacemaker family and the new INGEVITY™ MRI pacing leads. The proprietary technology is aimed at reducing MRI interference with device performance. In addition, the INGEVITY pacing lead
Read more →BSXBoston Scientific Launches Precision Spectra™ Spinal Cord Stimulator System In The United States Boston Scientific Corporation (NYSE: BSX) has received approval by the U.S. Food and Drug Administration and is beginning a limited launch of the...
More than 100 million Americans suffer from chronic pain. Living in constant pain for an extended period of time can have a devastating impact on quality of life for many patients. Without relief, or the hope for relief, many patients lose the ability to sleep, work and function
Read more →BSXBoston Scientific To Webcast Conference Call Discussing First Quarter 2013 Financial Results On April 25 Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2013 on ...
NATICK, Mass. , April 10, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the first quarter ended March 31, 2013 on Thursday, April 25 , at 8:00 a.m. ET . The call will be hosted by Mike Mahoney ,
Read more →BSXThe Boston Scientific PROMUS Element™ Platinum Chromium Stent Demonstrates Continued Low Event Rates Through Three Years Boston Scientific Corporation (NYSE: BSX) reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and...
NATICK, Mass. , March 10, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Coronary
Read more →BSXPresentation of Preliminary Results From Boston Scientific PREVAIL Clinical Trial Now Available Boston Scientific Corporation (NYSE: BSX) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at...
NATICK, Mass. , March 9, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at http://www.tctmd.com/show.aspx?id=118115 . PREVAIL evaluates the safety and efficacy of the
Read more →BSXThe Boston Scientific Watchman® Device Continues To Demonstrate Positive Clinical Outcomes For Patients With Atrial Fibrillation Boston Scientific Corporation (NYSE: BSX) reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints. The...
NATICK, Mass. , March 9, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints. The PREVAIL trial evaluates safety and efficacy of the WATCHMAN® Left Atrial Appendage (LAA)
Read more →BSXBoston Scientific Launches Rubicon™ Support Catheter in 0.035 and 0.018 Diameters Boston Scientific Corporation (NYSE: BSX) has begun the launch of its 0.035 and 0.018 Rubicon™ Support Catheter in the United States. The device is ...
NATICK, Mass. , March 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has begun the launch of its 0.035" and 0.018" Rubicon™ Support Catheter in the United States. The device is designed to assist physicians with placement and support of guidewires that are use
Read more →BSXBoston Scientific Updates PREVAIL Late Breaking Clinical Trials Presentation The Boston Scientific Corporation (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the...
NATICK, Mass. , March 6, 2013 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX ) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the 62nd Annual Scientific Sessions of the American College of Cardiology, and will incl
Read more →BSXBoston Scientific To Participate In 2013 RBC Capital Markets Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 RBC Capital Markets Healthcare Conference on February 26 in New...
NATICK, Mass. , Feb. 21, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2013 RBC Capital Markets Healthcare Conference on February 26 in New York . Executive Vice President and Chief Financial Officer Jeff Capello will particip
Read more →BSXBoston Scientific to Participate in the Citi 2013 Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Citi 2013 Global Healthcare Conference on February 25 in New York....
NATICK, Mass. , Feb. 20, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Citi 2013 Global Healthcare Conference on February 25 in New York . Executive Vice President and Chief Financial Officer Jeff Capello will participate in a
Read more →BSXPromus PREMIER™ Everolimus-Eluting Platinum Chromium Stent System Receives CE Mark Approval Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent...
NATICK, Mass. , Feb. 12, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) techno
Read more →BSXBoston Scientific To Participate In 2013 Leerink Swann Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Leerink Swann Global Healthcare Conference on February 13 in New...
NATICK, Mass. , Feb. 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2013 Leerink Swann Global Healthcare Conference on February 13 in New York . Boston Scientific Chief Financial Officer Jeff Capello will participate in a 25
Read more →BSXBoston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2012 Boston Scientific Corporation (NYSE: BSX) announces financial results for the fourth quarter and full year ended December 31, 2012, as well as sales...
NATICK, Mass. , Jan. 29, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces financial results for the fourth quarter and full year ended December 31, 2012 , as well as sales and earnings per share (EPS) guidance for the first quarter and full year 2013. Fo
Read more →BSXBoston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
NATICK, Mass. , Jan. 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the fourth quarter and full year ended December 31st, 2012 on Tuesday, January 29th , at 8:00 a.m. ET . The call will be hos
Read more →BSXFirst Patient Treated In The Boston Scientific ZERO AF Clinical Trial To Evaluate The Safety And Performance Of The Blazer® Open-Irrigated Temperature Ablation Catheter The first patient has been treated in the Boston Scientific Corporation (NYSE: BSX) ZERO AF clinical trial to evaluate the safety and effectiveness...
NATICK, Mass. , Jan. 16, 2013 /PRNewswire/ -- The first patient has been treated in the Boston Scientific Corporation (NYSE: BSX ) ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer® Open-Irrigated Temperature Ablation Catheter in patients with symptoma
Read more →BSXBoston Scientific To Host And Webcast Investor Day Meeting On February 12, 2013 Boston Scientific Corporation (NYSE: BSX) will host an Investor Day meeting on Tuesday, February 12, 2013. The meeting is scheduled to begin with a...
NATICK, Mass. , Jan. 8, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will host an Investor Day meeting on Tuesday, February 12 , 2013. The meeting is scheduled to begin with a presentation about the company at 9:00 a.m. ET , followed by a question and answer se
Read more →BSXBoston Scientific to Participate in 31st Annual J.P. Morgan Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on...
NATICK, Mass. , Dec. 20, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2013 . Mike Mahoney , president and chief executive officer, will mak
Read more →BSXBoston Scientific Begins Clinical Trial of Patients Implanted with INGEVITY™ Pacing Leads The first patient has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation INGEVITY™ pacing leads in a clinical trial...
NATICK, Mass. , Dec. 17, 2012 /PRNewswire/ -- The first patient has been implanted with the Boston Scientific Corporation (NYSE: BSX ) next generation INGEVITY™ pacing leads in a clinical trial designed to establish the safety, performance and effectiveness of the leads. Pacing l
Read more →BSXThe Boston Scientific Close the Gap Crossroads Classic Brings A Healthy Heart Message To Basketball Fans The Boston Scientific Corporation (NYSE: BSX) health equity initiative, Close the Gap, will once again be the title sponsor of the Crossroads...
NATICK, Mass. , Dec.12, 2012 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX ) health equity initiative, Close the Gap, will once again be the title sponsor of the Crossroads Classic, one of the premier non-conference events in college basketball. The Close the Gap C
Read more →BSXBoston Scientific Receives European Regulatory Approval For New Precision Spectra™ Spinal Cord Stimulator System Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval and has begun the European market launch of the Precision Spectra™ Spinal...
Chronic pain affects one in five adults in Europe , or about 95 million people 15 to 64 years of age. Living in constant pain for an extended period of time can have a devastating impact on quality of life for many patients. Without relief, or the hope for relief, many patients l
Read more →BSXFirst Patient Enrolled in Boston Scientific Randomized Study of Removable WallFlex® Biliary RX Fully Covered Stent for Patients Suffering From Chronic Pancreatitis The first patient has been enrolled in a Boston Scientific Corporation (NYSE: BSX) study comparing the WallFlex® Biliary RX Fully Covered...
NATICK, Mass. , Dec. 4, 2012 /PRNewswire/ -- The first patient has been enrolled in a Boston Scientific Corporation (NYSE: BSX ) study comparing the WallFlex® Biliary RX Fully Covered self-expanding metal stent (SEMS) to plastic stents for the treatment of benign bile duct strict
Read more →BSXFirst Patient Enrolled in the Boston Scientific Multicenter Study of the SYNERGY™ Coronary Stent System Featuring a Bioabsorbable Polymer Coating The first patient has been enrolled in the Boston Scientific Corporation (NYSE: BSX) EVOLVE II clinical trial, which is designed to further assess...
NATICK, Mass. , Nov. 30, 2012 /PRNewswire/ -- The first patient has been enrolled in the Boston Scientific Corporation (NYSE: BSX ) EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the SYNERGY Stent System and support U.S. Food and Dru
Read more →BSXLa marca CE certifica la larga duración de los desfibriladores de Boston Scientific Se calcula que estos dispositivos duren hasta el doble que productos similares Boston Scientific Corporation (NYSE: BSX) ha obtenido el marcado CE...
PARIS , November 20, 2012 /PRNewswire/ -- Se calcula que estos dispositivos duren hasta el doble que productos similares Boston Scientific Corporation (NYSE: BSX ) ha obtenido el marcado CE que acredita las excelentes proyecciones de longevidad de sus desfibriladores automático
Read more →BSXLes defibrillateurs de Boston Scientific obtiennent le marquage CE pour leur longevite etendue La longévité attendue pour ces dispositifs est deux fois plus étendue que celle de produits similaires Boston Scientific Corporation (NYSE : BSX)...
PARIS , November 20, 2012 /PRNewswire/ -- La longévité attendue pour ces dispositifs est deux fois plus étendue que celle de produits similaires Boston Scientific Corporation (NYSE : BSX ) vient d'obtenir une modification de marquage CE en reconnaissance de l'extension de longé
Read more →BSXDefibrillatoren von Boston Scientific erhalten CE-Kennzeichnung für längere funktionsdauer Prognose lässt eine bis zu zweimal höhere Funktionsdauer wie vergleichbare Geräte erwarten Boston Scientific Corporation (NYSE: BSX) hat die...
PARIS , November 20, 2012 /PRNewswire/ -- Prognose lässt eine bis zu zweimal höhere Funktionsdauer wie vergleichbare Geräte erwarten Boston Scientific Corporation (NYSE: BSX ) hat die CE-Kennzeichnung für die Langzeitprognose zur Funktionsdauer für die implantierbaren Defibrill
Read more →BSXBoston Scientific to Acquire Vessix Vascular, Inc. Boston Scientific Corporation (NYSE: BSX) is extending its reach into the strategically critical renal denervation market by signing a definitive...
NATICK, Mass. , Nov. 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is extending its reach into the strategically critical renal denervation market by signing a definitive agreement to acquire Vessix Vascular, Inc., a privately held company based in Laguna Hil
Read more →BSXImproved Device Programming Reduces Inappropriate Therapy and Risk of Death for Implantable Defibrillator Patients Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center presented positive results from the Multicenter Automatic...
NATICK, Mass. , Nov. 6, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) and the University of Rochester Medical Center presented positive results from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) clinical tria
Read more →BSXMichael F. Mahoney Assumes Role of Chief Executive Officer and President of Boston Scientific In an expected move that follows a previously announced leadership transition period, Boston Scientific Corporation (NYSE: BSX) today named Michael F....
NATICK, Mass. , Nov. 1, 2012 /PRNewswire/ -- In an expected move that follows a previously announced leadership transition period, Boston Scientific Corporation (NYSE: BSX ) today named Michael F. Mahoney its new chief executive officer and president. Mahoney succeeds interim CEO
Read more →BSXBoston Scientific Receives CE Mark Approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System...
NATICK, Mass. , Oct. 31, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) received CE Mark approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating. The SYNERGY Sten
Read more →BSXPROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy Boston Scientific Corporation (NYSE:BSX) has received approval to update the directions for use (DFU) labeling for PROMUS Element™ and PROMUS...
NATICK, Mass. , Oct. 24, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received approval to update the directions for use (DFU) labeling for PROMUS Element™ and PROMUS Element™ Plus Coronary Stent Systems to include three-month Dual Anti-Platelet Therapy (DA
Read more →BSXThe Boston Scientific PROMUS Element™ Platinum Chromium Stent Demonstrates Positive Outcomes in Patients with Long Coronary Lesions Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the ...
NATICK, Mass. , Oct. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent System in patient
Read more →BSXBoston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami Boston Scientific Corporation (NYSE: BSX) further demonstrated the strength of its structural heart program today at the 24th Annual Transcatheter...
NATICK, Mass. , Oct. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) further demonstrated the strength of its structural heart program today at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascula
Read more →BSXThe Boston Scientific Epic™ Stent Continues to Demonstrate Positive Clinical Outcomes for Patients with Iliac Artery Disease Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and...
NATICK, Mass. , Oct. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and effectiveness outcomes for the Epic™ Self-Expanding Nitinol Stent System in patients wit
Read more →BSXBoston Scientific Schedule of Major Presentations at Transcatheter Cardiovascular Therapies 2012 Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics...
NATICK, Mass. , Oct. 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, which
Read more →BSXBoston Scientific Announces Third Quarter 2012 Results Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.16 for the third quarter ended...
NATICK, Mass. , Oct. 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.735 billion and adjusted earnings per share of $0.16 for the third quarter ended September 30 , 2012. The company reported a GAAP loss of $0.52 per share, lower than pre
Read more →BSXFirst Patient Enrolled in REPRISE II TAVR Clinical Trial to Evaluate the Safety and Performance of the Lotus™ Valve System Boston Scientific (NYSE: BSX) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™...
NATICK, Mass. , Oct. 10, 2012 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™ Valve System in up to 120 patients with severe aortic valve disease. This internationa
Read more →BSXBoston Scientific Launches Victory Guidewire For Crossing Resistant Lesions In Peripheral Arteries Boston Scientific Corporation (NYSE: BSX) has begun the United States and European launch of its Victory™ guidewire, designed to facilitate crossing...
NATICK, Mass. , Oct. 9, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has begun the United States and European launch of its Victory™ guidewire, designed to facilitate crossing of resistant lesions and the placement and exchange of balloon catheters or other int
Read more →BSXBoston Scientific To Announce Third-Quarter 2012 Financial Results On October 18th Boston Scientific Corporation (NYSE: BSX) will webcast its third-quarter 2012 financial results conference call on Thursday, October 18th, at 8:00...
NATICK, Mass. , Oct. 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its third-quarter 2012 financial results conference call on Thursday, October 18th , at 8:00 a.m. Eastern Time . The call will be hosted by Hank Kucheman , chief executive office
Read more →BSXBoston Scientific to Acquire Rhythmia Medical, Inc. Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of...
NATICK, Mass. , Oct. 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of next-generation mapping and navigation solutions for use in cardiac catheter ablations
Read more →BSXNew Public Awareness Campaign Launched to Promote Awareness of Pelvic Floor Disorders and Treatment Options for Women Boston Scientific Corporation (NYSE: BSX) is a founding member of the Pelvic Floor Disorders (PFD) Alliance, a first-of-its-kind partnership formed...
NATICK, Mass. , Oct. 3, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is a founding member of the Pelvic Floor Disorders (PFD) Alliance, a first-of-its-kind partnership formed to raise awareness of Pelvic Floor Disorders (PFDs) and help improve the quality of li
Read more →BSXBoston Scientific Receives FDA Approval of First-in-Class S-ICD® System for Patients at Risk of Sudden Cardiac Arrest The U.S. Food and Drug Administration has granted Boston Scientific Corporation (NYSE: BSX) regulatory approval for its S-ICD® System, the world's...
NATICK, Mass. , Sept. 28, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration has granted Boston Scientific Corporation (NYSE: BSX ) regulatory approval for its S-ICD ® System, the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD)
Read more →BSXBoston Scientific Launches Vercise™ Deep Brain Stimulation System in Europe Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for use of its Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
NATICK, Mass. , Sept. 28, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) received CE Mark approval for use of its Vercise™ Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease. The Vercise DBS System is the first and only commercially avai
Read more →BSXBoston Scientific Launches Emerge™ PTCA Balloon Dilatation Catheter in the U.S. Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge™ Percutaneous Transluminal Coronary ...
NATICK, Mass. , Sept. 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received U.S. Food and Drug Administration clearance for the Emerge™ Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter and has begun marketing the device
Read more →BSXBoston Scientific Launches New Implantable Defibrillation Lead In Europe And Asia Boston Scientific Corporation (NYSE: BSX) has received regulatory approval to market the RELIANCE® 4-FRONT™ lead, its next generation implantable...
PARIS , Sept. 24, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has received regulatory approval to market the RELIANCE® 4-FRONT™ lead, its next generation implantable defibrillation lead now available in Europe and Asia . Defibrillation leads are insulated wire
Read more →BSXBoston Scientific to Acquire BridgePoint Medical, Inc. Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire BridgePoint Medical, Inc., a privately held company based in...
NATICK, Mass. , Sept. 19, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has signed a definitive agreement to acquire BridgePoint Medical, Inc., a privately held company based in Minneapolis , Minnesota. BridgePoint Medical has developed a proprietary, catheter-b
Read more →BSXBronchial Thermoplasty Awarded Category I CPT® Procedure Codes The American Medical Association (AMA) Current Procedural Terminology (CPT®1) Editorial Panel has assigned Category I CPT codes specifically for...
NATICK, Mass. , Sept. 19, 2012 /PRNewswire/ -- The American Medical Association (AMA) Current Procedural Terminology (CPT ® 1 ) Editorial Panel has assigned Category I CPT codes specifically for bronchial thermoplasty in its recently published CPT 2013 Professional Edition. Begin
Read more →BSXBoston Scientific to Participate in the 2012 Morgan Stanley Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2012 Morgan Stanley Global Healthcare Conference on September 12th in...
NATICK, Mass. , Sept. 6, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2012 Morgan Stanley Global Healthcare Conference on September 12th in New York. Company President Mike Mahoney and Executive Vice President and Chief Finan
Read more →BSXBoston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use European regulators have approved an expanded indication for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA)...
NATICK, Mass. , Aug. 26, 2012 /PRNewswire/ -- European regulators have approved an expanded indication for the Boston Scientific Corporation (NYSE: BSX ) WATCHMAN ® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients with atrial fibrillation (AF), and a
Read more →BSXLa famiglia di pacemaker INGENIO di Boston Scientific riceveilmarchio CE per la sua compatibilità con la risonanza magnetica Questa settimana sono stati eseguiti in Europa i primi impianti del pacemaker INGENIO™ MRI dotato della nuova tecnologia Image Ready™ Boston...
PARIGI, August 1, 2012 /PRNewswire/ -- Questa settimana sono stati eseguiti in Europa i primi impianti del pacemaker INGENIO™ MRI dotato della nuova tecnologia Image Ready™ Boston Scientific Corporation (NYSE: BSX ) ha ottenuto la marcatura CE, per l'impiego dei suoi pacemaker
Read more →BSXLa familia de marcapasos INGENIO de Boston Scientific obtiene el marcado CE para su uso durante las pruebas de resonancia magnética Esta semana se realizan los primeros implantes en Europa de los marcapasos INGENIO™ para RM con tecnología New Image Ready™ Boston Scientific...
PARÍS, August 1, 2012 /PRNewswire/ -- Esta semana se realizan los primeros implantes en Europa de los marcapasos INGENIO™ para RM con tecnología New Image Ready™ Boston Scientific Corporation (NYSE: BSX ) ha recibido la aprobación del marcado CE para el uso de los marcapasos IN
Read more →BSXLa gamme de stimulateurs cardiaques INGENIO de Boston Scientific obtient le marquage CE pour son utilisation avec l'imagerie par resonance magnetique (IRM) Les premières implantations en Europe du stimulateur cardiaque INGENIO™ MRI, doté de la nouvelle technologie Image Ready™, ont été effectuées cette...
PARIS , August 1, 2012 /PRNewswire/ -- Les premières implantations en Europe du stimulateur cardiaque INGENIO™ MRI, doté de la nouvelle technologie Image Ready™, ont été effectuées cette semaine Boston Scientific Corporation (NYSE: BSX ) a obtenu le marquage CE pour l'utilisati
Read more →BSXDie Familie der INGENIO-Herzschrittmacher erhält die CE-Kennzeichnung für den Einsatz bei MRT-Scans Die ersten europäischen Implantationen des INGENIO™-MRI-Herzschrittmachers mit der neuen Image Ready™ -Technologie wurden in dieser Woche...
PARIS , August 1, 2012 /PRNewswire/ -- Die ersten europäischen Implantationen des INGENIO™-MRI-Herzschrittmachers mit der neuen "Image Ready™"-Technologie wurden in dieser Woche durchgeführt. Boston Scientific Corporation (NYSE: BSX ) hat die CE-Kennzeichnung für den Einsatz de
Read more →BSXBoston Scientific Announces Second Quarter 2012 Results Boston Scientific Corporation (NYSE: BSX) generated sales of $1.828 billion and adjusted earnings per share of $0.17 for the second quarter ended...
NATICK, Mass. , July 26, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.828 billion and adjusted earnings per share of $0.17 for the second quarter ended June 30 , 2012. The company reported a GAAP loss of $2.39 per share, lower than previou
Read more →BSXBoston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting Boston Scientific Corporation (NYSE: BSX) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and...
NATICK, Mass. , July 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and only 16-contact percutaneous lead for spinal cord stimulation (SCS) therapy, and the
Read more →BSXBoston Scientific to Announce Second-Quarter 2012 Financial Results on July 26 Boston Scientific Corporation (NYSE: BSX) will webcast its second-quarter 2012 financial results conference call on Thursday, July 26, at 8:00 a.m....
NATICK, Mass. , July 12, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its second-quarter 2012 financial results conference call on Thursday, July 26 , at 8:00 a.m. Eastern Time . The call will be hosted by Hank Kucheman , chief executive officer,
Read more →BSXEl sistema S-ICD® de Boston Scientific reconocido como el producto más innovador en Cardiostim 2012 El sistema S-ICD® ha sido escogido como el más innovador en el sector de la electrofisiología y las técnicas cardiacas Los asistentes de Cardiostim...
PARÍS, July 4, 2012 /PRNewswire/ -- El sistema S-ICD ® ha sido escogido como el más innovador en el sector de la electrofisiología y las técnicas cardiacas Los asistentes de Cardiostim 2012, un congreso médico mundial celebrado recientemente en Niza, Francia, han escogido al si
Read more →BSXS-ICD® System von Boston Scientific auf dem Cardiostim 2012 zum innovativsten Produkt gekürt Das S-ICD®System wurde zum innovativsten Produkt im Bereich Elektrophysiologie und Kardiotechnik gewählt Die Teilnehmer der globalen medizinischen...
PARIS , July 4, 2012 /PRNewswire/ -- Das S-ICD ® System wurde zum innovativsten Produkt im Bereich Elektrophysiologie und Kardiotechnik gewählt Die Teilnehmer der globalen medizinischen Konferenz Cardiostim 2012, die in Nizza, Frankreich, stattfand, wählten das kürzlich von Bos
Read more →BSXIl sistema S-ICD® di Boston Scientific eletto il prodotto più innovativo a Cardiostim 2012 Il sistema S-ICD® è stato selezionato come il più innovativo nel settore dell'elettrofisiologia e delle tecniche cardiache I partecipanti a...
PARIGI, July 4, 2012 /PRNewswire/ -- Il sistema S-ICD ® è stato selezionato come il più innovativo nel settore dell'elettrofisiologia e delle tecniche cardiache I partecipanti a Cardiostim 2012, congresso mondiale che tratta temi clinici tenutosi di recente a Nizza (Francia) ,
Read more →BSXBoston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug...
NATICK, Mass. , July 2, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug Administration (FDA) approval for the WATCHMAN® Left Atrial Appendage (LAA) Closure device. The
Read more →BSXBoston Scientific Commends Congress on Passage of Bill Reauthorizing Medical Device User Fees Boston Scientific Corporation (NYSE: BSX) welcomes final passage today by the United States Senate of The Food and Drug Administration Safety and...
NATICK, Mass. , June 26, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) welcomes final passage today by the United States Senate of "The Food and Drug Administration Safety and Innovation Act." The bill reauthorizes medical device user fees negotiated as part of
Read more →BSXEl sistema de monitorización remota de pacientes LATITUDE® NXT de Boston Scientific ya es una realidad El sistema inalámbrico de nueva generación para la monitorización remota de pacientes, compatibilizado con la familia de marcapasos INGENIO™, ya se...
NATICK, Massachusetts , June 19, 2012 /PRNewswire/ -- El sistema inalámbrico de nueva generación para la monitorización remota de pacientes, compatibilizado con la familia de marcapasos INGENIO™, ya se utiliza en Europa Boston Scientific Corporation (NYSE: BSX ) ha comenzado a
Read more →BSXBoston Scientific annonce la première activation du systeme de suivi a distance LATITUDE™ NXT La dernière génération du système de surveillance des patients à distance, compatible avec la gamme de stimulateurs cardiaques INGENIO ™, est...
NATICK, Massachusetts et PARIS , June 19, 2012 /PRNewswire/ -- ™ , est désormais utilisée en Europe Boston Scientific Corporation (NYSE: BSX ) a débuté en Europe l'utilisation du système de suivi des patients à distance LATITUDE NXT. Le Dr. Roberto Verlato , chef du service de
Read more →BSXBoston Scientific gibt den ersten Einsatz des Patientenmanagementsystems LATITUDE™ NXT zur Fernüberwachung bekannt Das kabellose Patientenmanagementsystem, das abgestimmt ist auf die INGENIO™-Herzschrittmacherfamilie, kommt nun in Europa zum Einsatz Boston...
NATICK, Massachusetts und PARIS , June 18, 2012 /PRNewswire/ -- Das kabellose Patientenmanagementsystem, das abgestimmt ist auf die INGENIO ™ -Herzschrittmacherfamilie, kommt nun in Europa zum Einsatz Boston Scientific Corporation (NYSE: BSX ) hat mit dem Einsatz des LATITUDE-N
Read more →BSXBoston Scientific annuncia il monitoraggio remoto del primo paziente con il nuovo sistema di gestione remota LATITUDE™ NXT La nuova generazione del sistema wireless di gestione remota dei pazienti, abilitato per la famiglia di pacemaker INGENIO™, è ora in uso in Europa...
NATICK, Massachusetts e PARIGI, June 18, 2012 /PRNewswire/ -- La nuova generazione del sistema wireless di gestione remota dei pazienti , abilitato per la famiglia di pacemaker INGENIO ™ , è ora in uso in Europa Boston Scientific Corporation (NYSE: BSX ) ha introdotto l'utilizz
Read more →BSXBoston Scientific Closes Cameron Health Acquisition Boston Scientific Corporation (NYSE: BSX) has closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to...
NATICK, Mass. , June 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has closed its acquisition of Cameron Health, Inc. of San Clemente, California , and, as a result, added to its product portfolio the world's first and only commercially available subcutaneous
Read more →BSXBoston Scientific to Present an Overview of its Endoscopy Business Boston Scientific Corporation (NYSE: BSX) will hold a review of its Endoscopy business, including its Bronchial Thermoplasty opportunity, on Monday,...
NATICK, Mass. , June 6, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will hold a review of its Endoscopy business, including its Bronchial Thermoplasty opportunity, on Monday, June 11, 2012 , from 1:30 p.m. EDT to approximately 4:00 p.m. EDT . Mike Mahoney , pr
Read more →BSXBoston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element™ Plus Platinum Chromium Stent System The U.S. Food and Drug Administration (FDA) has provided Boston Scientific Corporation (NYSE: BSX) regulatory approval of 32 mm and 38 mm lengths for ...
NATICK, Mass. , June 4, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has provided Boston Scientific Corporation (NYSE: BSX ) regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element ™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System
Read more →BSXBoston Scientific Increases Longevity Projections for Its U.S. Defibrillators The U.S. Food and Drug Administration (FDA) has approved revised product labeling for the Boston Scientific Corporation (NYSE: BSX) INCEPTA™,...
NATICK, Mass. , May 31, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved revised product labeling for the Boston Scientific Corporation (NYSE: BSX ) INCEPTA™, ENERGEN™, PUNCTUA™, COGNIS® and TELIGEN® implantable cardioverter defibrillators (ICDs) and
Read more →BSXBoston Scientific Announces Expanded Indication For CRE Wireguided Balloon Dilator Boston Scientific Corporation (NYSE: BSX) announces the U.S. Food and Drug Administration has cleared an expanded use indication for the CRE™...
NATICK, Mass. , May 29, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the U.S. Food and Drug Administration has cleared an expanded use indication for the CRE™ Wireguided Balloon Dilator for endoscopic dilation of the Sphincter of Oddi following sphinc
Read more →BSXLe stent PROMUS Element™ demontre une sécurité d'emploi et une efficacité a long terme excellentes dans l'étude clinique PLATINUM « Petits vaisseaux » Les résultats cliniques à deux ans montrent un faible taux d'événements indésirables, sans aucun infarctus du myocarde ni thrombose de stent, pour le ...
NATICK, Massachusetts , May 24, 2012 /PRNewswire/ -- Les résultats cliniques à deux ans montrent un faible taux d'événements indésirables, sans aucun infarctus du myocarde ni thrombose de stent, pour le stent en platine-chrome PROMUS Element de Boston Scientific de diamètre 2,25
Read more →BSXLo stent PROMUS Element™ dimostra ottima sicurezza ed efficacia a lungo termine nello Studio PLATINUM Small Vessel I dati clinici a due anni dimostrano basse percentuali di eventi avversi, compresi nessun infarto del miocardio o trombosi dello stent, per lo stent...
NATICK, Massachusetts , May 22, 2012 /PRNewswire/ -- I dati clinici a due anni dimostrano basse percentuali di eventi avversi, compresi nessun infarto del miocardio o trombosi dello stent, per lo stent PROMUS Element in Platino-Cromo da 2,25 mm di Boston Scientific Boston Scien
Read more →BSXPLATINUM Small Vessel studie zeigt hervorragende Langzeitergebnisse zur Sicherheit und Wirksamkeit des PROMUS Element Stents Zweijahresdaten belegen für den 2,25 mm Platin Chrom Stent PROMUS Element von Boston Scientific geringe Raten an unerwünschten Ereignissen wie...
NATICK, Massachusetts , May 21, 2012 /PRNewswire/ -- Zweijahresdaten belegen für den 2,25 mm Platin Chrom Stent PROMUS Element von Boston Scientific geringe Raten an unerwünschten Ereignissen wie Myokardinfarkt oder Stentthrombose Die Boston Scientific Corporation (NYSE: BSX )
Read more →BSXEl stent PROMUS Element™ demuestra una seguridad y efectividad excelentes en el estudio PLATINUM Small Vessel Los datos clínicos al cabo de dos años con PROMUS Element, el stent de cromo-platino de 2,25mm de Boston Scientific, demuestran tasas bajas de...
NATICK , Massachussets, May 21, 2012 /PRNewswire/ -- Los datos clínicos al cabo de dos años con PROMUS Element, el stent de cromo-platino de 2,25 mm de Boston Scientific, demuestran tasas bajas de reacciones adversas, con ausencia de infarto de miocardio y trombosis del stent B
Read more →BSXLes donnees a un an de l'etude clinique EVOLVE confirment des resultats de securite et d'efficacite comparables entre le stent SYNERGY™ de Boston Scientific et le stent PROMUS Element™ en platine-chrome Présentation à EuroPCR des données de suivi de l'étude EVOLVE. EVOLVE évalue le stent coronaire en platine-chrome à libération d'everolimus de...
NATICK, Massachusetts , May 21, 2012 /PRNewswire/ -- Présentation à EuroPCR des données de suivi de l'étude EVOLVE. EVOLVE évalue le stent coronaire en platine-chrome à libération d'everolimus de dernière génération, avec polymère abluminal biodégradable ultrafin. Boston Scien
Read more →BSXBoston Scientific annonce les resultats positifs de l'etude clinique menee sur la valve aortique percutanee Lotus(TM) Les résultats de l'étude REPRISE I suggèrent que ce dispositif minimise la régurgitation aortique Boston Scientific Corporation (NYSE : BSX) a...
NATICK, Massachusetts , May 18, 2012 /PRNewswire/ -- Les résultats de l'étude REPRISE I suggèrent que ce dispositif minimise la régurgitation aortique Boston Scientific Corporation (NYSE : BSX ) a communiqué les résultats de l'étude de faisabilité REPRISE I, évaluant la sécurit
Read more →BSXPROMUS Element™ Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and...
NATICK, Mass. , May 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element™ Everolimus-Eluting Platinum Chromium
Read more →BSXBoston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® Boston Scientific Corporation (NYSE: BSX) announces that seven abstracts and additional clinical data analyses will be presented at Digestive Disease ...
NATICK, Mass. , May 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces that seven abstracts and additional clinical data analyses will be presented at Digestive Disease Week ® (DDW), May 19 – 22 in San Diego . The analyses involve the SpyGlass ® Direct
Read more →BSXBoston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration approval and market launch of the Epic™ Vascular Self-Expanding ...
NATICK, Mass. , May 17, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces U.S. Food and Drug Administration approval and market launch of the Epic™ Vascular Self-Expanding Stent System. The Epic Stent is designed to open blocked arteries in patients with i
Read more →BSXLos resultados al cabo de un año del estudio clínico EVOLVE confirman que los datos de seguridad y efectividad del stent SYNERGY™ de Boston Scientific son comparables a los del stent PROMUS Element™ de cromo-platino Presentados en EuroPCR los datos de seguimiento del estudio EVOLVE; en este estudio se está evaluando el stent coronario de nueva generación,...
NATICK, Massachusetts , May 16, 2012 /PRNewswire/ -- Presentados en EuroPCR los datos de seguimiento del estudio EVOLVE; en este estudio se está evaluando el stent coronario de nueva generación, liberador de everolimús, de cromo-platino, con un polímero abluminal bioabsorbible u
Read more →BSXEinjahresdatender klinischen studie EVOLVE bestätigen sicherheit und wirksamkeit des SYNERGY™ - stents im vergleich mit dem platin-chrom-stent promus Element™ Die Follow-Up Daten der EVOLVE-Studie zur Bewertung des Everolimus freisetzenden Platin-Chrom-Koronarstents mit ultradünner bioresorbierbarer...
NATICK, Massachusetts , May 15, 2012 /PRNewswire/ -- Die Follow-Up Daten der EVOLVE-Studie zur Bewertung des Everolimus freisetzenden Platin-Chrom-Koronarstents mit ultradünner bioresorbierbarer abluminaler Polymerbeschichtung wurden im Rahmen des EuroPCR-Kongresses vorgestellt.
Read more →BSXBoston Scientific annuncia i risultati positivi dello studio sulla valvola aortica transcatere, Lotus™ I risultati dello studio REPRISE I suggeriscono che il dispositivo riduce al minimo il rigurgito aortico Boston Scientific Corporation (NYSE: BSX)...
NATICK, Massachusetts , May 15, 2012 /PRNewswire/ -- I risultati dello studio REPRISE I suggeriscono che il dispositivo riduce al minimo il rigurgito aortico Boston Scientific Corporation (NYSE: BSX ) annuncia i risultati dello studio di fattibilità REPRISE I, che ha valutato l
Read more →BSXBoston Scientific gibt positive Daten von einer Studie zum Transkatheter Aortenklappen-System Lotus™ bekannt Die Resultate der REPRISE-I-Studie legen nahe, dass das Aortenklappen-System die paravalvulaere Regurgitation minimiert Boston Scientific Corporation ...
NATICK, Massachusetts und BOSTON , May 15, 2012 /PRNewswire/ -- Die Resultate der REPRISE-I-Studie legen nahe, dass das Aortenklappen-System die paravalvulaere Regurgitation minimiert Boston Scientific Corporation (NYSE: BSX ) hat die Ergebnisse der Projektstudie REPRISE I beka
Read more →BSXOne-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary...
NATICK, Mass. , May 15, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in treating de novo coronary artery lesion
Read more →BSXBoston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial Boston Scientific Corporation (NYSE: BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus™...
NATICK, Mass. , May 15, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus™ Aortic Valve System in patients with severe aortic valve disease. The Lotus Aortic Valve
Read more →BSXBoston Scientific annonce le marquage CE et le lancement europeen de son stent metallique nu auto-expansible Innova™ Un stent innovant conçu pour traiter les lésions vasculaires périphériques consécutives aux sténoses des artères situées au-dessus du genou Boston...
NATICK, Massachusetts , May 15, 2012 /PRNewswire/ -- Un stent innovant conçu pour traiter les lésions vasculaires périphériques consécutives aux sténoses des artères situées au-dessus du genou Boston Scientific Corporation (NYSE : BSX ) annonce le marquage CE et la commercialis
Read more →BSXI risultati ad un anno dello studio clinico EVOLVE confermano che lo stent SYNERGY™ possiede sicurezza ed efficacia comparabili a quelle dello stent promus Element™ in Platino-Cromo I dati del follow-up dello studio clinico EVOLVE presentati all'EuroPCR; in valutazione lo stent coronarico in cromo-platino, medicato con...
NATICK, Massachusetts , May 15, 2012 /PRNewswire/ -- I dati del follow-up dello studio clinico EVOLVE presentati all'EuroPCR; in valutazione lo stent coronarico in cromo-platino, medicato con Everolimus, di nuova generazione con un polimero ultrasottile, bioassorbibile, ablumina
Read more →BSXBoston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering Boston Scientific Corporation (NYSE: BSX) and Royal Philips Electronics (NYSE: PHG, AEX: PHI) announced a collaboration enabling Philips to sell...
NATICK and ANDOVER, Mass. , May 14, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) and Royal Philips Electronics (NYSE: PHG , AEX: PHI) announced a collaboration enabling Philips to sell Boston Scientific Imaging equipment in connection with its Allura Xper™ cath
Read more →BSXBoston Scientific Announces CE Mark and European Launch of Innova™ Self-expanding Bare-metal Stent System Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Innova™ Self-Expanding Bare-Metal Stent System, which...
NATICK, Mass. , May 14, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces CE Mark and European market launch of the Innova™ Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee, specifica
Read more →BSXBoston Scientific annuncia il ricevimento della marcatura ce e il lancio in europa dello stent autoespandibile Innova™ Uno stent innovativo progettato per il trattamento di lesioni vascolari periferiche stenotiche in arterie sopra il ginocchio Boston Scientific...
NATICK, Massachusetts , May 14, 2012 /PRNewswire/ -- Uno stent innovativo progettato per il trattamento di lesioni vascolari periferiche stenotiche in arterie sopra il ginocchio Boston Scientific Corporation (NYSE: BSX ) annuncia la marcatura CE e la commercializzazione in Euro
Read more →BSXBoston Scientific gibt ce-kennzeichnung und europäische markteinführung des selbstexpandierenden bare-metal-stentsystems Innova™ bekannt Ein innovativer Stent zur Behandlung von peripheren Gefäßläsionen bei Arterienstenosen oberhalb des Knies Boston Scientific Corporation (NYSE: BSX)...
NATICK und BOSTON, Massachusetts , May 14, 2012 /PRNewswire/ -- Ein innovativer Stent zur Behandlung von peripheren Gefäßläsionen bei Arterienstenosen oberhalb des Knies Boston Scientific Corporation (NYSE: BSX ) hat heute die CE-Kennzeichnung und die europäische Markteinführun
Read more →BSXBoston Scientific gibt eine branchenführende garantiezeit von 10 jahren für icd- und CRT-D-geräte bekannt Boston Scientific Corporation (NYSE: BSX) kündigt für die implantierbaren Kardioverter-Defibrillatoren (ICD) Energen™ und Incepta™ sowie die...
PARIS , May 11, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) kündigt für die implantierbaren Kardioverter-Defibrillatoren (ICD) Energen™ und Incepta™ sowie die Defibrillatoren zur kardialen Resynchronisationstherapie (CRT-Ds) die Verlängerung der Garantiezeite
Read more →BSXStudy of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy Boston Scientific Corporation (NYSE: BSX) announces results from the ASA Plavix (ASAP) Study, which studied the WATCHMAN® Left Atrial Appendage...
NATICK and BOSTON, Mass. , May 11, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces results from the ASA Plavix (ASAP) Study, which studied the WATCHMAN® Left Atrial Appendage Closure (LAAC) device. The data showed a reduction in the risk of ischemic stro
Read more →BSXBoston Scientific presenta la garanzia più estesa del settore: fino a 10 anni per i dispositivi icd e CRT-D Boston Scientific Corporation (NYSE: BSX) annuncia l'estensione digaranzia fino a un massimo di 10 anni, in base al modello, per i suoi...
PARIGI, May 11, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) annuncia l'estensione digaranzia fino a un massimo di 10 anni, in base al modello, per i suoi defibrillatori cardiaci impiantabili (ICD) e per quelli dedicati alla terapia di resincronizzazione cardi
Read more →BSXBoston Scientific innove en offrant des garanties etendues jusquà 10ans pour ses dai et CRT-D Boston Scientific Corporation (NYSE: BSX) annonce une extension de garantie, jusqu'à 10 ans en fonction des modèles, pour ses défibrillateurs...
PARIS , May 11, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) annonce une extension de garantie, jusqu'à 10 ans en fonction des modèles, pour ses défibrillateurs automatiques implantables (DAI) et défibrillateurs avec fonction de resynchronisation cardiaque (CR
Read more →BSXBoston Scientific presenta garantías de hasta 10 años para los dai y CRT-D líderes del mercado Boston Scientific Corporation (NYSE: BSX) ha anunciado que ampliará hasta 10 años, dependiendo del modelo, la garantía de los desfibriladores...
PARÍS, May 11, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha anunciado que ampliará hasta 10 años, dependiendo del modelo, la garantía de los desfibriladores automáticos implantables (DAI) Energen™ y de los desfibriladores con terapia de resincronización car
Read more →BSXBoston Scientific Announces Schedule For EuroPCR 2012 Boston Scientific Corporation (NYSE: BSX) announces its schedule of major events and sponsored clinical research at the annual EuroPCR Scientific...
NATICK, Mass. , May 10, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces its schedule of major events and sponsored clinical research at the annual EuroPCR Scientific Program, which takes place May 15 – 18 in Paris . "We are pleased to present 12-month c
Read more →BSXBoston Scientific Announces FDA Approval and First U.S. Implant of New Devices To Treat Bradycardia Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO™ and ADVANTIO™...
NATICK, Mass. , May 7, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO ™ and ADVANTIO ™ pacemakers and INVIVE ™ cardiac resynchronization therapy pacemakers (CRT-P). The fi
Read more →BSXBoston Scientific Announces Schedule for Heart Rhythm Society Scientific Sessions Boston Scientific Corporation (NYSE: BSX) announces its schedule of major events and sponsored research at Heart Rhythm 2012, the Heart Rhythm...
NATICK, Mass. , May 3, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces its schedule of major events and sponsored research at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, which takes place May 9 – 12 in Boston . The sche
Read more →BSXBoston Scientific To Participate In Deutsche Bank 37th Annual Health Care Conference On May 8 Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2012 Deutsche Bank Healthcare Conference on May 8 in Boston. Hank...
NATICK, Mass. , April 26, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2012 Deutsche Bank Healthcare Conference on May 8 in Boston . Hank Kucheman , chief executive officer, Mike Mahoney , president, and Jeff Capello , execut
Read more →BSXBoston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Emerge™ PTCA[1] Dilatation Catheter. The Emerge...
NATICK, Mass. , April 24, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces CE Mark and European market launch of the Emerge™ PTCA[1] Dilatation Catheter. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to off
Read more →BSXBoston Scientific Completes Enrollment in Clinical Trial to Evaluate Lotus™ Aortic Valve System Boston Scientific Corporation (NYSE: BSX) announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate...
NATICK, Mass. , April 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus™ Aortic Valve System, the first transcatheter aortic v
Read more →BSXBoston Scientific Announces First Quarter 2012 Results Boston Scientific Corporation (NYSE: BSX) announces financial results for the first quarter ended March 31, 2012, as well as sales and earnings per...
NATICK, Mass. , April 19, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces financial results for the first quarter ended March 31, 2012 , as well as sales and earnings per share (EPS) guidance for the second quarter and full year 2012. First quarter and
Read more →BSXBoston Scientific annonce le lancement en europe de la gamme de stimulateurs cardiaques INGENIO™ Des dispositifs médicaux de haute technologie conçus pour traiter l'insuffisance chronotrope, pathologie affectant jusqu'à 42% des patients porteurs...
NATICK, Massachusetts , April 11, 2012 /PRNewswire/ -- Des dispositifs médicaux de haute technologie conçus pour traiter l'insuffisance chronotrope, pathologie affectant jusqu'à 42% des patients porteurs de stimulateurs cardiaques Boston Scientific Corporation (NYSE: BSX ) anno
Read more →BSXBoston Scientific Announces U.S. Launch of Z Flex-270™ Steerable Sheath Boston Scientific Corporation (NYSE: BSX) announces the U.S. market launch of its Z Flex-270™ Steerable Sheath. The device is intended for use in a...
NATICK, Mass. , April 11, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the U.S. market launch of its Z Flex-270™ Steerable Sheath. The device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and p
Read more →BSXBoston Scientific Announces Launch of INGENIO™ Family of Pacemakers in Europe Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of its INGENIO™ and ADVANTIO™ pacemakers and INVIVE™...
NATICK, Mass. , April 10, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces CE Mark approval and European market launch of its INGENIO™ and ADVANTIO™ pacemakers and INVIVE™ cardiac resynchronization therapy pacemakers (CRT-P). One of the first implants of
Read more →BSXBoston Scientific to Announce First-Quarter 2012 Financial Results on April 19 Boston Scientific Corporation (NYSE: BSX) announces it will webcast its first-quarter 2012 financial results conference call on Thursday, April 19,...
NATICK, Mass. , April 10, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces it will webcast its first-quarter 2012 financial results conference call on Thursday, April 19 , at 8:00 a.m. Eastern Time . The call will be hosted by Hank Kucheman , chief execu
Read more →BSXBoston Scientific annuncia la commercializzazione in Europa della famiglia di pacemaker INGENIO™ Dispositivi avanzati progettati per trattare l'incompetenza cronotropa, che colpisce fino al 42% dei pazienti portatori di pacemaker Boston...
NATICK, Massachusetts , April 10, 2012 /PRNewswire/ -- Dispositivi avanzati progettati per trattare l'incompetenza cronotropa, che colpisce fino al 42% dei pazienti portatori di pacemaker Boston Scientific Corporation (NYSE: BSX ) annuncia di aver ottenuto la marcatura CE e l'a
Read more →BSXBoston Scientific meldet die einführung der INGENIO™-Herzschrittmacher in Europa Die neuen Geräte wurden zur Behandlung von chronotroper Inkompetenz entwickelt, von der bis zu 42% aller Herzschrittmacher-Patienten betroffen sind...
NATICK, Massachusetts , April 10, 2012 /PRNewswire/ -- Die neuen Geräte wurden zur Behandlung von chronotroper Inkompetenz entwickelt, von der bis zu 42% aller Herzschrittmacher-Patienten betroffen sind Boston Scientific Corporation (NYSE: BSX ) hat heute bekannt gegeben, dass
Read more →BSXBoston Scientific anuncia la comercialización en europa de la familia de marcapasos INGENIO™ Dispositivos avanzados diseñados para el tratamiento de la incompetencia cronotrópica, que afecta al 42 % de los pacientes portadores de marcapasos...
NATICK , Massachussets, April 10, 2012 /PRNewswire/ -- Dispositivos avanzados diseñados para el tratamiento de la incompetencia cronotrópica, que afecta al 42 % de los pacientes portadores de marcapasos Boston Scientific Corporation (NYSE: BSX ) anuncia la aprobación del marcad
Read more →BSXBoston Scientific Launches Innovative Device Used to Prevent Stone Migration in Urologic Procedures Boston Scientific Corporation (NYSE: BSX) announces the launch of its BackStop® Gel, a new technology designed to prevent stone migration during...
NATICK, Mass. , April 2, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the launch of its BackStop® Gel, a new technology designed to prevent stone migration during procedures used to break up and retrieve urinary stones. The Company is now marketing th
Read more →BSXBronchial Thermoplasty with Boston Scientific's Alair® System Meets All Criteria of California Technology Assessment Forum Boston Scientific Corporation (NYSE: BSX) announces the first published technology assessment in support of the safety, efficacy and long-term...
NATICK, Mass. , March 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the first published technology assessment in support of the safety, efficacy and long-term positive health outcomes of bronchial thermoplasty (BT) as delivered by the Alair ® Bronc
Read more →BSXBoston Scientific Supports New Clinical Trial to Evaluate Platinum Chromium Coronary Stents in Treating Heart Attack Patients Boston Scientific Corporation (NYSE: BSX) announces its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and...
NATICK, Mass. and CHICAGO , March 26, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromiu
Read more →BSXLandmark Analysis of Year Two Data From PLATINUM Workhorse Trial Demonstrates Superior Efficacy of PROMUS Element™ Platinum Chromium Stent Compared to PROMUS® (Xience V®) Stent Boston Scientific Corporation (NYSE: BSX) announces two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and...
NATICK, Mass. and CHICAGO , March 25, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Platinum Chromium (Pt
Read more →BSXAnalysis of Two Randomized Clinical Trials Identify No Cases of Longitudinal Stent Deformation With Boston Scientific Platinum Chromium Stents Boston Scientific Corporation (NYSE: BSX) announces results from a quantitative coronary angiographic (QCA) analysis of the incidence of longitudinal ...
NATICK, Mass. and CHICAGO , March 25, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces results from a quantitative coronary angiographic (QCA) analysis of the incidence of longitudinal stent deformation in the PERSEUS and PLATINUM randomized clinical tria
Read more →BSXBoston Scientific Begins U.S. and International Launch of WallFlex® Biliary Transhepatic Stent System Boston Scientific Corporation (NYSE: BSX) announces the U.S. and international launch of the WallFlex® Biliary Transhepatic Stent System. This...
NATICK, Mass. , March 22, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the U.S. and international launch of the WallFlex ® Biliary Transhepatic Stent System. This third-generation stent platform is now available with a percutaneous delivery system des
Read more →BSXBoston Scientific Announces New Clinical Data to be Presented at ACC 2012 on the Market-Leading PROMUS Element™ Stent Boston Scientific Corporation (NYSE: BSX) releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the...
NATICK, Mass. , March 20, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the American College of Cardiology/i2 Summit , March 24-27 in Chicago . "Two-year results
Read more →BSXBoston Scientific Welcomes Positive Private Insurance Coverage Decisions for Bronchial Thermoplasty Boston Scientific Corporation (NYSE: BSX) welcomes a milestone in private insurance reimbursement coverage for bronchial thermoplasty (BT) performed...
Bronchial thermoplasty delivered by the Alair System uses thermal energy to reduce the airway smooth muscle associated with airway constriction in asthma patients. The results of the AIR2 Trial, published in the January 15, 2010 issue of the American Journal of Respiratory and Cr
Read more →BSXBoston Scientific Announces Health Canada Approval of Blazer™ Open-Irrigated Catheter Boston Scientific Corporation (NYSE: BSX) today announced Health Canada approval of the Blazer™ Open-Irrigated Catheter, the Company's latest...
NATICK, Mass. , March 15, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced Health Canada approval of the Blazer™ Open-Irrigated Catheter, the Company's latest radiofrequency ablation (RFA) catheter designed to treat a variety of arrhythmias such as
Read more →BSXBoston Scientific annuncia l'acquisizione di Cameron Health, Inc. L'azienda ottiene la prima e unica tecnologia di ICD per via sottocutanea disponibile in commercio per offrire una terapia salvavita ai pazienti a...
NATICK , Massachussetts, March 13, 2012 /PRNewswire/ -- L'azienda ottiene la prima e unica tecnologia di ICD per via sottocutanea disponibile in commercio per offrire una terapia salvavita ai pazienti a rischio di arresto cardiaco improvviso Boston Scientific Corporation (NYSE:
Read more →BSXBoston Scientific comprará Cameron Health, Inc. La empresa se hace con la primera y única tecnología disponible para el implante subcutáneo de DAI, un tratamiento que salva la vida a los pacientes...
NATICK, Massachusetts , March 13, 2012 /PRNewswire/ -- La empresa se hace con la primera y única tecnología disponible para el implante subcutáneo de DAI, un tratamiento que salva la vida a los pacientes en riesgo de paro cardíaco súbito Boston Scientific Corporation (NYSE: BSX
Read more →BSXBoston Scientific vor der übernahme von Cameron Health, Inc. Damit erwirbt das Unternehmen die erste und einzige gewerblich verfügbare subkutane ICD-Technologie zur lebenserhaltenden Behandlung von Patienten,...
NATICK, Massachusetts , March 13, 2012 /PRNewswire/ -- Damit erwirbt das Unternehmen die erste und einzige gewerblich verfügbare subkutane ICD-Technologie zur lebenserhaltenden Behandlung von Patienten, bei denen ein Risiko von plötzlichem Herzstillstand vorliegt Boston Scienti
Read more →BSXAcquisition de Cameron Health, Inc. par Boston Scientific Boston Scientific va acquérir la première et seule technologie de défibrillateurs cardiaques implantables par voie sous-cutanée disponible sur le...
NATICK, Massachusetts , March 13, 2012 /PRNewswire/ -- Boston Scientific va acquérir la première et seule technologie de défibrillateurs cardiaques implantables par voie sous-cutanée disponible sur le marché, permettant de sauver la vie de patients à risque d'arrêt cardiaque. B
Read more →BSXBoston Scientific Renews Agreement with Lumenis® to Deliver Innovative Laser Products to Treat Urologic Conditions Boston Scientific Corporation (NYSE: BSX) and Lumenis, the market leader in holmium laser technology, announced the signing of a five-year contract...
NATICK, Mass. , March 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) and Lumenis, the market leader in holmium laser technology, announced the signing of a five-year contract extending the existing commercial agreement between the two companies and promoting c
Read more →BSXBoston Scientific to Acquire Cameron Health, Inc. Boston Scientific Corporation (NYSE: BSX) announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San ...
NATICK, Mass. , March 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San Clemente, California . Cameron Health has developed the world's first and only comm
Read more →BSXBoston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan Boston Scientific Corporation (NYSE: BSX) announces the launch of the PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System in...
NATICK, Mass. , March 1, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the launch of the PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. The product was recently approved by the Ministry of Health, Labor and Welfare
Read more →BSXBoston Scientific Announces First Implants of TELIGEN® Implantable Defibrillator in China Boston Scientific Corporation (NYSE: BSX) announces the first implants of a TELIGEN® implantable cardioverter defibrillator (ICD) in China. The...
NATICK, Mass. , Feb. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the first implants of a TELIGEN® implantable cardioverter defibrillator (ICD) in China. The implants were performed by Farong Shen, M.D., in Zhejiang Hospital, Hangzhou and Wei Hua
Read more →BSXBoston Scientific to Participate in 2012 RBC Capital Markets' Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2012 RBC Capital Markets' Global Healthcare Conference on February 29 in ...
NATICK, Mass. , Feb. 22, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2012 RBC Capital Markets' Global Healthcare Conference on February 29 in New York . Hank Kucheman , Chief Executive Officer, and Jeff Capello , Executive V
Read more →BSXBoston Scientific Receives Industry's First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients Boston Scientific Corporation's (NYSE: BSX) ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting...
NATICK, Mass. , Feb. 22, 2012 /PRNewswire/ -- Boston Scientific Corporation's (NYSE: BSX ) ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System have received U.S. Food and Drug Administration (FDA) approval f
Read more →BSXMoody's Raises Boston Scientific's Credit Rating To Investment Grade Boston Scientific Corporation (NYSE: BSX) announces that Moody's Investors Service has upgraded the Company's corporate credit rating to an...
NATICK, Mass. , Feb. 13, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces that Moody's Investors Service has upgraded the Company's corporate credit rating to an investment grade rating, Baa3, with a stable outlook. Fitch Ratings and Standard & Poor's cur
Read more →BSXBoston Scientific Launches Innovative Crossing Device to Treat Complete Blockages in Peripheral Arteries Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of the TruePath™ CTO Device, designed to facilitate the crossing of chronic total ...
NATICK, Mass. , Feb. 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the U.S. launch of the TruePath™ CTO Device, designed to facilitate the crossing of chronic total occlusions (CTOs, or complete blockages) within the peripheral vasculature. The Comp
Read more →BSXBoston Scientific WallFlex® Enteral Stents Shown To Be Safe and Effective in Three Clinical Registries Boston Scientific Corporation (NYSE: BSX) welcomes positive results from three studies of the WallFlex® Enteral Stent Systems, a family of...
NATICK, Mass. , Feb. 7, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) welcomes positive results from three studies of the WallFlex® Enteral Stent Systems, a family of self-expanding metal stents (SEMS) used to alleviate obstructive symptoms caused by cancers of
Read more →BSXBoston Scientific to Participate in Leerink Swann 2012 Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink Swann 2012 Global Healthcare Conference on February 15 in New...
NATICK, Mass. , Feb. 7, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Leerink Swann 2012 Global Healthcare Conference on February 15 in New York . Hank Kucheman , Chief Executive Officer, Mike Mahoney , President, and Jeff Cap
Read more →BSXBoston Scientific Announces Global Launch of Expect™ 19 Flex Endoscopic Ultrasound Aspiration Needle Boston Scientific Corporation (NYSE: BSX) announces the global launch of the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle, used for...
NATICK, Mass. , Feb. 6, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the global launch of the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples under Endoscopic Ultrasound (EUS) guidance for cancer diagnosis in
Read more →BSXBoston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2011 Boston Scientific Corporation (NYSE: BSX) announces financial results for the fourth quarter and full year ended December 31, 2011, as well as sales...
NATICK, Mass. , Feb. 2, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces financial results for the fourth quarter and full year ended December 31, 2011 , as well as sales and earnings per share (EPS) guidance for the first quarter and full year 2012. Fou
Read more →BSXBoston Scientific anuncia el primer implante y la presentación en el mercado del Stent Coronario Promus Element™ plus en Europa El stent de cromo- platino con un sistema de liberación mejorado ya está disponible en Europa y otros países Boston Scientific Corporation (NYSE:...
NATICK, Massachusetts , February 1, 2012 /PRNewswire/ -- El stent de cromo- platino con un sistema de liberación mejorado ya está disponible en Europa y otros países Boston Scientific Corporation (NYSE: BSX ) ha anunciado la presentación en el mercado europeo y el uso en el pri
Read more →BSXBoston Scientific annuncia il primo impianto e la commercializzazione in Europa dello Stent Promus Element™ Plus Lo stent coronarico in platino e cromo con un sistema avanzato di delivery è adesso disponibile in Europa e in altri Paesi Boston Scientific...
NATICK, Massachusetts , February 1, 2012 /PRNewswire/ -- Lo stent coronarico in platino e cromo con un sistema avanzato di delivery è adesso disponibile in Europa e in altri Paesi Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi il primo impianto supaziente e la co
Read more →BSXBoston Scientific gibt erste implantation des stent-systems PROMUS Element™ PLUS in Europa bekannt Platin-Chrom-Koronarstent mit verbessertem Einführsystem ist jetzt in Europa und anderen Ländern der Welt erhältlich Boston Scientific Crporation...
NATICK, Massachusetts , February 1, 2012 /PRNewswire/ -- Platin-Chrom-Koronarstent mit verbessertem Einführsystem ist jetzt in Europa und anderen Ländern der Welt erhältlich Boston Scientific Crporation (NYSE: BSX ) hat den erstmaligen Einsatz des Everolimus freisetzenden Plati
Read more →BSXBoston Scientific annonce la première implantation et la commercialisation du stent PROMUS Element™ Plus en Europe Le stent coronaire en platine-chrome avec système de mise en placeoptimisé estdésormais disponibleen Europe et dans d'autres pays Boston Scientific...
NATICK, Massachusetts , February 1, 2012 /PRNewswire/ -- Le stent coronaire en platine-chrome avec système de mise en placeoptimisé estdésormais disponibleen Europe et dans d'autres pays Boston Scientific Corporation (NYSE. : BSX) annonce la première implantation et la commerci
Read more →BSXBoston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe Boston Scientific Corporation (NYSE: BSX) announces first patient use and European market launch of the PROMUS Element™ Plus Everolimus-Eluting...
NATICK, Mass. , Feb. 1, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces first patient use and European market launch of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System. The first patient implant in Europe using the new
Read more →BSXBoston Scientific Announces Favorable Ruling in Patent Infringement Case Boston Scientific Corporation (NYSE: BSX) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in ...
NATICK, Mass. , Jan. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Johnson & Johnson to be invalid and entered judgment in favor of
Read more →BSXBoston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2011 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
NATICK, Mass. , Jan. 20, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the fourth quarter and full year ended December 31, 2011 on Thursday, February 2 , at 8:00 a.m. Eastern Time . The call will
Read more →BSXBoston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial Boston Scientific Corporation (NYSE: BSX) reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for the...
NATICK, Mass. and MIAMI , Jan. 16, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for the Company's Epic™ Self-Expanding Nitinol Stent System in patients with iliac a
Read more →BSXBoston Scientific to Participate in 30th Annual J.P. Morgan Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Hank...
NATICK, Mass. , Jan. 3, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco . Hank Kucheman , Chief Executive Officer, will make a presentation about the Company on Wedn
Read more →BSXBoston Scientific Launches Charger™ PTA Balloon Catheter Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of its Charger™ PTA Balloon Catheter, a 0.035 percutaneous transluminal...
NATICK, Mass. , Dec. 12, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces the U.S. launch of its Charger™ PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty (PTA) balloon catheter designed for a wide range of peripheral angioplasty proce
Read more →BSXBoston Scientific Receives FDA Approval for New Infinion™ 16 Percutaneous Lead for Precision Plus™ Spinal Cord Stimulator System Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous Lead for its...
(Photo: http://photos.prnewswire.com/prnh/20111208/NE19468 ) SCS leads are designed to deliver electrical pulses from an implantable pulse generator to the spinal cord to mask pain signals to the brain. Until now, percutaneous leads have offered a maximum of eight stimulating co
Read more →BSXBoston Scientific Introduces Industry-Leading ICD and CRT-D Device Warranties Boston Scientific Corporation (NYSE: BSX) announced that, along with today's introduction of a new family of INCEPTA™ and ENERGEN™ implantable...
NATICK, Mass. , Nov. 30, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced that, along with today's introduction of a new family of INCEPTA™ and ENERGEN™ implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (C
Read more →BSXBoston Scientific to Participate in 2011 Piper Jaffray 23rd Annual Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray 23rd Annual Healthcare Conference on November 30 in New...
NATICK, Mass. , Nov. 18, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Piper Jaffray 23 rd Annual Healthcare Conference on November 30 in New York . Jeff Capello , Executive Vice President and Chief Financial Officer, will par
Read more →BSXBoston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America Boston Scientific Corporation's (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device has been implanted in the first patients in Latin...
NATICK, Mass. , Nov. 16, 2011 /PRNewswire/ -- Boston Scientific Corporation's (NYSE: BSX ) WATCHMAN® Left Atrial Appendage (LAA) Closure Device has been implanted in the first patients in Latin America . The novel device is designed for use in patients in atrial fibrillation who
Read more →BSXBoston Scientific Applauds Introduction of Patient Access to Medical Innovation Act Boston Scientific Corporation (NYSE: BSX) commends the leadership of Senator Al Franken (D-MN), Senator Lamar Alexander (R-TN) and Senator John Kerry ...
NATICK, Mass. , Nov. 15, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) commends the leadership of Senator Al Franken (D-MN), Senator Lamar Alexander (R-TN) and Senator John Kerry (D-MA) for their introduction today of the Patient Access to Medical Innovation Act
Read more →BSXBoston Scientific SYNERGY™ Stent Demonstrates Comparable Safety and Effectiveness Outcomes Versus PROMUS Element™ Platinum Chromium Stent Boston Scientific Corporation (NYSE: BSX) reports results from the EVOLVE First Human Use trial demonstrating the non-inferiority of the SYNERGY™...
NATICK, Mass. and SAN FRANCISCO , Nov. 11, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports results from the EVOLVE First Human Use trial demonstrating the non-inferiority of the SYNERGY™ Everolimus-Eluting Stent System compared to the PROMUS Element™ Evero
Read more →BSXCryoPlasty® Therapy With Boston Scientific PolarCath™ Dilatation System Reduces Restenosis Rates by Nearly 50 Percent in Peripheral Stenting Procedures Boston Scientific Corporation (NYSE: BSX) welcomed positive outcomes from the COBRA clinical trial, which evaluated post-dilation of nitinol stents...
NATICK, Mass. and SAN FRANCISCO , Nov. 11, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) welcomed positive outcomes from the COBRA clinical trial, which evaluated post-dilation of nitinol stents using CryoPlasty® Therapy with the PolarCath™ Peripheral Dilatation
Read more →BSXBoston Scientific CRE™ Wireguided Balloon Dilator CE Marked for Expanded Indication Now available for endoscopic dilation of the Sphincter of Oddi following sphincterotomy Boston Scientific Corporation's (NYSE: BSX) CRE™ Wireguided...
PARIS , November 9, 2011 /PRNewswire/ -- Now available for endoscopic dilation of the Sphincter of Oddi following sphincterotomy Boston Scientific Corporation's (NYSE: BSX ) CRE™ Wireguided Balloon Dilator is now CE marked for endoscopic dilation of the Sphincter of Oddi follow
Read more →BSXBoston Scientific's PROMUS Element™ Platinum Chromium Stent Demonstrates Excellent Outcomes in Patients With Long Coronary Lesions Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent outcomes for...
NATICK, Mass. and SAN FRANCISCO , Nov. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent outcomes for the PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent
Read more →BSXBoston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program Boston Scientific Corporation (NYSE: BSX) reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year...
NATICK, Mass. and SAN FRANCISCO , Nov. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION™ (TAXUS Element) Paclit
Read more →BSXBoston Scientific Carotid WALLSTENT® Found Safe in Study of High Surgical Risk Patients in Routine Clinical Practice Boston Scientific Corporation (NYSE: BSX) reports positive outcomes from the CABANA post-approval study of the Carotid WALLSTENT® Monorail®...
NATICK, Mass. and SAN FRANCISCO , Nov. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) reports positive outcomes from the CABANA post-approval study of the Carotid WALLSTENT ® Monorail ® Endoprosthesis used in conjunction with its FilterWire EZ™ Embolic Protect
Read more →BSXBoston Scientific SpyGlass® Direct Visualization System Demonstrates High Procedural Success Rate in Published Study Boston Scientific Corporation (NYSE: BSX) welcomes study results published in the October issue of Gastrointestinal Endoscopy showing an overall...
NATICK, Mass. , Nov. 2, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) welcomes study results published in the October issue of Gastrointestinal Endoscopy showing an overall procedural success rate of 89 percent for the SpyGlass® Direct Visualization System, a si
Read more →BSXBoston Scientific Announces Schedule of Events at TCT Scientific Symposium Boston Scientific Corporation (NYSE: BSX) releases the schedule of its major events and product-related clinical research for the Cardiovascular...
NATICK, Mass. , Nov. 1, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) releases the schedule of its major events and product-related clinical research for the Cardiovascular Research Foundation's (CRF) 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) s
Read more →BSXBoston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares Boston Scientific Corporation (NYSE: BSX) announces financial results for the third quarter ended September 30, 2011, as well as updated sales and...
NATICK, Mass. , Oct. 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces financial results for the third quarter ended September 30, 2011 , as well as updated sales and earnings per share (EPS) guidance for the fourth quarter and full year 2011. Third q
Read more →BSXBoston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent Boston Scientific Corporation (NYSE: BSX) has completed enrollment in a clinical trial to evaluate its WallFlex® Biliary RX Fully Covered Stent for...
NATICK, Mass. , Oct. 18, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has completed enrollment in a clinical trial to evaluate its WallFlex® Biliary RX Fully Covered Stent for the treatment of benign bile duct strictures (narrowing or blockages). This multi-cen
Read more →BSXBoston Scientific Launches Promus Element™ Stent System In China Boston Scientific Corporation (NYSE: BSX) has begun a phased launch of its PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System ...
NATICK, Mass. , Oct. 17, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has begun a phased launch of its PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System in China . The launch campaign will be expanded within the country based upon recei
Read more →BSXBoston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate Boston Scientific Corporation (NYSE: BSX) welcomes yesterday's introduction of the Medical Device Regulatory Improvement Act, sponsored by Sen. Amy...
NATICK, Mass. , Oct. 14, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) welcomes yesterday's introduction of the Medical Device Regulatory Improvement Act, sponsored by Sen. Amy Klobuchar (D-MN) and cosponsored by Sens. Richard Burr (R-NC) and Michael Bennet (D-C
Read more →BSXBoston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
NATICK, Mass. , Oct. 11, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the third quarter ended September 30, 2011 on Thursday, October 20 , at 8:00 a.m. ET . The call will be hosted by Hank Kuche
Read more →BSXBoston Scientific Begins Clinical Trial Enrollment for OMEGA™ Platinum Chromium Stent System Boston Scientific Corporation (NYSE: BSX) has started patient enrollment in the OMEGA clinical trial, designed to evaluate the safety and...
NATICK, Mass. , Oct. 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has started patient enrollment in the OMEGA clinical trial, designed to evaluate the safety and effectiveness of the Company's OMEGA™ Platinum Chromium Bare-Metal Coronary Stent System in trea
Read more →BSXBoston Scientific Begins Enrollment in NECTAR-HF Clinical Trial Boston Scientific Corporation (NYSE: BSX) has enrolled the first patients in its NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) clinical trial. ...
NATICK, Mass. , Sept. 29, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has enrolled the first patients in its NECTAR-HF ( NE ural C ardiac T her A py fo R H eart F ailure) clinical trial. NECTAR-HF is a prospective, randomized, international clinical feasibilit
Read more →BSXBoston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Court of Appeals for the Federal Circuit found in favor of the Company in a...
NATICK, Mass. , Sept. 28, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that the U.S. Court of Appeals for the Federal Circuit found in favor of the Company in a 1998 patent infringement suit involving Johnson & Johnson. About Boston Scientific
Read more →BSXLes données cliniques démontrent la sécurité à long terme du système de thermoplastie bronchique Alair[TM] de Boston Scientific - Les données à cinq ans de l'étude RISA (« Research in Severe Asthma ») démontrent le maintien d'une fonction pulmonaire stable et l'absence de...
PARIS , September 27, 2011 /PRNewswire/ -- - Les données à cinq ans de l'étude RISA (« Research in Severe Asthma ») démontrent le maintien d'une fonction pulmonaire stable et l'absence de complications cliniques tardives. - Les patients européens atteints d'asthme sévère peuvent
Read more →BSXLos datos clínicos demuestran la seguridad a largo plazo de Alair™, el sistema de termoplastia bronquial de Boston Scientific - Los datos obtenidos a lo largo de cinco años en el estudio RISA (Research in Severe Asthma) demuestran el mantenimiento de la estabilidad de la...
PARÍS, September 27, 2011 /PRNewswire/ -- - Los datos obtenidos a lo largo de cinco años en el estudio RISA (Research in Severe Asthma) demuestran el mantenimiento de la estabilidad de la función pulmonar y la ausencia de complicaciones clínicas tardías - Los pacientes con asma
Read more →BSXKlinische daten zeigen langzeit-sicherheit des Alair[tm]-systems zur bronchialen thermoplastie von Boston Scientific - Fünf-Jahres-D aten aus der Forschungsstudie RISA ( Research in Severe Asthma ) beweisen die Erhaltung einer stabilen Lungenfunktion bei Abwesenheit ...
PARIS , September 27, 2011 /PRNewswire/ -- - Fünf-Jahres-D aten aus der Forschungsstudie RISA ("Research in Severe Asthma") beweisen die Erhaltung einer stabilen Lungenfunktion bei Abwesenheit später klinischer Komplikationen. - Europäische Patienten mit schwerem Asthma können n
Read more →BSXI dati clinici dimostrano la sicurezza a lungo termine di Alair[tm], il sistema di termoplastica bronchiale di Boston Scientific I dati a cinque anni dallo studio Research in Severe Asthma (RISA) dimostrano un mantenimento della funzione polmonare stabile e un'assenza di...
PARIGI, Francia , September 27, 2011 /PRNewswire/ -- I dati a cinque anni dallo studio Research in Severe Asthma (RISA) dimostrano un mantenimento della funzione polmonare stabile e un'assenza di complicanze cliniche successive al trattamento I pazienti europei affetti da asma
Read more →BSXClinical Data Demonstrates Long-Term Safety of Boston Scientific's Alair[TM]Bronchial Thermoplasty System - Five-year data from Research in Severe Asthma (RISA) Trial demonstrate maintenance of stable lung function and absence of late clinical...
PARIS , September 27, 2011 /PRNewswire/ -- - Five-year data from Research in Severe Asthma (RISA) Trial demonstrate maintenance of stable lung function and absence of late clinical complications - Patients in Europe with severe asthma can now benefit from unique and proven non-
Read more →BSXBoston Scientific Launches Coyote™ Balloon Catheter Boston Scientific Corporation (NYSE: BSX) has launched its Coyote™ Balloon Catheter, a highly deliverable and ultra-low profile 0.014 inch balloon...
NATICK, Mass. , Sept. 19, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has launched its Coyote™ Balloon Catheter, a highly deliverable and ultra-low profile 0.014 inch balloon dilatation catheter designed to treat patients undergoing peripheral angioplasty proc
Read more →BSXBoston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders Boston Scientific Corporation (NYSE: BSX) is further supporting the advancement of women's health as the founding sponsor of the American...
NATICK, Mass. , Sept. 15, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is further supporting the advancement of women's health as the founding sponsor of the American Urogynecologic Society's new patient website, Take the Floor – Voices of PFD, which launches a
Read more →BSXBoston Scientific Names Michael F. Mahoney as Company President, Announces CEO Transition Plan Attracting one of med-tech's most inspiring leaders, Boston Scientific Corporation (NYSE: BSX) has named Michael Mahoney, 46, as President of the...
NATICK, Mass. , Sept. 13, 2011 /PRNewswire/ -- Attracting one of med-tech's most inspiring leaders, Boston Scientific Corporation (NYSE: BSX ) has named Michael Mahoney , 46, as President of the Company, effective October 17, 2011 . Mahoney, Worldwide Chairman of the Medical Devi
Read more →BSXBoston Scientific Issues Statement Regarding FDA Advisory Committee Meeting on Surgical Mesh to Treat Pelvic Organ Prolapse and Stress Urinary Incontinence Boston Scientific Corporation (NYSE: BSX) today issued the following statement from John Pedersen, Senior Vice President and President of the...
NATICK, Mass. , Sept. 9, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today issued the following statement from John Pedersen , Senior Vice President and President of the Company's Urology and Women's Health Division, following the conclusion of a two-day meeti
Read more →BSXBoston Scientific to Participate in 2011 Morgan Stanley Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14 in New York. ...
NATICK, Mass. , Sept. 2, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14 in New York . Ray Elliott , President and Chief Executive Officer, and Jeff Capello , Executive
Read more →BSXBoston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation Boston Scientific Corporation (NYSE: BSX) has launched its Neuromodulation Learning Institute™ (NLI), a clinical education program and online...
NATICK, Mass. , Aug. 10, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has launched its Neuromodulation Learning Institute™ (NLI), a clinical education program and online resource center for healthcare providers to enhance their knowledge and awareness of spinal
Read more →BSXBoston Scientific Announces Favorable Court Ruling Dismissing Securities Fraud Case Boston Scientific Corporation (NYSE: BSX) today announces the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities...
NATICK, Mass. , Aug. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announces the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the recall of the Company's TAXUS® Express2 Paclitaxel-
Read more →BSXBoston Scientific Second Quarter Results Exceed Consensus Sales and EPS; Full-Year Guidance Raised oston Scientific Corporation (NYSE: BSX) today announces financial results for the second quarter ended June 30, 2011, as well as net sales and...
NATICK, Mass. , July 28, 2011 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX ) today announces financial results for the second quarter ended June 30, 2011 , as well as net sales and earnings per share (EPS) guidance for the third quarter and updated guidance for the ful
Read more →BSXBoston Scientific Announces $1.0B Share Repurchase Program Boston Scientific Corporation's (NYSE: BSX) Board of Directors has approved a new program authorizing the repurchase of up to $1.0 billion of its...
NATICK, Mass. , July 28, 2011 /PRNewswire/ -- Boston Scientific Corporation's (NYSE: BSX ) Board of Directors has approved a new program authorizing the repurchase of up to $1.0 billion of its common stock and re-approving the approximately 37 million shares remaining under an ex
Read more →BSXBoston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion Boston Scientific Corporation's (NYSE: BSX) Board of Directors has approved a five-year, $150 million investment in China to expand its commercial...
NATICK, Mass. , July 27, 2011 /PRNewswire/ -- Boston Scientific Corporation's (NYSE: BSX ) Board of Directors has approved a five-year, $150 million investment in China to expand its commercial presence in one of the world's largest and fastest-growing medical device markets. Thi
Read more →BSXBoston Scientific's Credit Rating Raised to Investment Grade Boston Scientific Corporation (NYSE: BSX) announces that Fitch Ratings has upgraded the Company's corporate credit rating to an investment grade...
NATICK, Mass. , July 21, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announces that Fitch Ratings has upgraded the Company's corporate credit rating to an investment grade rating, BBB-, with a stable outlook. Additionally, Moody's Investors Service recently r
Read more →BSXBoston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2011 on ...
NATICK, Mass. , July 14, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the second quarter ended June 30, 2011 on Thursday, July 28 , at 8:00 a.m. ET . The call will be hosted by Ray Elliott , Pre
Read more →BSXBoston Scientific Completes Clinical Trial Enrollment for Adapt™ Monorail™ Carotid Stent System Boston Scientific Corporation (NYSE: BSX) has completed patient enrollment in the ASTI post-market clinical follow-up study designed to evaluate its...
NATICK, Mass. , July 12, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has completed patient enrollment in the ASTI post-market clinical follow-up study designed to evaluate its Adapt™ Monorail™ Carotid Stent System in combination with its FilterWire EZ™ Embolic
Read more →BSXBoston Scientific Welcomes Publication of Landmark Report on Chronic Pain Boston Scientific Corporation (NYSE: BSX) welcomes the recent landmark report to Congress by the Institute of Medicine (IOM) of the National Academy...
NATICK, Mass. , June 30, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) welcomes the recent landmark report to Congress by the Institute of Medicine (IOM) of the National Academy of Sciences titled Relieving Pain in America: A Blueprint for Transforming Preventio
Read more →BSXBoston Scientific Announces U.S. and European Launch of Interlock™ - 35 Fibered IDC™ Occlusion System Boston Scientific Corporation (NYSE: BSX) today announced the immediate U.S. and European launch of its Interlock™ – 35 Fibered IDC™ Occlusion System....
NATICK, Mass. , June 30, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the immediate U.S. and European launch of its Interlock™ – 35 Fibered IDC™ Occlusion System. Earlier this year, the system received clearance from the U.S. Food and Drug Admin
Read more →BSXBoston Scientific Welcomes Passage of Patent Reform Bill Boston Scientific Corporation (NYSE: BSX) today welcomed approval by the U.S. House of Representatives of the America Invents Act of 2011. The...
NATICK, Mass. , June 27, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed approval by the U.S. House of Representatives of the America Invents Act of 2011. The legislation, introduced by Rep. Lamar Smith (R- Texas ), is a bipartisan bill intended to
Read more →BSXBoston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 inch...
NATICK, Mass. , June 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the global launch of its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 inch percutaneous transluminal angioplasty (PTA) catheter designed for a wide range of perip
Read more →BSXBoston Scientific to Participate in 2011 Wells Fargo Securities Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2011 Wells Fargo Securities Healthcare Conference on June 22 in Boston....
NATICK, Mass. , June 16, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2011 Wells Fargo Securities Healthcare Conference on June 22 in Boston . Ray Elliott , President and Chief Executive Officer, and Jeff Capello , Executive
Read more →BSXBoston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S....
As part of a 2007 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS® Everolimus-Eluting Coronary Stent System infringed these four patents, known as the Wright/Falotico patents. The patents relate to coatings (drug and polymer) for drug-eluting stents. "We are plea
Read more →BSXBoston Scientific Announces Voluntary Recall of iCross™ Coronary Imaging Catheters Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling all of its iCross™ Coronary Imaging Catheters used in...
NATICK, Mass. , May 27, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it is voluntarily recalling all of its iCross™ Coronary Imaging Catheters used in intravascular ultrasound (IVUS) imaging in patients who are candidates for transluminal c
Read more →BSXBoston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its...
NATICK, Mass. , May 25, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its 2.25 mm PROMUS ® Everolimus-Eluting Coronary Stent System for use in vessels as small as
Read more →BSXLa nueva fijación Click(TM) de Boston Scientific para el sistema de estimulación de la médula espinal Precision Plus(TM) obtiene el marcado ce Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy la aprobación del sistema de fijación Click(TM) para el sistema de estimulación de la...
El Dr. Kliment Gatzinsky , que ejerce en el Sahlgrenska University Hospital de Göteborg, Suecia, y ha sido el primer médico de Europa en evaluar la fijación Click en la práctica, declaró que <<la fijación Click es fácil de usar. Agradezco la sencillez de su mecanismo de cierre me
Read more →BSXBoston Scientific obtient le marquage ce pour le nouveau dispositif Clik(TM) Anchor du système de stimulation médullaire Precision Plus(TM) Boston Scientific Corporation (NYSE: BSX) a annoncé aujourd'hui l'obtention du marquage CE de Clik(TM) Anchor, dispositif utilisé avec le système de...
Le docteur Kliment Gatzinsky, de l'hôpital universitaire Sahlgrenska (Göteborg, Suède), premier médecin européen à avoir évalué Clik Anchor lors d'une intervention, a déclaré : << Clik Anchor est facile à utiliser. En plus des sutures de fixation conçues pour améliorer l'ancrage
Read more →BSXBoston Scientific gibt CE-Kennzeichnung des neuen CLIK(TM) -Ankers für das Rückenmarkstimulations-System PRECISION PLUS(TM) bekannt Boston Scientific Corporation (NYSE: BSX) hat heute die CE-Kennzeichnung des Clik(TM)-Ankers für sein Rückenmarkstimulations-System (SCS) Precision...
Dr. Kliment Gatzinsky vom Sahlgrenska Universitätskrankenhaus in Göteborg, Schweden, der erste Arzt in Europa, der den Clik-Anker operativ verwendet hat, erklärte: "Die Verwendung des Clik-Ankers ist einfach. Mir gefällt der separate Verschlussmechanismus mit Sechskant zusätzlich
Read more →BSXEl stent PROMUS Element(TM) demuestra una seguridad y efectividad excepcionales en el estudio PLATINUM Small Vessel Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy los resultados a 12 meses del estudio PLATINUM Small Vessel, que demuestran la seguridad y ...
NATICK, Massachusetts y PARIS , May 23, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy los resultados a 12 meses del estudio PLATINUM Small Vessel, que demuestran la seguridad y efectividad excelentes del stent de Cromo-Platino, de 2,25 mm, liber
Read more →BSXBoston Scientific riceve la marcatura ce del nuovo sistema di ancoraggio Clik(TM) per il sistema di stimolazione del midollo spinale Precision Plus(TM) Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi di aver ricevuto la marcatura CE per sistema di ancoraggio Clik(TM) (Clik Anchor(TM))...
Clik Anchor presenta un sistema di bloccaggio innovativo disegnato per migliorare l'ancoraggio e il funzionamento nel tempo dell'elettrodo. Il nuovo ancoraggio si blocca in posizione sull'elettrodo con un semplice movimento rotatorio della chiave esagonale a brugola e fornisce ai
Read more →BSXLo stent PROMUS Element(TM) dimostra sicurezza ed efficacia straordinarie nello studio PLATINUM Small Vessel La Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi i risultati a 12 mesi del suo studio PLATINUM Small Vessel che dimostrano sicurezza...
NATICK, Massachusetts e PARIGI, May 23, 2011 /PRNewswire/ -- La Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi i risultati a 12 mesi del suo studio PLATINUM Small Vessel che dimostrano sicurezza ed efficacia eccellenti del sistema di stent da 2,25 mm PROMUS Element
Read more →BSXL'étude clinique PLATINUM Petits vaisseaux demontre une sécurité d'emploi et une efficacité exceptionnelles pour le stent PROMUS Element(TM) Boston Scientific Corporation (NYSE: BSX) a annoncé aujourd'hui les résultats à 12 mois de l'étude PLATINUM Petits vaisseaux ( Small Vessel...
NATICK, Massachusetts et PARIS , May 23, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) a annoncé aujourd'hui les résultats à 12 mois de l'étude PLATINUM << Petits vaisseaux >> (<< Small Vessel >>) qui démontrent une sécurité d'emploi et une efficacité excellente
Read more →BSXPLATINUM Small Vessel zeigt hervorragende Sicherheits- und Wirksamkeitsergebnisse für den PROMUS Element(TM) Stent Boston Scientific Corporation (NYSE: BSX) hat heute die 12-Monatsergebnisse seiner Studie PLATINUM Small Vessel bekanntgegeben, aus denen sich...
NATICK, Massachusetts und PARIS , May 23, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) hat heute die 12-Monatsergebnisse seiner Studie PLATINUM Small Vessel bekanntgegeben, aus denen sich ausgezeichnete Sicherheits- und Wirksamkeitsergebnisse für das Everolimus
Read more →BSXPROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent safety and...
NATICK, Mass. and PARIS , May 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element™ Everolimus-Eluting Pl
Read more →BSXFavorable Clinical Study Results Reported With Dual Anti-Platelet Therapy After LAA Closure With WATCHMAN® Device Boston Scientific Corporation (NYSE: BSX) today announced results from a clinical study evaluating the use of its WATCHMAN® Left Atrial Appendage...
NATICK, Mass. and Paris , May 18, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from a clinical study evaluating the use of its WATCHMAN® Left Atrial Appendage Closure Device in patients with atrial fibrillation who have a contraindicatio
Read more →BSXLong-term Safety and Effectiveness of Bronchial Thermoplasty Demonstrated in Treating Severe Asthma Boston Scientific Corporation (NYSE: BSX) today announced long-term safety data from the Research in Severe Asthma (RISA) Trial, which demonstrated...
NATICK, Mass. and DENVER , May 16, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced long-term safety data from the Research in Severe Asthma (RISA) Trial, which demonstrated the maintenance of stable lung function and the absence of clinical complic
Read more →BSXBoston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the District Court for the District of Delaware found that Cordis...
NATICK, Mass. , May 11, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that a jury in the District Court for the District of Delaware found that Cordis Corporation owed Boston Scientific approximately $19.5 million for infringing its Jang patent,
Read more →BSXBoston Scientific commercializza in tutto il mondo l'ago per aspirazione ecoendoscopica Expect(TM) Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi l'immissione in commercio a livello mondiale del suo ago per aspirazione ecoendoscopica...
NATICK, Massachusetts , May 11, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi l'immissione in commercio a livello mondiale del suo ago per aspirazione ecoendoscopica Expect(TM), usato per acquisire campioni di tessuto per la diagnosi e la stad
Read more →BSXBoston Scientific Announces Retirement of Ray Elliott as President and CEO Effective End of 2011 Boston Scientific Corporation (NYSE: BSX) today announced that Ray Elliott will retire as President and Chief Executive Officer on December 31, 2011. ...
NATICK, Mass. , May 10, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that Ray Elliott will retire as President and Chief Executive Officer on December 31, 2011 . The Board has created a special CEO search committee, on which Elliott will serve a
Read more →BSXBoston Scientific bringt weltweit die Aspirationsnadel EXPECT(TM) für die Ultraschall-Endoskopie auf den Markt Boston Scientific Corporation (NYSE: BSX) hat heute die weltweite Markteinführung seiner Aspirationsnadel Expect(TM) für die Ultraschall- Endoskopie...
NATICK, Massachusetts , May 10, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) hat heute die weltweite Markteinführung seiner Aspirationsnadel Expect(TM) für die Ultraschall- Endoskopie bekannt gegeben, welche für die Entnahme von Gewebeproben zur Diagnose und St
Read more →BSXBoston Scientific Supports Asthma Awareness Month With Donation to Asthma Foundation Boston Scientific Corporation (NYSE: BSX) today announced its donation to the Asthma and Allergy Foundation of America (AAFA) to support education...
NATICK, Mass. , May 10, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced its donation to the Asthma and Allergy Foundation of America (AAFA) to support education initiatives designed to increase public awareness of asthma management and treatment. T
Read more →BSXBoston Scientific debute la commercialisation mondiale d'Expect(TM), aiguille d'aspiration pour écho-endoscopie Boston Scientific Corporation (NYSE: BSX) annonce la commercialisation mondiale de l'aiguille d'aspiration pour écho-endoscopie Expect(TM) , destinée ...
NATICK, Massachusetts , May 10, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) annonce la commercialisation mondiale de l'aiguille d'aspiration pour écho-endoscopie Expect(TM) , destinée à prélever des échantillons tissulaires afin de diagnostiquer et déterminer
Read more →BSXBoston Scientific Begins U.S. and International Launch of Expect™ Endoscopic Ultrasound Aspiration Needle Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle,...
NATICK, Mass. , May 9, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples for diagnosing and staging malignancies in organs adj
Read more →BSXBoston Scientific débute la commercialisation et les premières implantations internationales de ses dispositifs de derniere génération pour le traitement de l'insuffisance cardiaque et de la mort subite cardiaque Boston Scientific Corporation (NYSE: BSX) annonce la commercialisation et les premières implantations, en Europe et à l'International, d'ENERGEN(TM)...
NATICK, Massachusetts , May 9, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) annonce la commercialisation et les premières implantations, en Europe et à l'International, d'ENERGEN(TM) et de PUNCTUA(TM), défibrillateurs avec fonction de resynchronisation cardiaqu
Read more →BSXBoston Scientific beginnt mit der internationaler Vermarktung und dem Einsatz einer neuen Gerätegeneration zur Behandlung von Herzinsuffizienz und plötzlichem Herztod Die Boston Scientific Corporation (NYSE: BSX) hat heute die Markteinführung und die ersten Implantationen der neuen Defibrillatoren zur kardialen...
NATICK, Massachusetts , May 9, 2011 /PRNewswire/ -- Die Boston Scientific Corporation (NYSE: BSX ) hat heute die Markteinführung und die ersten Implantationen der neuen Defibrillatoren zur kardialen Resynchronisationstherapie (CRT-D) und der implantierbaren Cardioverter-Defibrill
Read more →BSXBoston Scientific Lanza Al Mercado en Todo El Mundo La Aguja de Aspiración Guiada por Ecografía Endoscópica Expect(TM) Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy el lanzamiento al mercado en todo el mundo de la aguja de aspiración para ecoendoscopia...
NATICK, Massachusetts , May 9, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy el lanzamiento al mercado en todo el mundo de la aguja de aspiración para ecoendoscopia Expect(TM), utilizada para extraer muestras de tejidos con el fin de diagnostica
Read more →BSXPresentación en el mercado internacional y primeros implantes de dispositivos de nueva generación de Boston Scientific para el tratamiento de la insuficiencia cardiaca y de la muerte súbita cardiaca Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy el lanzamiento al mercado y los primeros implantes de sus desfibriladores con terapia de...
NATICK, Massachusetts , May 6, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy el lanzamiento al mercado y los primeros implantes de sus desfibriladores con terapia de resincronización cardíaca (CRT-D) y sus desfibriladores automáticos implantable
Read more →BSXBoston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death Boston Scientific Corporation (NYSE: BSX) today announced the launch and first implants of its ENERGEN™ and PUNCTUA™ cardiac resynchronization...
NATICK, Mass. , May 6, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the launch and first implants of its ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs) in Europe
Read more →BSXBoston Scientific Offers New CRT-D Warranty Program Covering Phrenic Nerve Stimulation Boston Scientific Corporation (NYSE: BSX) today announced that it is offering a new warranty program in the U.S. that covers its cardiac...
NATICK, Mass. , May 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it is offering a new warranty program in the U.S. that covers its cardiac resynchronization therapy defibrillator (CRT-D) devices and leads in the event of chronic phrenic
Read more →BSXALTITUDE Clinical Data Show ICD Therapy Saves Lives Without Mortality Increase from Device Shock Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of its ALTITUDE® Clinical Science program, which demonstrated that ...
NATICK, Mass. and SAN FRANCISCO , May 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of its ALTITUDE ® Clinical Science program, which demonstrated that defibrillator therapy saves lives from lethal arrhythmias without
Read more →BSXBoston Scientific's SpyGlass® Direct Visualization System Achieves Global Utilization Milestones Boston Scientific Corporation (NYSE: BSX) today announced several milestones in the adoption of its SpyGlass® Direct Visualization System since its...
NATICK, Mass. , May 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced several milestones in the adoption of its SpyGlass® Direct Visualization System since its worldwide launch in July 2007 . The SpyGlass System guides visualization and accessory
Read more →BSXBoston Scientific Announces CE Mark Approval and First Use of Blazer™ Open-Irrigated Catheter in Europe Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and first use in Europe of its Blazer™ Open-Irrigated Catheter, the...
NATICK, Mass. , May 3, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced CE Mark approval and first use in Europe of its Blazer™ Open-Irrigated Catheter, the Company's latest radiofrequency ablation (RFA) catheter designed to treat a variety of arrhy
Read more →BSXBoston Scientific Announces Its Schedule for Heart Rhythm Society Scientific Sessions Boston Scientific Corporation (NYSE: BSX) today announced its schedule of major events and sponsored research at the 32nd Annual Scientific Sessions...
NATICK, Mass. , May 2, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced its schedule of major events and sponsored research at the 32nd Annual Scientific Sessions of the Heart Rhythm Society (HRS), May 4 – 7 in San Francisco . The scheduled clinical
Read more →BSXBoston Scientific to Participate in Bank of America Merrill Lynch 2011 Health Care Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2011 Health Care Conference on May 11 in...
NATICK, Mass. , April 27, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Bank of America Merrill Lynch 2011 Health Care Conference on May 11 in Las Vegas . Ray Elliott , President and Chief Executive Officer, will participate i
Read more →BSXBoston Scientific To Participate in Deutsche Bank 36th Annual Health Care Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 36th Annual Healthcare Conference on May 2 in Boston. Ray...
NATICK, Mass. , April 26, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Deutsche Bank 36th Annual Healthcare Conference on May 2 in Boston . Ray Elliott , President and Chief Executive Officer, and Jeff Capello , Executive Vic
Read more →BSXBoston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting...
NATICK, Mass. , April 25, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company's third-generation drug-elutin
Read more →BSXBoston Scientific Announces Results for First Quarter Ended March 31, 2011 Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2011, as well as net sales and...
NATICK, Mass. , April 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced financial results for the first quarter ended March 31, 2011 , as well as net sales and earnings per share (EPS) guidance for the second quarter and updated guidance for the
Read more →BSXBoston Scientific to Webcast Conference Call Discussing First Quarter 2011 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2011 on ...
NATICK, Mass. , April 14, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the first quarter ended March 31, 2011 on Thursday, April 21 , at 8:00 a.m. ET . The call will be hosted by Ray Elliott , P
Read more →BSXEl stent Promus Element(TM) de cromo-platino de Boston Scientific demuestra resultados de seguridad y efectividad comparables frente al stent farmacoactivo de refenencia en el estudio platinum workhorse Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy los resultados a 12 meses del estudio PLATINUM Workhorse en el que se comparan la...
NATICK, Massachusetts y NUEVA ORLEÁNS, Louisiana , April 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy los resultados a 12 meses del estudio PLATINUM Workhorse en el que se comparan la seguridad y la efectividad del stent coronario de cromo-p
Read more →BSXBoston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the SuperNOVA clinical trial, an international,...
NATICK, Mass. , April 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the
Read more →BSXL'Etude clinique PLATINUM Workhorse démontre une sécurité d'emploi et une efficacité comparables entre le stent en platine chrome PROMUS Element(TM) de Boston Scientific et le stent à elution de médicament de référence Boston Scientific Corporation (NYSE: BSX) a annoncé aujourd'hui les résultats à douze mois de l'essai pivot PLATINUM Workhorse qui compare le stent...
NATICK, Massachusetts et NEW ORLEANS , Los Angeles , April 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) a annoncé aujourd'hui les résultats à douze mois de l'essai pivot PLATINUM Workhorse qui compare le stent coronaire à libération d'everolimus PROMUS Eleme
Read more →BSXPROMUS Element(TM), il sistema di stent in platino e cromo di Boston Scientific, ha dimostrato nello studio PLATINUM Workhorse, risultati di sicurezza ed efficacia sovrapponibili a quelli dei principali stent a rilascio di farmaco Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi i risultati a 12 mesi dello studio pivotal PLATINUM Workhorse che mette a confronto la...
NATICK, Massachusetts e NEW ORLEANS , April 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi i risultati a 12 mesi dello studio pivotal PLATINUM Workhorse che mette a confronto la sicurezza e l'efficacia del sistema di stent coronarici in plat
Read more →BSXPLATINUM-Studie zeigt vergleichbare Sicherheits- und Wirksamkeitsergebnisse für das Platin-Chrom-Stentsystem PROMUS Element (TM) gegenüber dem führenden medikamentenfreisetzenden Stent Boston Scientific Corporation (NYSE: BSX) hat heute die 12-Monatsergebnisse der Pivot-Studie PLATINUM Workhorse bekannt gegeben, in der die...
NATICK, Massachusetts und NEW ORLEANS , April 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) hat heute die 12-Monatsergebnisse der Pivot-Studie PLATINUM Workhorse bekannt gegeben, in der die Sicherheit und Wirksamkeit des Everolimus-freisetzenden Platin-Chrom-
Read more →BSXBoston Scientific's Promus Element™ Platinum Chromium Stent System Demonstrates Comparable Safety And Effectiveness Outcomes Versus Leading Drug-Eluting Stent In Platinum Workhorse Trial Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from the pivotal PLATINUM Workhorse trial comparing the safety and...
NATICK, Mass. and NEW ORLEANS , April 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced 12-month results from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Platinum Chromium (
Read more →BSXBoston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data Boston Scientific Corporation (NYSE: BSX) today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial...
NATICK, Mass. and NEW ORLEANS , April 3, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favo
Read more →BSXBoston Scientific Announces Its ACC 2011 Schedule Boston Scientific Corporation (NYSE: BSX) today announced its clinical trial news and events schedule at the 60th Annual Scientific Session of the...
NATICK, Mass. , March 29, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced its clinical trial news and events schedule at the 60th Annual Scientific Session of the American College of Cardiology/i2 Summit, April 2-5, 2011 in New Orleans . "Twelve-m
Read more →BSXBoston Scientific Receives FDA Approval of New Clik(TM) Anchor for Precision Plus(TM) Spinal Cord Stimulator System Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Clik™ Anchor for...
"The Clik Anchor is easy to use and gives me confidence that the lead is secure," said Salim Hayek , M.D., Ph.D., of the University Hospitals Case Medical Center in Cleveland, Ohio . "This new product will benefit my patients and my practice with simpler, more consistent lead anc
Read more →BSXBoston Scientific gibt erste Implantationen des Platin-Chrom-Koronarstentsystems OMEGA(TM) in Deutschland bekannt - Unbeschichteter Metallstent der dritten Generation in Deutschland implantiert Die Boston Scientific Corporation (NYSE: BSX) hat heute die erste...
RATINGEN, Deutschland, March 23, 2011 /PRNewswire/ -- - Unbeschichteter Metallstent der dritten Generation in Deutschland implantiert Die Boston Scientific Corporation (NYSE: BSX ) hat heute die erste Implantation des unbeschichteten Platin-Chrom-Koronarstent-systems OMEGA(TM),
Read more →BSXBoston Scientific to Webcast Analyst Event Boston Scientific Corporation (NYSE: BSX) today announced that it will hold an analyst event on April 4, 2011 at the 60th Annual Scientific Session...
NATICK, Mass. , March 22, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it will hold an analyst event on April 4, 2011 at the 60th Annual Scientific Session of the American College of Cardiology/i2 Summit in New Orleans . The Company will pr
Read more →BSXBoston Scientific annuncia i primi impianti dello stent OMEGA(TM) in Platino Cromo - Lo stent non-medicato di terza generazione impiegato per la prima volta in Italia Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi il...
MILANO, March 21, 2011 /PRNewswire/ -- - Lo stent non-medicato di terza generazione impiegato per la prima volta in Italia Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi il primo impianto dello stent non-medicato OMEGA(TM) in Platino Cromo, la tecnologia di terza
Read more →BSXBoston Scientific anuncia los primeros implantes en España del stent coronario de cromo-platino OMEGA(TM) - Stent metálico de tercera generación implantado en España Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy el primer implante en España...
MADRID, March 21, 2011 /PRNewswire/ -- - Stent metálico de tercera generación implantado en España Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy el primer implante en España del stent metálico de cromo-platino OMEGA(TM), que recientemente recibió la marca CE. Este
Read more →BSXBoston Scientific gibt europäische Zulassung und Markteinführung des Platin-Chrom-Stentsystems OMEGA(TM) bekannt - Unbeschichteter Metallstent der dritten Generation bietet bessere akute Performance bei der Behandlung von Patienten mit koronarer Herzerkrankung...
NATICK, Massachusetts, March 10, 2011 /PRNewswire/ -- - Unbeschichteter Metallstent der dritten Generation bietet bessere akute Performance bei der Behandlung von Patienten mit koronarer Herzerkrankung Die Boston Scientific Corporation (NYSE: BSX ) hat heute bekannt gegeben, da
Read more →BSXBoston Scientific to Present at Barclays Capital 2011 Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference in Miami. Jeff Capello,...
NATICK, Mass. , March 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference in Miami . Jeff Capello , Executive Vice President and Chief Financial Officer, will make a 25-minute presen
Read more →BSXBOSTON SCIENTIFIC annonce LE MARQUAGE CE ET LA COMMERCIALISATION EN EUROPE D'OMEGA(TM), STENT EN ALLIAGE PLATINE-CHROME - Le stent métallique nu de troisième génération améliore les Performances du traitement des patients atteints de maladie coronarienne Boston...
NATICK, Massachusetts, March 7, 2011 /PRNewswire/ -- - Le stent métallique nu de troisième génération améliore les Performances du traitement des patients atteints de maladie coronarienne Boston Scientific Corporation (NYSE : BSX ) a annoncé aujourd'hui l'obtention du marquage
Read more →BSXBOSTON SCIENTIFIC ANNUNCIA L'APPROVAZIONE IN EUROPA ED IL LANCIO dello stent OMEGA(TM) IN PLATINO E CROMO - Lo stent non medicato di terza generazione garantisce migliori prestazioni in urgenza per il trattamento di pazienti che presentano malattia...
NATICK, Massachusetts, March 7, 2011 /PRNewswire/ -- - Lo stent non medicato di terza generazione garantisce migliori prestazioni in urgenza per il trattamento di pazienti che presentano malattia coronarica Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi di aver r
Read more →BSXBoston Scientific anuncia la aprobación y comercialización en Europa del stent coronario de cromo-platino OMEGA(TM) - El stent metálico de tercera generación ofrece un mejor rendimiento en el tratamiento de pacientes con enfermedad de la arteria coronaria Boston...
NATICK, Massachusetts, March 7, 2011 /PRNewswire/ -- - El stent metálico de tercera generación ofrece un mejor rendimiento en el tratamiento de pacientes con enfermedad de la arteria coronaria Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy la obtención del marcado
Read more →BSXBOSTON SCIENTIFIC ANNOUNCES EUROPEAN APPROVAL AND LAUNCH OF OMEGA(TM) PLATINUM CHROMIUM STENT SYSTEM - Third-generation bare-metal stent now available in CE Mark countries Boston Scientific Corporation (NYSE: BSX) today announced it has received CE...
NATICK, Massachusetts , March 7, 2011 /PRNewswire-FirstCall/ -- - Third-generation bare-metal stent now available in CE Mark countries Boston Scientific Corporation (NYSE: BSX ) today announced it has received CE Mark for its OMEGA(TM) Platinum Chromium Bare-Metal Coronary Sten
Read more →BSXBoston Scientific Strengthens Structural Heart Product Portfolio By Completing Acquisition of Atritech Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Atritech, Inc. of Plymouth, Minnesota. The completion...
NATICK, Mass. , March 3, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the completion of its acquisition of Atritech, Inc. of Plymouth, Minnesota . The completion of the transaction follows the signing of a definitive merger agreement announced o
Read more →BSXBoston Scientific Launches PROMUS® Element™ and TAXUS® Element™ Stent Systems in India Boston Scientific Corporation (NYSE: BSX) today announced its launch of the PROMUS® Element™ Everolimus-Eluting Coronary Stent System and TAXUS®...
NATICK, Mass. , Feb. 17, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced its launch of the PROMUS ® Element™ Everolimus-Eluting Coronary Stent System and TAXUS ® Element™ Paclitaxel-Eluting Coronary Stent System in India . Both Element Systems inco
Read more →BSXBoston Scientific to Participate in 2011 RBC Capital Markets' Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2011 RBC Capital Markets' Healthcare Conference on March 2 in New York....
NATICK, Mass. , Feb. 16, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the 2011 RBC Capital Markets' Healthcare Conference on March 2 in New York . Ray Elliott , President and Chief Executive Officer, and Jeff Capello , Executive
Read more →BSXBoston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of two novel technologies to treat peripheral chronic total occlusions...
NATICK, Mass. , Feb. 15, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the acquisition of two novel technologies to treat peripheral chronic total occlusions (CTOs). These acquisitions add technology platforms that complement the Company's world-
Read more →BSXBoston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine Boston Scientific Corporation (NYSE: BSX) today announced that it has established a $1.7 million endowment to fund the Donald S. Baim, M.D., '75...
NATICK, Mass. , Feb. 15, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has established a $1.7 million endowment to fund the "Donald S. Baim, M.D., '75 Scholarship Fund" for Yale School of Medicine . This scholarship fund will honor the la
Read more →BSXBoston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of a sub-analysis of the MADIT-CRT trial data in the current issue of the...
NATICK, Mass. , Feb. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of a sub-analysis of the MADIT-CRT trial data in the current issue of the Journal of American College of Cardiology that showed women received a greater clinical
Read more →BSXBoston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2010 Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as...
NATICK, Mass. , Feb. 1, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced financial results for the fourth quarter and full year ended December 31, 2010 , as well as net sales and earnings per share (EPS) guidance for the full year and first quarter
Read more →BSXBoston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved its Renegade® HI-FLO™ Fathom® ...
NATICK, Mass. , Jan. 31, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that the U.S. Food and Drug Administration (FDA) has approved its Renegade® HI-FLO™ Fathom® Pre-Loaded System for selective access and delivery of diagnostic, embolic and ther
Read more →BSXBoston Scientific Responds to DOJ Civil Lawsuit Boston Scientific Corporation (NYSE: BSX) today announced that yesterday afternoon, the Civil Division of the U.S. Department of Justice (DOJ) filed...
NATICK, Mass. , Jan. 28, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that yesterday afternoon, the Civil Division of the U.S. Department of Justice (DOJ) filed a civil False Claims Act complaint against Boston Scientific, Guidant LLC and other
Read more →BSXBoston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S. Boston Scientific Corporation (NYSE: BSX) today announced the first use of the Blazer® Open-Irrigated Catheter in the U.S. as part of the BLOCk-CTI...
NATICK, Mass. , Jan. 27, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the first use of the Blazer® Open-Irrigated Catheter in the U.S. as part of the BLOCk-CTI clinical trial. BLOCk-CTI is a prospective, randomized trial evaluating the safety an
Read more →BSXBoston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent Boston Scientific Corporation (NYSE: BSX) today announced the beginning of patient enrollment in the PLATINUM China clinical trial, which is designed ...
NATICK, Mass. , Jan. 26, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the beginning of patient enrollment in the PLATINUM China clinical trial, which is designed to evaluate the safety and effectiveness of the Company's PROMUS Element™ Everolimu
Read more →BSXBoston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to...
NATICK, Mass. , Jan. 24, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY™ Coronary
Read more →BSXBoston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and year ended...
NATICK, Mass. , Jan. 19, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the fourth quarter and year ended December 31, 2010 on Wednesday, February 2 , at 8:00 a.m. ET . The call will be hosted by
Read more →BSXBoston Scientific to Acquire Atritech Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which the Company will acquire...
NATICK, Mass. , Jan. 19, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the signing of a definitive merger agreement, under which the Company will acquire Atritech, Inc., a privately held company based in Plymouth, Minnesota . Atritech has develop
Read more →BSXBoston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan Boston Scientific Corporation (NYSE: BSX) today announced that its subsidiary, Boston Scientific Japan K.K., has reached an agreement with Fukuda...
NATICK, Mass. , Jan. 19, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that its subsidiary, Boston Scientific Japan K.K., has reached an agreement with Fukuda Denshi Co., Ltd. to market and sell its cardiac rhythm management (CRM) devices and acc
Read more →BSXBoston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate ...
NATICK, Mass. , Jan. 10, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac
Read more →BSXBoston Scientific Acquires Intelect Medical Boston Scientific Corporation (NYSE: BSX) today announced it has acquired Intelect Medical, Inc., a development-stage company located in Boston....
NATICK and BOSTON, Mass. , Jan. 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has acquired Intelect Medical, Inc., a development-stage company located in Boston . Intelect Medical is developing advanced neuromodulation technologies for deep
Read more →BSXStatement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article Boston Scientific Corporation (NYSE: BSX) today issued the following statement from Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm...
NATICK, Mass. , Jan. 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today issued the following statement from Kenneth Stein , M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article that was published online today by the Journal of the American M
Read more →BSXBoston Scientific Completes Acquisition of Sadra Medical Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Sadra Medical, Inc. of Los Gatos, California. The...
NATICK, Mass. , Jan. 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the completion of its acquisition of Sadra Medical, Inc. of Los Gatos, California . The transaction follows the definitive merger agreement announced on November 19, 2010 . Und
Read more →BSXBoston Scientific Completes Sale of Neurovascular Business Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the sale of its Neurovascular business to Stryker Corporation. The...
NATICK, Mass. , Jan. 3, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has completed the sale of its Neurovascular business to Stryker Corporation. The sale price is $1.5 billion , of which $1.45 billion was received at closing (including
Read more →BSXBoston Scientific to Present at 29th Annual J.P. Morgan Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco. Ray Elliott, ...
NATICK, Mass. , Dec. 27, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco . Ray Elliott , President and Chief Executive Officer, will make a 25-minute presentat
Read more →BSXBoston Scientific Announces Election of Dr. Kristina M. Johnson to its Board of Directors Boston Scientific Corporation (NYSE: BSX) today announced that the Company's Board of Directors has elected Kristina M. Johnson, Ph.D., as a...
NATICK, Mass. , Dec. 20, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that the Company's Board of Directors has elected Kristina M. Johnson , Ph.D., as a Director, effective January 1, 2011 . Dr. Johnson previously served as a Director
Read more →BSXBoston Scientific Welcomes Publication of Analysis of Patients Monitored by the LATITUDE® Patient Management System Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis from its ALTITUDE® Clinical Science program in the current...
NATICK, Mass. , Dec. 7, 2010 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of an analysis from its ALTITUDE® Clinical Science program in the current issue of Circulation that showed patients followed by the LATITUDE® Patient Management
Read more →BSXBoston Scientific to Participate in Piper Jaffray Health Care Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference on December 1 in New York City. Ray ...
NATICK, Mass. , Nov. 22, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Piper Jaffray Health Care Conference on December 1 in New York City . Ray Elliott , President and Chief Executive Officer, and Jeff Capello , Exe
Read more →BSXBoston Scientific to Acquire Sadra Medical Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire...
NATICK, Mass. and LOS GATOS, Calif. , Nov. 19, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire Sadra Medical, Inc., a development-stage company in Lo
Read more →BSXBoston Scientific annuncia l'approvazione della marcatura CE e i primi impianti dei nuovi dispositivi per trattare l'insufficienza cardiaca e la morte cardiaca improvvisa Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi l'approvazione della marcatura CE per INCEPTA(TM), ENERGEN(TM) e PUNCTUA(TM): i suoi...
NATICK, Massachusetts, November 19, 2010 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi l'approvazione della marcatura CE per INCEPTA(TM), ENERGEN(TM) e PUNCTUA(TM): i suoi defibrillatori cardaci impiantabili (ICD) e quelli dedicati alla terapia di
Read more →BSXBoston Scientific Announces CE Mark Approval and First Implants for New Devices to Treat Heart Failure and Sudden Cardiac Death Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy...
NATICK, Mass. , Nov. 19, 2010 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced CE Mark approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs). They are
Read more →BSXAlair® Bronchial Thermoplasty System Named 'Best of What's New' By Popular Science Boston Scientific Corporation (NYSE: BSX) today announced that its newly acquired subsidiary, Asthmatx, Inc., was awarded the 2010 Popular Science...
NATICK, Mass. , Nov. 17, 2010 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that its newly acquired subsidiary, Asthmatx, Inc., was awarded the 2010 Popular Science "Best of What's New" Award in the Health category for its Alair ® Bronchial Thermoplas
Read more →BSXBoston Scientific Announces Sponsorship of World Diabetes Day Campaign 2010 Boston Scientific Corporation (NYSE: BSX) today announced its sponsorship of World Diabetes Day for the third year in a row. The campaign is led by ...
NATICK, Mass. , Nov. 11 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced its sponsorship of "World Diabetes Day" for the third year in a row. The campaign is led by the International Diabetes Federation (IDF) and represents its primary global awareness i
Read more →BSXBoston Scientific To Webcast Investor Day Meeting Boston Scientific Corporation (NYSE: BSX) today announced that it will be hosting an Investor Day meeting, which will be simultaneously webcast on...
NATICK, Mass. , Nov. 10, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it will be hosting an Investor Day meeting, which will be simultaneously webcast on Friday, November 19, 2010 . The meeting is scheduled to begin at 8:00 a.m. E
Read more →BSXBoston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease Boston Scientific Corporation (NYSE: BSX) today announced the first implantation of its Vercise™ Deep Brain Stimulation (DBS) System as part of the...
NATICK, Mass. , Nov. 9, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the first implantation of its Vercise™ Deep Brain Stimulation (DBS) System as part of the VANTAGE clinical trial. VANTAGE is a multi-center, prospective trial designe
Read more →BSXBronchial Thermoplasty Demonstrates Long-Term Asthma Control in Patients With Severe Asthma Boston Scientific Corporation (NYSE: BSX) today announced that its newly acquired subsidiary, Asthmatx, Inc., presented two-year results from the...
NATICK, Mass. and VANCOUVER , Nov. 2, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that its newly acquired subsidiary, Asthmatx, Inc., presented two-year results from the Asthma Intervention Research 2 (AIR2) Trial demonstrating the lo
Read more →BSXBoston Scientific Agrees to Sell Neurovascular Business to Stryker Boston Scientific Corporation (NYSE: BSX) today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston ...
NATICK, Mass. , Oct. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion , payab
Read more →BSXBoston Scientific Completes Acquisition of Asthmatx Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Asthmatx, Inc. of Sunnyvale, California. The...
NATICK, Mass. , Oct. 26 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the completion of its acquisition of Asthmatx, Inc. of Sunnyvale, California . The transaction follows the definitive agreement announced on September 20 . Under the terms
Read more →BSXBoston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent Boston Scientific Corporation (NYSE: BSX) today announced that its WallFlex® Biliary RX Fully Covered Stent has received CE Mark approval for the...
NATICK, Mass. , Oct. 22 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that its WallFlex® Biliary RX Fully Covered Stent has received CE Mark approval for the treatment of benign biliary strictures. "The WallFlex Biliary RX Fully Covered Stent has pro
Read more →BSXBoston Scientific Annuncia l'approvazione della marcatura CE per l'espansione dell'indicazione dello stent biliare RX WallFlex(R) - Lo stent metallico totalmente coperto prodotto dall'azienda ha ricevuto l'approvazione per l'uso nel trattamento delle stenosi biliari benigne...
NATICK, Massachusetts, October 22, 2010 /PRNewswire/ -- - Lo stent metallico totalmente coperto prodotto dall'azienda ha ricevuto l'approvazione per l'uso nel trattamento delle stenosi biliari benigne Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi che il suo sten
Read more →BSXBoston Scientific annuncia l'autorizzazione della FDA e l'approvazione della Marcatura CE per gli stent biliari Advanix(TM) - Le ultime innovazioni tecnologiche nel campo degli stent biliari in plastica annoverano caratteristiche che permettono un miglior posizionamento ed ...
NATICK, Massachusetts, October 21, 2010 /PRNewswire/ -- - Le ultime innovazioni tecnologiche nel campo degli stent biliari in plastica annoverano caratteristiche che permettono un miglior posizionamento ed aumentano l'efficienza ed il controllo procedurale Boston Scientific Cor
Read more →BSXBoston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE...
NATICK, Mass. , Oct. 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of bi
Read more →BSXBoston Scientific Announces Results for Third Quarter Ended September 30, 2010 Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2010, as well as guidance for...
NATICK, Mass. , Oct. 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced financial results for the third quarter ended September 30, 2010 , as well as guidance for net sales and earnings per share (EPS) for the fourth quarter and full year 2010
Read more →BSXBoston Scientific Announces Global Launch of Journey™ Guidewire Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Journey™ Guidewire, an innovative 0.014 guidewire designed for...
NATICK, Mass. , Oct. 13 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the global launch of its Journey™ Guidewire, an innovative 0.014" guidewire designed for use in challenging, small vessel peripheral angioplasty procedures. The Journey Guidewire st
Read more →BSXBoston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
NATICK, Mass. , Oct. 7 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) will webcast its conference call discussing financial results for the third quarter ended September 30, 2010 on Tuesday, October 19 , at 5:30 p.m. ET . The timing of the call was set to av
Read more →BSXBoston Scientific annuncia la pubblicazione di un'analisi che dimostra l'aumento della sopravvivenza a lungo termine grazie alla terapia con ICD - L'analisi dei risultati a otto anni dello studio MADIT II mostra che viene salvata una vita per ogni otto pazienti che ricevono un ICD. Boston...
NATICK, Massachusetts, September 29, 2010 /PRNewswire/ -- - L'analisi dei risultati a otto anni dello studio MADIT II mostra che viene salvata una vita per ogni otto pazienti che ricevono un ICD. Boston Scientific Corporation (NYSE: BSX ) è lieta di annunciare la pubblicazione
Read more →BSXBoston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis of long-term data from the MADIT II clinical trial in the...
NATICK, Mass. , Sept. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of an analysis of long-term data from the MADIT II clinical trial in the current issue of Circulation . The analysis demonstrates that the life-saving bene
Read more →BSXHORIZONS-AMI Trial Provides Superior Outcomes Data at Three Years with TAXUS® Drug-Eluting Stent in Heart Attack Patients Boston Scientific Corporation (NYSE: BSX) today announced three-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the...
NATICK, Mass. , Sept. 25 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced three-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the Cardiovascular Research Foundation (CRF) with grant support from Boston Scientific and The Medici
Read more →BSXBoston Scientific annuncia i dati clinici a supporto della sicurezza e dell'efficacia dello stent in platino e cromo Promus Element(TM) - Risultati a nove mesi del programma clinico PLATINUM presentati al TCT Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi i dati dello...
NATICK, Massachusetts, September 23, 2010 /PRNewswire/ -- - Risultati a nove mesi del programma clinico PLATINUM presentati al TCT Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi i dati dello studio PLATINUM QCA, ideato al fine di valutare PROMUS Element(TM), lo s
Read more →BSXLong-Term Data Show Advantages for TAXUS® Liberte® Stent in Small Vessels and Long Lesions Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective,...
NATICK, Mass. , Sept. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS® Liberte® Paclitaxel-Eluting Stent Syste
Read more →BSXBoston Scientific's TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the...
NATICK, Mass. , Sept. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in
Read more →BSXBostonScientific Anuncia los Datos Clínicos que Avalan la Seguridad y Eficacia del Stent de Cromo-Platino PROMUS Element(TM) - Resultados a los mueve meses del programa clínico PLATINUM, presentados en el simposio TCT Boston Scientific Corporation (NYSE: BSX) ha anunciado...
NATICK, Massachusetts, September 22, 2010 /PRNewswire/ -- - Resultados a los mueve meses del programa clínico PLATINUM, presentados en el simposio TCT Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy los datos correspondientes al estudio PLATINUM QCA, diseñado para e
Read more →BSXPROMUS® Element™ Stent Approved for Use in Diabetic and Heart Attack Patients in CE Mark Countries Boston Scientific Corporation (NYSE: BSX) today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark...
NATICK, Mass. , Sept. 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with diabetes(1) and those experiencing an acute myoc
Read more →BSXBoston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Element™ Stent Boston Scientific Corporation (NYSE: BSX) today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS...
NATICK, Mass. , Sept. 21 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent. The results provided 30-day and n
Read more →BSXApprovazione Dello Stent Promus(R) Element(TM) Per L'utilizzo in Pazienti Diabetici E Colpiti Da Infarto Nei Paesi Che Richiedono la Marcatura CE Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi che il suo stent coronarico a rilascio di Everolimus PROMUS(R) Element(TM) ha ottenuto...
NATICK, Massachusetts, September 21, 2010 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi che il suo stent coronarico a rilascio di Everolimus PROMUS(R) Element(TM) ha ottenuto la marcatura CE per l'utilizzo in pazienti diabetici[1] e nei pazienti ch
Read more →BSXBoston Scientific to Acquire Asthmatx Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire...
NATICK, Mass. and SUNNYVALE, Calif. , Sept. 20 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire Asthmatx, Inc., a privately held company in Sunnyvale, Cali
Read more →BSXEspansione delle indicazioni per i dispositivi CRTD Boston Scientific - L'approvazione da parte dell'FDA si basa sui risultati derivanti dall'importante studio MADIT-CRT condotto dall'Azienda Boston Scientific...
NATICK, Massachusetts, September 20, 2010 /PRNewswire/ -- - L'approvazione da parte dell'FDA si basa sui risultati derivanti dall'importante studio MADIT-CRT condotto dall'Azienda Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi l'approvazione da parte della Food a
Read more →BSXBoston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for...
NATICK, Mass. , Sept. 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its cardiac resynchronization therapy defibrillators (CRT-Ds), including the COGN
Read more →BSXBoston Scientific Announces Schedule of Events at TCT Scientific Symposium Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular...
NATICK, Mass. , Sept. 14 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) sci
Read more →BSXBoston Scientific to Participate in Morgan Stanley Global Healthcare Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14th in New...
NATICK, Mass. , Sept. 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14th in New York City . Ray Elliott , President and Chief Executive Officer and Jeff Capello ,
Read more →BSXBoston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association Boston Scientific Corporation (NYSE: BSX) today announced that results from studies involving the Company's Women's Health products will be presented ...
NATICK, Mass. , Aug. 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that results from studies involving the Company's Women's Health products will be presented at the Joint Annual Meeting of the International Continence Society (ICS) and I
Read more →BSXBoston Scientific Resolves Corporate Warning Letter Boston Scientific Corporation (NYSE: BSX) today announced that it has been notified by the U.S. Food and Drug Administration that all issues cited in ...
NATICK, Mass. , Aug. 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has been notified by the U.S. Food and Drug Administration that all issues cited in the Company's corporate warning letter have been resolved. "The resolution of
Read more →BSXBoston Scientific inizia l'arruolamento per il trial clinico sul nuovo stent coronarico, con polimero bioassorbibile e a rilascio di everolimus - Lo studio EVOLVE valuterà lo stent coronarico a rilascio di farmaco di quarta generazione SYNERGY(TM), prodotto da Boston Scientific Boston...
NATICK, Massachusetts, August 5, 2010 /PRNewswire/ -- - Lo studio EVOLVE valuterà lo stent coronarico a rilascio di farmaco di quarta generazione SYNERGY(TM), prodotto da Boston Scientific Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi l'avvio dell'arruolamento d
Read more →BSXBoston Scientific lança sistema de stents Neuroform EZ(TM) nos Estados Unidos e na Europa - Empresa expande a família líder de mercado de stents neurovasculares A Boston Scientific Corporation (NYSE: BSX) anunciou hoje o lançamento nos...
NATICK, Massachusetts, August 2, 2010 /PRNewswire/ -- - Empresa expande a família líder de mercado de stents neurovasculares A Boston Scientific Corporation (NYSE: BSX ) anunciou hoje o lançamento nos Estados Unidos e na Europa do Sistema de Stents Neuroform EZ(TM), a sua quart
Read more →BSXIl sistema di stent Neuroform EZ(TM) di Boston Scientific viene lanciato negli Stati Uniti e in Europa - L'azienda espande la famiglia degli stent neurovascolari leader del mercato Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi...
NATICK, Massachusetts, July 28, 2010 /PRNewswire/ -- - L'azienda espande la famiglia degli stent neurovascolari leader del mercato Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi l'immediata immissione in commercio - sia negli USA che in Europa- di Neuroform EZ(TM
Read more →BSXBoston Scientific annuncia l'arruolamento del primo paziente nello studio clinico MultiSENSE Boston Scientific Corporation (quotata alla New York Stock Exchange BSX) annuncia oggi l'arruolamento del primo paziente nello studio clinico...
NATICK, Massachusetts, July 8, 2010 /PRNewswire/ -- Boston Scientific Corporation (quotata alla New York Stock Exchange BSX) annuncia oggi l'arruolamento del primo paziente nello studio clinico MultiSENSE. Lo studio è stato disegnato per valutare l'efficacia di sensori fisiologic
Read more →BSXSecondo i dati dello studio MADIT-CRT le pazienti di sesso femminile beneficiano maggiormente dall'impianto di dispositivi CRT-D rispetto ai pazienti di sesso maschile La Boston Scientific Corporation (quotata alla New York Stock Exchange come BSX) ha annunciato oggi i risultati di una sotto-analisi dello studio...
NATICK, Massachusetts e NIZZA, Francia, June 18, 2010 /PRNewswire/ -- La Boston Scientific Corporation (quotata alla New York Stock Exchange come BSX) ha annunciato oggi i risultati di una sotto-analisi dello studio MADIT-CRT, secondo cui le pazienti di sesso femminile beneficere
Read more →BSXBoston Scientific Inicia el Estudio PLATINUM PLUS Para el Stent PROMUS(R) Element(TM) - Estudio Randomizado en el qué Participarán Cerca de 3.000 Pacientes Para Evaluar el Stent Liberador de Fármaco de Tercera Generación de la Compañía ...
NATICK, Massachussetts y PARIS, May 26, 2010 /PRNewswire/ -- - Estudio Randomizado en el qué Participarán Cerca de 3.000 Pacientes Para Evaluar el Stent Liberador de Fármaco de Tercera Generación de la Compañía Boston Scientific Corporation (NYSE: BSX ) anunció hoy qué ha inici
Read more →BSXBoston Scientific da' il Via Allo Studio PLATINUM PLUS Sul Sistema di Stent PROMUS(R) Element(TM) - La Terza Generazione Della Tecnologia di Stent ad Eluizione di Farmaco è Valutata Mediante uno Studio Randomizzato su Circa 3.000 Pazienti La...
NATICK, Massachusetts e PARIGI, May 26, 2010 /PRNewswire/ -- - La Terza Generazione Della Tecnologia di Stent ad Eluizione di Farmaco è Valutata Mediante uno Studio Randomizzato su Circa 3.000 Pazienti La Boston Scientific Corporation (NYSE: BSX ) annuncia oggi l'avvio dello st
Read more →BSXBoston Scientific annuncia la disponibilità di un nuovo connettore ideato per semplificare la procedura di impianto Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi l'immissione in commercio in Europa di un sistema di connessione composto...
PARIGI, March 24, 2010 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi l'immissione in commercio in Europa di un sistema di connessione composto dall'elettrocatetere per la defibrillazione ENDOTAK RELIANCE(R) 4-SITE e dai dispositivi con esso compati
Read more →BSXBoston Scientific anuncia la disponibilidad de un nuevo sistema conector diseñado para simplificar el procedimiento de implantación Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy la disponibilidad en el mercado europeo del nuevo sistema de conexión fabricado por la...
PARÍS, March 24, 2010 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy la disponibilidad en el mercado europeo del nuevo sistema de conexión fabricado por la empresa, integrado por los electrodos de desfibrilación ENDOTAK RELIANCE(R) 4-SITE, los desfibr
Read more →BSXEl Grupo Asesor de la FDA recomienda unánimemente la ampliación de la indicación para los Dispositivos para el tratamiento de la insuficiencia cardíaca de Boston Scientific basándose en el ensayo de referencia MADIT-CRT - Recomendación de los CRT-D de la empresa para pacientes con insuficiencia cardíaca asintomáticos o con síntomas leves Boston Scientific Corporation ...
NATICK, Massachusetts, March 23, 2010 /PRNewswire/ -- - Recomendación de los CRT-D de la empresa para pacientes con insuficiencia cardíaca asintomáticos o con síntomas leves Boston Scientific Corporation (NYSE: BSX ) anunció hoy que el Grupo Asesor sobre Dispositivos para el Ap
Read more →BSXSulla base dell'importante studio MADIT-CRT la Commissione consultiva della FDA raccomanda di espandere l'indicazione dei Dispositivi Boston Scientific per l'insufficienza cardiaca - I dispositivi CRT-D dell'azienda sono stati raccomandati per pazienti con insufficienza cardiaca asintomatica e lieve Boston Scientific Corporation ...
NATICK, Massachusetts, March 23, 2010 /PRNewswire/ -- - I dispositivi CRT-D dell'azienda sono stati raccomandati per pazienti con insufficienza cardiaca asintomatica e lieve Boston Scientific Corporation (quotata alla New York Stock Exchange come BSX) ha annunciato oggi che la
Read more →BSXI risultati dello studio PERSEUS dimostrano esiti positivi in termini di efficacia e sicurezza per lo stent in platino e cromo di Boston Scientific TAXUS(R) Element(TM) La Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi i risultati a 12 mesi del programma clinico PERSEUS che ha dimostrato esiti positivi...
NATICK, Massachussets and ATLANTA, Georgia, March 16, 2010 /PRNewswire/ -- La Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi i risultati a 12 mesi del programma clinico PERSEUS che ha dimostrato esiti positivi in termini di efficacia e sicurezza nelle lesioni discr
Read more →BSXI pazienti trattati con il sistema di gestione remota Latitude (R) di Boston Scientific Raggiungono il migliaio - Pazienti e medici apprezzano il valore aggiunto offerto dal servizio Sono ben mille i pazienti europei trattati con il sistema di gestione remota...
PARIGI, Francia, March 15, 2010 /PRNewswire/ -- - Pazienti e medici apprezzano il valore aggiunto offerto dal servizio Sono ben mille i pazienti europei trattati con il sistema di gestione remota LATITUDE, prodotto e distribuito da Boston Scientific Corporation (quotata come BS
Read more →BSXBoston Scientific annuncia l'arruolamento del primo paziente nello studio del sistema di stent RX biliare WallFlex(R) per la cura della stenosi benigna Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi che è stato arruolato il primo paziente nello studio clinico per valutare il suo stent...
NATICK, Massachusetts e DUSSELDORF, Germania, January 15 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi che è stato arruolato il primo paziente nello studio clinico per valutare il suo stent RX biliare WallFlex(R) completamente coperto per la cura
Read more →BSXBoston Scientific annuncia che è stato completato l'arruolamento nello studio clinico sul coiling degli aneurismi Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi di aver completato l'arruolamento nel suo studio clinico MAPS(TM) (Matrix and Platinum...
NATICK, Massachusetts, January 5 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) ha annunciato oggi di aver completato l'arruolamento nel suo studio clinico MAPS(TM) (Matrix and Platinum Science), nel quale viene studiato il coiling degli aneurismi intracranici. L'arr
Read more →BSXBoston Scientific termina el reclutamiento en el ensayo clínico sobre el aneurisma - Boston Scientific anuncia la finalización del periodo de INCLUSIÓN en UN ESTUDIO clínico sobre embolización de aneurismas INTRACRANEALES con coils...
NATICK, Massachusetts, January 5 /PRNewswire/ -- - Boston Scientific anuncia la finalización del periodo de INCLUSIÓN en UN ESTUDIO clínico sobre embolización de aneurismas INTRACRANEALES con coils Boston Scientific Corporation (NYSE: BSX ) ha anunciado hoy que ha completado la
Read more →Competitive Position
How BSX ranks across every disease it competes inCompetitive Position is a premium feature
See how BSX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial